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Preamble
The medical profession should play a central role in evaluating
the evidence related to drugs, devices, and procedures for thedetection, management, and prevention of disease. When
properly applied, expert analysis of available data on the
benefits and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most effective
strategies. An organized and directed approach to a thorough
review of evidence has resulted in the production of clinical
practice guidelines that assist physicians in selecting the best
management strategy for an individual patient. Moreover, clinical
practice guidelines can provide a foundation for other applications,
such as performance measures, appropriate use criteria, and both
quality improvement and clinical decision support tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
jointly produced guidelines in the area of cardiovascular
disease since 1980. The ACCF/AHA Task Force on
Practice Guidelines (Task Force), charged with developing,
updating, and revising practice guidelines for cardiovascular
diseases and procedures, directs and oversees this effort.
Writing committees are charged with regularly reviewing
and evaluating all available evidence to develop balanced,
patient-centric recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-specific data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a formal literature review;
weigh the strength of evidence for or against particular tests,
treatments, or procedures; and include estimates of expected
outcomes where such data exist. Patient-specific modifiers,
comorbidities, and issues of patient preference that may
influence the choice of tests or therapies are considered.
When available, information from studies on cost is con-
sidered, but data on efficacy and outcomes constitute the
primary basis for the recommendations contained herein.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force (1). The
Class of Recommendation (COR) is an estimate of the size
of the treatment effect considering risks versus benefits in
addition to evidence and/or agreement that a given treat-
ment or procedure is or is not useful/effective or in some
situations may cause harm. The Level of Evidence (LOE) is
an estimate of the certainty or precision of the treatment
effect. The writing committee reviews and ranks evidence
supporting each recommendation with the weight of evi-
dence ranked as LOE A, B, or C according to specific
definitions that are included in Table 1. Studies are identi-
fied as observational, retrospective, prospective, or random-
ized where appropriate. For certain conditions for which
inadequate data are available, recommendations are based
on expert consensus and clinical experience and are ranked
as LOE C. When recommendations at LOE C are sup-
ported by historical clinical data, appropriate references
(including clinical reviews) are cited if available. For issues
for which sparse data are available, a survey of current
Level o
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December 6, 2011:e44–122 2011 ACCF/AHA/SCAI PCI Guidelinepractice among the clinicians on the writing committee is
the basis for LOE C recommendations and no references
are cited. The schema for COR and LOE is summarized
in Table 1, which also provides suggested phrases for
writing recommendations within each COR. A new
addition to this methodology is separation of the Class
III recommendations to delineate if the recommendation
is determined to be of “no benefit” or is associated with
“harm” to the patient. In addition, in view of the
increasing number of comparative effectiveness studies,
comparator verbs and suggested phrases for writing
recommendations for the comparative effectiveness of
one treatment or strategy versus another have been added
Table 1. Applying Classification of Recommendations and Leve
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak
Although randomized trials are unavailable, there may be a very clear clinical consensus that a
*Data available from clinical trials or registries about the usefulness/efficacy in different subp
failure, and prior aspirin use. †For comparative effectiveness recommendations (Class I and IIa;
comparisons of the treatments or strategies being evaluated.for COR I and IIa, LOE A or B only.In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as defined by
ACCF/AHA guideline recommended therapies (primarily
Class I). This new term, GDMT, will be used herein and
throughout all future guidelines.
Because the ACCF/AHA practice guidelines address
patient populations (and healthcare providers) residing in
North America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing committee reviews the
vidence
important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
lar test or therapy is useful or effective.
ons, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
f Evidence A and B only), studies that support the use of comparator verbs should involve directl of E
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ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to
assist healthcare providers in clinical decision making by
describing a range of generally acceptable approaches to the
diagnosis, management, and prevention of specific diseases
or conditions. The guidelines attempt to define practices
that meet the needs of most patients in most circumstances.
The ultimate judgment regarding care of a particular patient
must be made by the healthcare provider and patient in light
of all the circumstances presented by that patient. As a
result, situations may arise for which deviations from these
guidelines may be appropriate. Clinical decision making
should involve consideration of the quality and availability
of expertise in the area where care is provided. When these
guidelines are used as the basis for regulatory or payer
decisions, the goal should be improvement in quality of care.
The Task Force recognizes that situations arise in which
additional data are needed to inform patient care more
effectively; these areas will be identified within each respec-
tive guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack
of patient understanding and adherence may adversely affect
outcomes, physicians and other healthcare providers should
make every effort to engage the patient’s active participation
in prescribed medical regimens and lifestyles. In addition,
patients should be informed of the risks, benefits, and
alternatives to a particular treatment and be involved in
shared decision making whenever feasible, particularly for
COR IIa and IIb, where the benefit-to-risk ratio may be
lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conflicts of interest that may arise as
a result of industry relationships or personal interests among
the members of the writing committee. All writing com-
mittee members and peer reviewers of the guideline are
asked to disclose all such current relationships, as well as
those existing 12 months previously. In December 2009, the
ACCF and AHA implemented a new policy for relation-
ships with industry and other entities (RWI) that requires
the writing committee chair plus a minimum of 50% of the
writing committee to have no relevant RWI (Appendix 1 for
he ACCF/AHA definition of relevance). These statements
re reviewed by the Task Force and all members during each
onference call and/or meeting of the writing committee
nd are updated as changes occur. All guideline recommen-
ations require a confidential vote by the writing committee
nd must be approved by a consensus of the voting mem-
ers. Members are not permitted to write, and must recuse
hemselves from voting on, any recommendation or section to
hich their RWI apply. Members who recused themselves
rom voting are indicated in the list of writing committee
embers, and section recusals are noted in Appendix 1.
uthors’ and peer reviewers’ RWI pertinent to this guidelinere disclosed in Appendixes 1 and 2, respectively. Additionally,
o ensure complete transparency, writing committee members’
omprehensive disclosure information—including RWI not
ertinent to this document—is available as an online supple-
ent. Comprehensive disclosure information for the Task
orce is also available online at www.cardiosource.org/ACC/
bout-ACC/Leadership/Guidelines-and-Documents-Task-
orces.aspx. The work of the writing committee was supported
xclusively by the ACCF, AHA, and the Society for Cardio-
ascular Angiography and Interventions (SCAI) without com-
ercial support. Writing committee members volunteered
heir time for this activity.
In an effort to maintain relevance at the point of care for
racticing physicians, the Task Force continues to oversee
n ongoing process improvement initiative. As a result, in
esponse to pilot projects, several changes to these guide-
ines will be apparent, including limited narrative text, a
ocus on summary and evidence tables (with references
inked to abstracts in PubMed) and more liberal use of
ummary recommendation tables (with references that sup-
ort LOE) to serve as a quick reference.
In April 2011, the Institute of Medicine released 2
eports: Finding What Works in Health Care: Standards for
ystematic Reviews and Clinical Practice Guidelines We Can
rust (2,3). It is noteworthy that the ACCF/AHA guide-
ines were cited as being compliant with many of the
tandards that were proposed. A thorough review of these
eports and of our current methodology is under way, with
urther enhancements anticipated.
The recommendations in this guideline are considered
urrent until they are superseded by a focused update or the
ull-text guideline is revised. Guidelines are official policy of
oth the ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA, Chair
ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are, when-
ever possible, evidence based. An extensive evidence review
was conducted through November 2010, as well as selected
other references through August 2011. Searches were lim-
ited to studies, reviews, and other evidence conducted in
human subjects and that were published in English. Key
search words included but were not limited to the following:
ad hoc angioplasty, angioplasty, balloon angioplasty, clinical
rial, coronary stenting, delayed angioplasty, meta-analysis,
ercutaneous transluminal coronary angioplasty, randomized
ontrolled trial (RCT), percutaneous coronary intervention
PCI) and angina, angina reduction, antiplatelet therapy,
bare-metal stents (BMS), cardiac rehabilitation, chronic stable
angina, complication, coronary bifurcation lesion, coronary
calcified lesion, coronary chronic total occlusion (CTO), coronary
ostial lesions, coronary stent (BMS and drug-eluting stents
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distal protection, elderly, ethics, late stent thrombosis, medical
herapy, microembolization, mortality, multiple lesions, multi-
essel, myocardial infarction (MI), non–ST-elevation myocar-
dial infarction (NSTEMI), no-reflow, optical coherence tomog-
raphy, proton pump inhibitor (PPI), return to work, same-day
ngioplasty and/or stenting, slow flow, stable ischemic heart
isease (SIHD), staged angioplasty, STEMI, survival, and
unstable angina (UA). Additional searches cross-referenced
these topics with the following subtopics: anticoagulant
therapy, contrast nephropathy, PCI-related vascular complica-
tions, unprotected left main PCI, multivessel coronary artery
isease (CAD), adjunctive percutaneous interventional devices,
ercutaneous hemodynamic support devices, and secondary pre-
ention. Additionally, the committee reviewed documents
elated to the subject matter previously published by the
CCF and AHA. References selected and published in this
ocument are representative and not all-inclusive.
To provide clinicians with a comprehensive set of data,
henever deemed appropriate or when published, the ab-
olute risk difference and number needed to treat or harm
ill be provided in the guideline, along with confidence
ntervals (CIs) and data related to the relative treatment
ffects such as odds ratio (OR), relative risk, hazard ratio
HR), or incidence rate ratio.
The focus of this guideline is the safe, appropriate, and
fficacious performance of PCI. The risks of PCI must be
alanced against the likelihood of improved survival, symp-
oms, or functional status. This is especially important in
atients with SIHD.
1.2. Organization of the Writing Committee
The committee was composed of physicians with expertise
in interventional cardiology, general cardiology, critical care
cardiology, cardiothoracic surgery, clinical trials, and health
services research. The committee included representatives
from the ACCF, AHA, and SCAI.
1.3. Document Review and Approval
This document was reviewed by 2 official reviewers nomi-
nated by the ACCF, AHA, and SCAI, as well as 21
individual content reviewers (including members of the
ACCF Interventional Scientific Council and ACCF Sur-
geons’ Scientific Council). All information on reviewers’
RWI was distributed to the writing committee and is
published in this document (Appendix 2). This document
was approved for publication by the governing bodies of the
ACCF, AHA, and SCAI.
1.4. PCI Guidelines: History and Evolution
In 1982, a 2-page manuscript titled “Guidelines for the
Performance of Percutaneous Transluminal Coronary An-
gioplasty” was published in Circulation (4). The document,
hich addressed the specific expertise and experience phy-
icians should have to perform balloon angioplasty, as well
s laboratory requirements and the need for surgical sup-port, was written by an ad hoc group whose members
included Andreas Grüntzig. In 1980, the ACC and the
AHA established the Task Force on Assessment of Diag-
nostic and Therapeutic Cardiovascular Procedures, which
was charged with the development of guidelines related to
the role of new therapeutic approaches and of specific
noninvasive and invasive procedures in the diagnosis and
management of cardiovascular disease. The first ACC/
AHA Task Force report on guidelines for coronary balloon
angioplasty was published in 1988 (5). The 18-page docu-
ment discussed and made recommendations about lesion
classification and success rates, indications for and contra-
indications to balloon angioplasty, institutional review of
angioplasty procedures, ad hoc angioplasty after angiogra-
phy, and on-site surgical backup. Further iterations of the
guidelines were published in 1993 (6), 2001 (7), and 2005
(8). In 2007 and 2009, focused updates to the guideline
were published to expeditiously address new study results
and recent changes in the field of interventional cardiology
(9,10). The 2009 focused update is notable in that there
was direct collaboration between the writing committees
for the STEMI guidelines and the PCI guidelines,
resulting in a single publication of focused updates on
STEMI and PCI (10).
The evolution of the PCI guideline reflects the growth of
knowledge in the field and parallels the many advances and
innovations in the field of interventional cardiology, includ-
ing primary PCI, BMS and DES, intravascular ultrasound
(IVUS) and physiologic assessments of stenosis, and newer
antiplatelet and anticoagulant therapies. The 2011 iteration
of the guideline continues this process, addressing ethical
aspects of PCI, vascular access considerations, CAD
revascularization including hybrid revascularization, re-
vascularization before noncardiac surgery, optical coher-
ence tomography, advanced hemodynamic support de-
vices, no-reflow therapies, and vascular closure devices.
Most of this document is organized according to “patient
flow,” consisting of preprocedural considerations, proce-
dural considerations, and postprocedural considerations.
In a major undertaking, the STEMI, PCI, and coronary
artery bypass graft (CABG) surgery guidelines were
written concurrently, with additional collaboration with
the SIHD guideline writing committee, allowing greater
collaboration between the different writing committees
on topics such as PCI in STEMI and revascularization
strategies in patients with CAD (including unprotected
left main PCI, multivessel disease revascularization, and
hybrid procedures).
In accordance with direction from the Task Force and
feedback from readers, in this iteration of the guideline,
the text has been shortened, with an emphasis on
summary statements rather than detailed discussion of
numerous individual trials. Online supplemental evidence
and summary tables have been created to document the
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recommendations.
2. CAD Revascularization
Recommendations and text in this section are the result of
extensive collaborative discussions between the PCI and
CABG writing committees, as well as key members of the
SIHD and UA/NSTEMI writing committees. Certain
issues, such as older versus more contemporary studies,
primary analyses versus subgroup analyses, and prospective
versus post hoc analyses, have been carefully weighed in
designating COR and LOE; they are addressed in the
appropriate corresponding text. The goals of revasculariza-
tion for patients with CAD are to 1) improve survival
and/or 2) relieve symptoms.
Revascularization recommendations in this section are
predominantly based on studies of patients with symptom-
atic SIHD and should be interpreted in this context. As
discussed later in this section, recommendations on the type
of revascularization are, in general, applicable to patients
with UA/NSTEMI. In some cases (e.g., unprotected left
main CAD), specific recommendations are made for pa-
tients with UA/NSTEMI or STEMI.
Historically, most studies of revascularization have been
based on and reported according to angiographic criteria.
Most studies have defined a “significant” stenosis as 70%
diameter narrowing; therefore, for revascularization deci-
sions and recommendations in this section, a “significant”
stenosis has been defined as 70% diameter narrowing
50% for left main CAD). Physiological criteria, such as
n assessment of fractional flow reserve (FFR), has been
sed in deciding when revascularization is indicated. Thus,
or recommendations about revascularization in this section,
oronary stenoses with FFR0.80 can also be considered to
e “significant” (11,12).
As noted, the revascularization recommendations have
een formulated to address issues related to 1) improved
urvival and/or 2) improved symptoms. When one method
f revascularization is preferred over the other for improved
urvival, this consideration, in general, takes precedence
ver improved symptoms. When discussing options for
evascularization with the patient, he or she should under-
tand when the procedure is being performed in an attempt
o improve symptoms, survival, or both.
Although some results from the SYNTAX (Synergy
etween Percutaneous Coronary Intervention with TAXUS
nd Cardiac Surgery) study are best characterized as sub-
roup analyses and “hypothesis generating,” SYNTAX
onetheless represents the latest and most comprehensive
omparison of PCI and CABG (13,14). Therefore, the
esults of SYNTAX have been considered appropriately
hen formulating our revascularization recommendations.
lthough the limitations of using the SYNTAX score forertain revascularization recommendations are recognized,the SYNTAX score is a reasonable surrogate for the extent
of CAD and its complexity and serves as important infor-
mation that should be considered when making revascular-
ization decisions. Recommendations that refer to SYNTAX
scores use them as surrogates for the extent and complexity
of CAD.
Revascularization recommendations to improve survival and
symptoms are provided in the following text and are summa-
rized in Tables 2 and 3. References to studies comparing
revascularization with medical therapy are presented when
available for each anatomic subgroup.
See Online Data Supplements 1 and 2 for additional data
egarding the survival and symptomatic benefits with CABG or
CI for different anatomic subsets.
2.1. Heart Team Approach to
Revascularization Decisions: Recommendations
CLASS I
1. A Heart Team approach to revascularization is recommended in
patients with unprotected left main or complex CAD (14–16). (Level
of Evidence: C)
CLASS IIa
1. Calculation of the Society of Thoracic Surgeons (STS) and SYNTAX
scores is reasonable in patients with unprotected left main and
complex CAD (13,14,17–22). (Level of Evidence: B)
One protocol used in RCTs (14–16,23) often involves a
multidisciplinary approach referred to as the Heart Team.
Composed of an interventional cardiologist and a cardiac
surgeon, the Heart Team 1) reviews the patient’s medical
condition and coronary anatomy, 2) determines that PCI
and/or CABG are technically feasible and reasonable, and
3) discusses revascularization options with the patient before
a treatment strategy is selected. Support for using a Heart
Team approach comes from reports that patients with
complex CAD referred specifically for PCI or CABG in
concurrent trial registries have lower mortality rates than
those randomly assigned to PCI or CABG in controlled
trials (15,16).
The SIHD, PCI, and CABG guideline writing commit-
tees endorse a Heart Team approach in patients with
unprotected left main CAD and/or complex CAD in whom
the optimal revascularization strategy is not straightforward.
A collaborative assessment of revascularization options, or
the decision to treat with GDMT without revascularization,
involving an interventional cardiologist, a cardiac surgeon,
and (often) the patient’s general cardiologist, followed by
discussion with the patient about treatment options, is
optimal. Particularly in patients with SIHD and unpro-
tected left main and/or complex CAD for whom a revas-
cularization strategy is not straightforward, an approach has
been endorsed that involves terminating the procedure after
diagnostic coronary angiography is completed: this allows a
thorough discussion and affords both the interventional
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Anatomic
Setting COR LOE References
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C (14–16)
CABG and PCI IIa—Calculation of STS and SYNTAX scores B (13,14,17–22)
UPLM*
CABG I B (24–30)
PCI IIa—For SIHD when both of the following are present:
● Anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood
of good long-term outcome (e.g., a low SYNTAX score of 22, ostial or trunk left main CAD)
● Clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (e.g.,
STS-predicted risk of operative mortality 5%)
B (13,17,19,23,31–48)
IIa—For UA/NSTEMI if not a CABG candidate B (13,36–39,44,45,47–49)
IIa—For STEMI when distal coronary flow is TIMI flow grade 3 and PCI can be performed more rapidly
and safely than CABG
C (33,50,51)
IIb—For SIHD when both of the following are present:
● Anatomic conditions associated with a low to intermediate risk of PCI procedural complications and
an intermediate to high likelihood of good long-term outcome (e.g., low-intermediate SYNTAX score
of 33, bifurcation left main CAD)
● Clinical characteristics that predict an increased risk of adverse surgical outcomes (e.g., moderate-
severe COPD, disability from prior stroke, or prior cardiac surgery; STS-predicted risk of operative
mortality 2%)
B (13,17,19,23,31–48,52)
III: Harm—For SIHD in patients (versus performing CABG) with unfavorable anatomy for PCI and who are
good candidates for CABG
B (13,17,19,24–32)
3-vessel disease with or without proximal LAD artery disease*
CABG I B (26,30 53–56)
IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel CAD (e.g., SYNTAX score
22) who are good candidates for CABG.
B (32,46,56,71,72)
PCI IIb—Of uncertain benefit B (26,46,53,56,82)
2-vessel disease with proximal LAD artery disease*
CABG I B (26,30,53–56)
PCI IIb—Of uncertain benefit B (26,53,56,82)
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B (60–63)
IIb—Of uncertain benefit without extensive ischemia C (56)
PCI IIb—Of uncertain benefit B (26,53,56,82)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term benefit B (30,56,69,70)
PCI IIb—Of uncertain benefit B (26,53,56,82)
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B (30,53,60,61,94–98)
PCI III: Harm B (30,53,60,61,94–98)
LV dysfunction
CABG IIa—EF 35% to 50% B (30,64–68)
CABG IIb—EF 35% without significant left main CAD B (30,64–68,83,84)
PCI Insufficient data N/A
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B (57–59)
PCI I C (57)
No anatomic or physiologic criteria for revascularization
CABG III: Harm B (30,53,60,61,94–98)
PCI III: Harm B (30,53,60,61,94–98)
*In patients with multivessel disease who also have diabetes, it is reasonable to choose CABG (with LIMA) over PCI (62,74–81) (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD, left anterior
descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; STEMI,
ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial
Infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.
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revascularization options with the patient. Because the STS
score and the SYNTAX score have been shown to predict
dverse outcomes in patients undergoing CABG and PCI,
espectively, calculation of these scores is often useful in
aking revascularization decisions (13,14,17–22).
2.2. Revascularization to Improve
Survival: Recommendations
Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is recommended for patients with signif-
icant (50% diameter stenosis) left main coronary artery stenosis
(24–30). (Level of Evidence: B)
CLASS IIa
1. PCI to improve survival is reasonable as an alternative to CABG in
selected stable patients with significant (50% diameter stenosis)
unprotected left main CAD with: 1) anatomic conditions associated
with a low risk of PCI procedural complications and a high likelihood
of good long-term outcome (e.g., a low SYNTAX score [22], ostial
or trunk left main CAD); and 2) clinical characteristics that predict a
significantly increased risk of adverse surgical outcomes (e.g.,
STS-predicted risk of operative mortality 5%) (13,17,19,23,31–48).
(Level of Evidence: B)
2. PCI to improve survival is reasonable in patients with UA/NSTEMI
when an unprotected left main coronary artery is the culprit lesion
and the patient is not a candidate for CABG (13,36–39,44,45,47–
49). (Level of Evidence: B)
3. PCI to improve survival is reasonable in patients with acute STEMI
when an unprotected left main coronary artery is the culprit lesion,
distal coronary flow is less than TIMI (Thrombolysis In Myocardial
Infarction) grade 3, and PCI can be performed more rapidly and
safely than CABG (33,50,51). (Level of Evidence: C)
CLASS IIb
1. PCI to improve survival may be reasonable as an alternative to
CABG in selected stable patients with significant (50% diameter
stenosis) unprotected left main CAD with: 1) anatomic conditions
Table 3. Revascularization to Improve Symptoms With Signific
r Physiological (FFR<0.80) Coronary Artery Stenoses
Clinical Setting
1 significant stenoses amenable to revascularization and unacceptable
angina despite GDMT
1 significant stenoses and unacceptable angina in whom GDMT cannot b
implemented because of medication contraindications, adverse effects,
patient preferences
Previous CABG with 1 significant stenoses associated with ischemia and
unacceptable angina despite GDMT
Complex 3-vessel CAD (e.g., SYNTAX score 22) with or without involveme
the proximal LAD artery and a good candidate for CABG
Viable ischemic myocardium that is perfused by coronary arteries that are
amenable to grafting
No anatomic or physiologic criteria for revascularization
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, class of recomm
N/A, not applicable; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Per
revascularization.associated with a low to intermediate risk of PCI procedural com-plications and an intermediate to high likelihood of good long-term
outcome (e.g., low-intermediate SYNTAX score of 33, bifurcation
left main CAD); and 2) clinical characteristics that predict an
increased risk of adverse surgical outcomes (e.g., moderate-severe
chronic obstructive pulmonary disease, disability from previous
stroke, or previous cardiac surgery; STS-predicted risk of operative
mortality 2%) (13,17,19,23,31–48,52). (Level of Evidence: B)
CLASS III: HARM
1. PCI to improve survival should not be performed in stable patients
with significant (50% diameter stenosis) unprotected left main
CAD who have unfavorable anatomy for PCI and who are good
candidates for CABG (13,17,19,24–32). (Level of Evidence: B)
Non–Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is beneficial in patients with significant
(70% diameter) stenoses in 3 major coronary arteries (with or
without involvement of the proximal left anterior descending [LAD]
artery) or in the proximal LAD plus 1 other major coronary artery
(26,30,53–56). (Level of Evidence: B)
2. CABG or PCI to improve survival is beneficial in survivors of sudden
cardiac death with presumed ischemia-mediated ventricular tachy-
cardia caused by significant (70% diameter) stenosis in a major
coronary artery. (CABG Level of Evidence: B [57–59]; PCI Level of
Evidence: C [57])
CLASS IIa
1. CABG to improve survival is reasonable in patients with significant
(70% diameter) stenoses in 2 major coronary arteries with severe
or extensive myocardial ischemia (e.g., high-risk criteria on stress
testing, abnormal intracoronary hemodynamic evaluation, or20%
perfusion defect by myocardial perfusion stress imaging) or target
vessels supplying a large area of viable myocardium (60–63). (Level
of Evidence: B)
2. CABG to improve survival is reasonable in patients with mild-
moderate left ventricular (LV) systolic dysfunction (ejection fraction
[EF] 35% to 50%) and significant (70% diameter stenosis) multi-
vessel CAD or proximal LAD coronary artery stenosis, when viable
myocardium is present in the region of intended revascularization
natomic (>50% Left Main or >70% Non–Left Main CAD)
COR LOE References
ICABG
IPCI
A (82,99–108)
IIaCABG
IIaPCI
C N/A
IIaPCI C (86,89,92)
IIbCABG C (93)
IIaCABG preferred
over PCI
B (32,46,56,71,72)
IIbTMR as an
adjunct to CABG
B (109–113)
III: HarmCABG
III: HarmPCI
C N/A
n; FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; LOE, level of evidence;
us Coronary Intervention with TAXUS and Cardiac Surgery; and TMR, transmyocardial laserant A
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survival is reasonable in patients with significant (70% diameter)
stenosis in the proximal LAD artery and evidence of extensive
ischemia (30,56,69,70). (Level of Evidence: B)
. It is reasonable to choose CABG over PCI to improve survival in
patients with complex 3-vessel CAD (e.g., SYNTAX score 22), with
or without involvement of the proximal LAD artery who are good
candidates for CABG (32,46,56,71,72). (Level of Evidence: B)
. CABG is probably recommended in preference to PCI to improve
survival in patients with multivessel CAD and diabetes mellitus,
particularly if a LIMA graft can be anastomosed to the LAD artery
(62,74–81). (Level of Evidence: B)
CLASS IIb
1. The usefulness of CABG to improve survival is uncertain in patients
with significant (70%) diameter stenoses in 2 major coronary
arteries not involving the proximal LAD artery and without extensive
ischemia (56). (Level of Evidence: C)
. The usefulness of PCI to improve survival is uncertain in patients
with 2- or 3-vessel CAD (with or without involvement of the proximal
LAD artery) or 1-vessel proximal LAD disease (26,53,56,82). (Level
of Evidence: B)
. CABG might be considered with the primary or sole intent of
improving survival in patients with SIHD with severe LV systolic
dysfunction (EF35%) whether or not viablemyocardium is present
(30,64–68,83,84). (Level of Evidence: B)
. The usefulness of CABG or PCI to improve survival is uncertain in
patients with previous CABG and extensive anterior wall ischemia
on noninvasive testing (85–93). (Level of Evidence: B)
CLASS III: HARM
1. CABG or PCI should not be performed with the primary or sole intent
to improve survival in patients with SIHD with 1 or more coronary
stenoses that are not anatomically or functionally significant (e.g.,
70% diameter non–left main coronary artery stenosis, FFR0.80,
no or only mild ischemia on noninvasive testing), involve only the
left circumflex or right coronary artery, or subtend only a small area
of viable myocardium (30,53,60,61,94–98). (Level of Evidence: B)
2.3. Revascularization to Improve Symptoms:
Recommendations
CLASS I
1. CABG or PCI to improve symptoms is beneficial in patients with 1 or
more significant (70% diameter) coronary artery stenoses ame-
nable to revascularization and unacceptable angina despite GDMT
(82,99–108). (Level of Evidence: A)
CLASS IIa
1. CABG or PCI to improve symptoms is reasonable in patients with 1
or more significant (70% diameter) coronary artery stenoses and
unacceptable angina for whom GDMT cannot be implemented
because of medication contraindications, adverse effects, or patient
preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous
CABG, 1 or more significant (70% diameter) coronary artery
stenoses associated with ischemia, and unacceptable angina de-
spite GDMT (86,89,92). (Level of Evidence: C)
. It is reasonable to choose CABG over PCI to improve symptoms inpatients with complex 3-vessel CAD (e.g., SYNTAX score 22), withor without involvement of the proximal LAD artery who are good
candidates for CABG (32,46,56,72,73). (Level of Evidence: B)
CLASS IIb
1. CABG to improve symptoms might be reasonable for patients with
previous CABG, 1 or more significant (70% diameter) coronary
artery stenoses not amenable to PCI, and unacceptable angina
despite GDMT (93). (Level of Evidence: C)
. Transmyocardial laser revascularization (TMR) performed as an
adjunct to CABG to improve symptoms may be reasonable in
patients with viable ischemic myocardium that is perfused by
arteries that are not amenable to grafting (109–113). (Level of
Evidence: B)
CLASS III: HARM
1. CABG or PCI to improve symptoms should not be performed in
patients who do not meet anatomic (50% diameter left main or
70% non–left main stenosis diameter) or physiological (e.g.,
abnormal FFR) criteria for revascularization. (Level of Evidence: C)
2.4. CABG Versus Contemporaneous
Medical Therapy
In the 1970s and 1980s, 3 RCTs established the survival
benefit of CABG compared with contemporaneous (al-
though minimal by current standards) medical therapy
without revascularization in certain subjects with stable
angina: the Veterans Affairs Cooperative Study (114), Eu-
ropean Coronary Surgery Study (55), and CASS (Coronary
Artery Surgery Study) (115). Subsequently, a 1994 meta-
analysis of 7 studies that randomized a total of 2,649
patients to medical therapy or CABG (30) showed that
CABG offered a survival advantage over medical therapy for
patients with left main or 3-vessel CAD. The studies also
established that CABG is more effective than medical
therapy for relieving anginal symptoms. These studies
have been replicated only once during the past decade. In
MASS II (Medicine, Angioplasty, or Surgery Study II),
patients with multivessel CAD who were treated with
CABG were less likely than those treated with medical
therapy to have a subsequent MI, need additional revas-
cularization, or experience cardiac death in the 10 years
after randomization (104).
Surgical techniques and medical therapy have improved
substantially during the intervening years. As a result, if
CABG were to be compared with GDMT in RCTs today,
the relative benefits for survival and angina relief observed
several decades ago might no longer be observed. Con-
versely, the concurrent administration of GDMT may
substantially improve long-term outcomes in patients
treated with CABG in comparison with those receiving
medical therapy alone. In the BARI 2D (Bypass Angio-
plasty Revascularization Investigation 2 Diabetes) trial of
patients with diabetes mellitus, no significant difference in
risk of mortality in the cohort of patients randomized to
GDMT plus CABG or GDMT alone was observed,
although the study was not powered for this endpoint,
excluded patients with significant left main CAD, and
included only a small percentage of patients with proximal
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(116). The PCI and CABG guideline writing committees
endorse the performance of the ISCHEMIA (International
Study of Comparative Health Effectiveness with Medical
and Invasive Approaches) trial, which will provide contem-
porary data on the optimal management strategy (medical
therapy or revascularization with CABG or PCI) of patients
with SIHD, including multivessel CAD, and moderate to
severe ischemia.
2.5. PCI Versus Medical Therapy
Although contemporary interventional treatments have
lowered the risk of restenosis compared with earlier tech-
niques, meta-analyses have failed to show that the intro-
duction of BMS confers a survival advantage over balloon
angioplasty (117–119) or that the use of DES confers a
survival advantage over BMS (119,120).
No study to date has demonstrated that PCI in patients
with SIHD improves survival rates (26,53,56,82,116,
119,121–124). Neither COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation)
(82) nor BARI 2D (116), which treated all patients with
contemporary optimal medical therapy, demonstrated any
survival advantage with PCI, although these trials were not
specifically powered for this endpoint. Although 1 large anal-
ysis evaluating 17 RCTs of PCI versus medical therapy
(including 5 trials of subjects with acute coronary syndromes
[ACS]) found a 20% reduction in death with PCI compared
with medical therapy (123), 2 other large analyses did not
(119,122). An evaluation of 13 studies reporting the data from
5,442 patients with nonacute CAD showed no advantage of
PCI over medical therapy for the individual endpoints of
all-cause death, cardiac death or MI, or nonfatal MI (124).
Evaluation of 61 trials of PCI conducted over several decades
shows that despite improvements in PCI technology and
pharmacotherapy, PCI has not been demonstrated to reduce
the risk of death or MI in patients without recent ACS (119).
The findings from individual studies and systematic reviews
of PCI versus medical therapy can be summarized as follows:
• PCI reduces the incidence of angina (82,99,104,
107,108,125).
• PCI has not been demonstrated to improve survival in
stable patients (119,121,122).
• PCI may increase the short-term risk of MI (82,121,
125,126).
• PCI does not lower the long-term risk of MI (82,116,
119,121,122,126).
2.6. CABG Versus PCI
The results of 26 RCTs comparing CABG and PCI have
been published: Of these, 9 compared CABG with balloon
angioplasty (75,105,128–142), 14 compared CABG with
BMS implantation (88,143–160), and 3 compared CABG
with DES implantation (14,161,162).2.6.1. CABG Versus Balloon Angioplasty or BMS
A systematic review of the 22 RCTs comparing CABG
with balloon angioplasty or BMS implantation concluded
the following (163):
1. Survival was similar for CABG and PCI (with balloon
angioplasty or BMS) at 1 year and 5 years. Survival was
similar for CABG and PCI in subjects with 1-vessel
CAD (including those with disease of the proximal
portion of the LAD artery) or multivessel CAD.
2. Incidence of MI was similar at 5 years after randomiza-
tion.
3. Procedural stroke occurred more commonly with CABG
than with PCI (1.2% versus 0.6%).
4. Relief of angina was accomplished more effectively with
CABG than with PCI 1 year after randomization and 5
years after randomization.
5. During the first year after randomization, repeat coro-
nary revascularization was performed less often after
CABG than after PCI (3.8% versus 26.5%). This was
also demonstrated after 5 years of follow-up (9.8% versus
46.1%). This difference was more pronounced with
balloon angioplasty than with BMS.
A collaborative analysis of data from 10 RCTs comparing
CABG with balloon angioplasty (6 trials) or with BMS
implantation (4 trials) (164) permitted subgroup analyses of
the data from the 7,812 patients. No difference was noted
with regard to mortality rate 5.9 years after randomization
or the composite endpoint of death or MI. Repeat revascu-
larization and angina were noted more frequently in those
treated with balloon angioplasty or BMS implantation
(164). The major new observation of this analysis was that
CABG was associated with better outcomes in patients with
diabetes mellitus and in those 65 years old. Of interest,
the relative outcomes of CABG and PCI were not influ-
enced by other patient characteristics, including the number
of diseased coronary arteries.
The aforementioned meta-analysis and systematic review
(163,164) comparing CABG and balloon angioplasty or
BMS implantation were limited in several ways:
1. Many trials did not report outcomes for other important
patient subsets. For example, the available data are
insufficient to determine if race, obesity, renal dysfunc-
tion, peripheral arterial disease, or previous coronary
revascularization affected the comparative outcomes of
CABG and PCI.
2. Most of the patients enrolled in these trials were male,
and most had 1- or 2-vessel CAD and normal LV
systolic function (EF 50%)—subjects known to be
unlikely to derive a survival benefit and less likely to
experience complications after CABG (30).
3. The patients enrolled in these trials represented only a
small fraction (generally5% to 10%) of those who were
screened. For example, most screened patients with
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considered for randomization.
ee Online Data Supplements 3 and 4 for additional data
omparing CABG with PCI.
.6.2. CABG Versus DES
lthough the results of 9 observational studies comparing
ABG and DES implantation have been published
32,165–172), most of them had short (12 to 24 months)
ollow-up periods. In a meta-analysis of 24,268 patients with
ultivessel CAD treated with CABG or DES (173), the
ncidences of death and MI were similar for the 2 procedures,
ut the frequency with which repeat revascularization was
erformed was roughly 4 times higher after DES implantation.
nly 1 large RCT comparing CABG and DES implantation
as been published. The SYNTAX trial randomly assigned
,800 patients (of a total of 4,337 who were screened) to
eceive DES or CABG (14,46). Major adverse cardiac events
MACE), a composite of death, stroke, MI, or repeat revas-
ularization during the 3 years after randomization, occurred in
0.2% of CABG patients and 28.0% of those undergoing DES
mplantation (p0.001). The rates of death and stroke were
imilar; however, MI (3.6% for CABG, 7.1% for DES) and
epeat revascularization (10.7% for CABG, 19.7% for DES)
ere more likely to occur with DES implantation (46).
In SYNTAX, the extent of CAD was assessed using the
YNTAX score, which is based on the location, severity, and
xtent of coronary stenoses, with a low score indicating less
omplicated anatomic CAD. In post hoc analyses, a low score
as defined as 22; intermediate, 23 to 32; and high, 33.
he occurrence of MACE correlated with the SYNTAX score
or DES patients but not for those undergoing CABG. At
2-month follow-up, the primary endpoint was similar for
ABG and DES in those with a low SYNTAX score. In
ontrast, MACE occurred more often after DES implantation
Figure 1. Cumulative Incidence of MACE in Patients With 3-Vesse
n the SYNTAX Trial Treated With Either CABG or PCI
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; MACE, m
and SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS andhan after CABG in those with an intermediate or high nYNTAX score (14). At 3 years of follow-up, the mortality
ate was greater in subjects with 3-vessel CAD treated with
CI than in those treated with CABG (6.2% versus 2.9%). The
ifferences in MACE between those treated with PCI or CABG
ncreased with an increasing SYNTAX score (Figure 1) (46).
Although the utility of using a SYNTAX score in
everyday clinical practice remains uncertain, it seems rea-
sonable to conclude from SYNTAX and other data that
outcomes of patients undergoing PCI or CABG in those
with relatively uncomplicated and lesser degrees of CAD are
comparable, whereas in those with complex and diffuse
CAD, CABG appears to be preferable (46).
See Online Data Supplements 5 and 6 for additional data
comparing CABG with DES.
2.7. Left Main CAD
2.7.1. CABG or PCI Versus Medical Therapy for
Left Main CAD
CABG confers a survival benefit over medical therapy in
patients with left main CAD. Subgroup analyses from RCTs
performed 3 decades ago included 91 patients with left main
CAD in the Veterans Administration Cooperative Study (28).
A meta-analysis of these trials demonstrated a 66% reduction
in relative risk in mortality with CABG, with the benefit
extending to 10 years (30). The CASS Registry (24) contained
data from 1,484 patients with 50% diameter stenosis left
ain CAD initially treated surgically or nonsurgically. Median
urvival duration was 13.3 years in the surgical group; and 6.6
ears in the medical group. The survival benefit of CABG over
edical therapy appeared to extend to 53 asymptomatic
atients with left main CAD in the CASS Registry (29).
ther therapies that subsequently have been shown to be
ssociated with improved long-term outcome, such as the use
f aspirin, statins, and internal mammary artery grafting, were
Based on SYNTAX Score at 3-Year Follow-Up
dverse cardiovascular event; PCI, percutaneous coronary intervention;
c Surgery. Adapted with permission from Kappetein (46).l CAD
ajor aot widely used in that era.
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medical therapy in patients with “unprotected” left main
CAD do not exist.
2.7.2. Studies Comparing PCI Versus CABG for
Left Main CAD
Of all subjects undergoing coronary angiography, approxi-
mately 4% are found to have left main CAD (175), 80%
of whom have significant (70% diameter) stenoses in
other epicardial coronary arteries.
Published cohort studies have found that major clinical
outcomes are similar with PCI or CABG 1 year after
revascularization and that mortality rates are similar at 1, 2,
and 5 years of follow-up; however, the risk of needing
target-vessel revascularization is significantly higher with
stenting than with CABG.
In the SYNTAX trial, 45% of screened patients with
unprotected left main CAD had complex disease that
prevented randomization; 89% of these underwent CABG
(13,14). In addition, 705 of the 1,800 patients who were
randomized had revascularization for unprotected left main
CAD. The majority of patients with left main CAD and a
low SYNTAX score had isolated left main CAD or left
main CAD plus 1-vessel CAD; the majority of those with
an intermediate score had left main CAD plus 2-vessel
CAD; and most of those with a high SYNTAX score had
left main CAD plus 3-vessel CAD. At 1 year, rates of
all-cause death and MACE were similar for the 2 groups
(13). Repeat revascularization rates were higher in the PCI
group than the CABG group (11.8% versus 6.5%), but
stroke occurred more often in the CABG group (2.7%
versus 0.3%). At 3 years of follow-up, the incidence of death
in those undergoing left main CAD revascularization with
low or intermediate SYNTAX scores (32) was 3.7% after
PCI and 9.1% after CABG (p0.03), whereas in those with
a high SYNTAX score (33), the incidence of death after
3 years was 13.4% after PCI and 7.6% after CABG
(p0.10) (46). Because the primary endpoint of SYNTAX
was not met (i.e., noninferiority comparison of CABG and
PCI), these subgroup analyses need to be considered in that
context.
In the LE MANS (Study of Unprotected Left Main
Stenting Versus Bypass Surgery) trial (23), 105 patients
with left main CAD were randomized to receive PCI or
CABG. Although a low proportion of patients treated with
PCI received DES (35%) and a low proportion of patients
treated with CABG received internal mammary grafts
(72%), the outcomes at 30 days and 1 year were similar
between the groups. In the PRECOMBAT (Premier of
Randomized Comparison of Bypass Surgery versus Angio-
plasty Using Sirolimus-Eluting Stent in Patients with Left
Main Coronary Artery Disease) trial of 600 patients with
left main disease, the composite endpoint of death, MI, or
stroke at 2 years occurred in 4.4% of patients treated with
PCI patients and 4.7% of patients treated with CABG, but
ischemia-driven target-vessel revascularization was moreoften required in the patients treated with PCI (9.0% versus
4.2%) (52).
The results from these 3 RCTs suggest (but do not
definitively prove) that major clinical outcomes in selected
patients with left main CAD are similar with CABG and
PCI at 1- to 2-year follow-up, but repeat revascularization
rates are higher after PCI than after CABG. RCTs with
extended follow-up of 5 years are required to provide
definitive conclusions about the optimal treatment of left
main CAD. In a meta-analysis of 8 cohort studies and 2
RCTs (41), death, MI, and stroke occurred with similar
frequency in the PCI- and CABG-treated patients at 1, 2,
and 3 years of follow-up. Target-vessel revascularization was
performed more often in the PCI group at 1 year (OR:
4.36), 2 years (OR: 4.20), and 3 years (OR: 3.30).
See Online Data Supplements 7 to 12 for additional data
comparing PCI with CABG for left main CAD.
2.7.3. Revascularization Considerations for
Left Main CAD
Although CABG has been considered the “gold standard”
for unprotected left main CAD revascularization, more
recently PCI has emerged as a possible alternative mode of
revascularization in carefully selected patients. Lesion loca-
tion is an important determinant when considering PCI for
unprotected left main CAD. Stenting of the left main
ostium or trunk is more straightforward than treating distal
bifurcation or trifurcation stenoses, which generally requires
a greater degree of operator experience and expertise (176).
In addition, PCI of bifurcation disease is associated with
higher restenosis rates than when disease is confined to the
ostium or trunk (39,177). Although lesion location influ-
ences technical success and long-term outcomes after PCI,
location exerts a negligible influence on the success of
CABG. In subgroup analyses, patients with left main CAD
and a SYNTAX score 33 with more complex or extensive
CAD had a higher mortality rate with PCI than with
CABG (46). Physicians can estimate operative risk for all
CABG candidates using a standard instrument, such as the
risk calculator from the STS database. The above consid-
erations are important factors when choosing among revas-
cularization strategies for unprotected left main CAD and
have been factored into revascularization recommendations.
Use of a Heart Team approach has been recommended in
cases in which the choice of revascularization is not straight-
forward. As discussed in Section 2.9.7, the ability of the
patient to tolerate and comply with dual antiplatelet therapy
(DAPT) is also an important consideration in revascular-
ization decisions.
The 2005 PCI guideline (8) recommended routine an-
giographic follow-up 2 to 6 months after stenting for
unprotected left main CAD. However, because angiography
has limited ability to predict stent thrombosis and the
results of SYNTAX suggest good intermediate-term results
for PCI in subjects with left main CAD, this recommen-
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update (10).
Experts have recommended immediate PCI for unpro-
tected left main CAD in the setting of STEMI (51). The
impetus for such a strategy is greatest when left main CAD
is the site of the culprit lesion, antegrade coronary flow is
diminished (e.g., TIMI flow grade 0, 1, or 2), the patient is
hemodynamically unstable, and it is believed that PCI can
be performed more quickly than CABG. When possible,
the interventional cardiologist and cardiac surgeon should
decide together on the optimal form of revascularization for
these subjects, although it is recognized that these patients
are usually critically ill and therefore not amenable to a
prolonged deliberation or discussion of treatment options.
2.8. Proximal LAD Artery Disease
A cohort study (53) and a meta-analysis (30) from the 1990s
suggested that CABG confers a survival advantage over
contemporaneous medical therapy for patients with disease
in the proximal segment of the LAD artery. Cohort studies
and RCTs (30,133,146,148,161,178 –181) as well as
collaborative- and meta-analyses (164,182–184) showed
that PCI and CABG result in similar survival rates in these
patients.
See Online Data Supplement 13 for additional data regarding
proximal LAD artery revascularization.
2.9. Clinical Factors That May Influence the Choice
of Revascularization
2.9.1. Diabetes Mellitus
An analysis performed in 2009 of data on 7,812 patients
(1,233 with diabetes) in 10 RCTs demonstrated a worse
long-term survival rate in patients with diabetes mellitus
after balloon angioplasty or BMS implantation than after
CABG (164). The BARI 2D trial (116) randomly assigned
2,368 patients with type 2 diabetes and CAD to undergo
intensive medical therapy or prompt revascularization with
PCI or CABG, according to whichever was thought to be
more appropriate. By study design, those with less extensive
CAD more often received PCI, whereas those with more
extensive CAD were more likely to be treated with CABG.
Figure 2. 1-Year Mortality After Revascularization for Multivessel
An OR of 1 suggests an advantage of CABG over PCI. ARTS I indicates Arterial Rev
tigation I (74); CABG, coronary artery bypass graft; CAD, coronary artery disease; CARDia
cine, Angioplasty, or Surgery Study II (78); OR, odds ratio; PCI, percutaneous coronary inte
TAXUS and Cardiac Surgery; and W, weighted (76).The study was not designed to compare PCI with CABG.
At 5-year follow-up, no difference in rates of survival or
MACE between the medical therapy group and those
treated with revascularization was noted. In the PCI stra-
tum, no significant difference in MACE between medical
therapy and revascularization was demonstrated (DES in
35%; BMS in 56%); in the CABG stratum, MACE
occurred less often in the revascularization group. One-year
follow-up data from the SYNTAX study demonstrated a
higher rate of repeat revascularization in patients with diabetes
mellitus treated with PCI than with CABG, driven by a tendency
for higher repeat revascularization rates in those with higher
SYNTAX scores undergoing PCI (76). In summary, in
subjects requiring revascularization for multivessel CAD,
current evidence supports diabetes mellitus as an impor-
tant factor when deciding on a revascularization strategy,
particularly when complex or extensive CAD is present
(Figure 2).
See Online Data Supplements 14 and 15 for additional data
regarding diabetes mellitus.
2.9.2. Chronic Kidney Disease
Cardiovascular morbidity and mortality rates are markedly
increased in patients with chronic kidney disease (CKD)
when compared with age-matched controls without CKD.
The mortality rate for patients on hemodialysis is20% per
year, and approximately 50% of deaths among these patients
are due to a cardiovascular cause (187,188).
To date, randomized comparisons of coronary revascu-
larization (with CABG or PCI) and medical therapy in
patients with CKD have not been reported. Some, but not
all, observational studies or subgroup analyses have demon-
strated an improved survival rate with revascularization
compared with medical therapy in patients with CKD and
multivessel CAD (189–191), despite the fact that the
incidence of periprocedural complications (e.g., death, MI,
stroke, infection, renal failure) is increased in patients with
CKD compared with those without renal dysfunction.
Some studies have shown that CABG is associated with a
greater survival benefit than PCI among patients with severe
renal dysfunction (190–196).
se and Diabetes Mellitus
rization Therapy Study I (185); BARI I, Bypass Angioplasty Revascularization Inves-
nary Artery Revascularization in Diabetes (186); CI, confidence interval; MASS II, Medi-Disea
ascula
, Cororvention; SYNTAX, Synergy between Percutaneous Coronary Intervention with
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Most patients undergoing CABG receive complete or
nearly complete revascularization, which seems to influence
long-term prognosis positively (197). In contrast, complete
revascularization is accomplished less often in subjects
receiving PCI (e.g., in 70% of patients), but the extent to
which the absence of complete initial revascularization
influences outcome is less clear. Rates of late survival and
survival free of MI appears to be similar in patients with and
without complete revascularization after PCI. Nevertheless,
the need for subsequent CABG is usually higher in those
whose initial revascularization procedure was incomplete
(compared with those with complete revascularization) after
PCI (198–200).
2.9.4. LV Systolic Dysfunction
Several older studies and a meta-analysis of the data from
these studies reported that patients with LV systolic dys-
function (predominantly mild to moderate in severity) had
better survival with CABG than with medical therapy alone
(30,64–68). For patients with more severe LV systolic
dysfunction, however, the evidence that CABG results in
better survival compared with medical therapy is lacking. In
the STICH (Surgical Treatment for Ischemic Heart Fail-
ure) trial of subjects with LVEF 35% with or without
viability testing, CABG and GDMT resulted in similar
rates of survival (death from any cause, the study’s primary
outcome) after 5 years of follow-up. For a number of
secondary outcomes at this time point, including 1) death
from any cause or hospitalization for heart failure, 2) death
from any cause or hospitalization for cardiovascular causes,
3) death from any cause or hospitalization for any cause, or
4) death from any cause or revascularization with PCI or
CABG, CABG was superior to GDMT. Although the
primary outcome (death from any cause) was similar in the
2 treatment groups after an average of 5 years of follow-up,
the data suggest the possibility that outcomes would differ if
the follow-up were longer in duration; as a result, the study
is being continued to provide follow-up for up to 10 years
(83,84).
Only very limited data comparing PCI with medical
therapy in patients with LV systolic dysfunction are avail-
able (68). In several ways, these data are suboptimal, in that
many studies compared CABG with balloon angioplasty,
many were retrospective, and many were based on cohort or
registry data. Some of the studies demonstrated a similar
survival rate in patients having CABG and PCI
(71,164,201–203), whereas others showed that those under-
going CABG had better outcomes (32). The data that exist
at present on revascularization in patients with CAD and
LV systolic dysfunction are more robust for CABG than for
PCI, although data from contemporary RCTs in this
patient population are lacking. Therefore, the choice of
revascularization in patients with CAD and LV systolic
dysfunction is best based on clinical variables (e.g., coronaryanatomy, presence of diabetes mellitus, presence of CKD),
magnitude of LV systolic dysfunction, patient preferences,
clinical judgment, and consultation between the interven-
tional cardiologist and the cardiac surgeon.
2.9.5. Previous CABG
In patients with recurrent angina after CABG, repeat
revascularization is most likely to improve survival in
subjects at highest risk, such as those with obstruction of
the proximal LAD artery and extensive anterior ischemia
(85–93). Patients with ischemia in other locations and
those with a patent LIMA to the LAD artery are unlikely
to experience a survival benefit from repeat revasculariza-
tion (92).
Cohort studies comparing PCI and CABG among post-
CABG patients report similar rates of mid- and long-term
survival after the 2 procedures (85,88–91,93,204). In the
patient with previous CABG who is referred for revascu-
larization for medically refractory ischemia, factors that may
support the choice of repeat CABG include vessels unsuit-
able for PCI, number of diseased bypass grafts, availability
of the internal mammary artery for grafting chronically
occluded coronary arteries, and good distal targets for bypass
graft placement. Factors favoring PCI over CABG include
limited areas of ischemia causing symptoms, suitable PCI
targets, a patent graft to the LAD artery, poor CABG
targets, and comorbid conditions.
2.9.6. Unstable Angina/Non–ST-Elevation
Myocardial Infarction
The main difference between management of the patient
with SIHD and the patient with UA/NSTEMI is that the
impetus for revascularization is stronger in the setting of
UA/NSTEMI, because myocardial ischemia occurring as
part of an ACS is potentially life threatening, and associated
anginal symptoms are more likely to be reduced with a
revascularization procedure than with GDMT (205–207).
Thus, the indications for revascularization are strengthened
by the acuity of presentation, the extent of ischemia, and the
ability to achieve full revascularization. The choice of
revascularization method is generally dictated by the same
considerations used to decide on PCI or CABG for patients
with SIHD.
2.9.7. DAPT Compliance and
Stent Thrombosis: Recommendation
CLASS III: HARM
1. PCI with coronary stenting (BMS or DES) should not be performed if
the patient is not likely to be able to tolerate and comply with DAPT
for the appropriate duration of treatment based on the type of stent
implanted (208–211). (Level of Evidence: B)
The risk of stent thrombosis is increased dramatically in
patients who prematurely discontinue DAPT, and stent
thrombosis is associated with a mortality rate of 20% to 45%
(208). Because the risk of stent thrombosis with BMS is
greatest in the first 14 to 30 days, this is the generally
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these individuals. Consensus in clinical practice is to treat
DES patients for at least 12 months with DAPT to avoid
late (after 30 days) stent thrombosis (208,212). Therefore,
the ability of the patient to tolerate and comply with at least
30 days of DAPT with BMS treatment and at least 12
months of DAPT with DES treatment is an important
consideration in deciding whether to use PCI to treat
patients with CAD.
2.10. TMR as an Adjunct to CABG
TMR has been used on occasion in patients with severe
angina refractory to GDMT in whom complete revascular-
ization cannot be achieved with PCI and/or CABG. Al-
though the mechanism by which TMR might be efficacious
in these patients is unknown (213,214), several RCTs of
TMR as sole therapy demonstrated a reduction in anginal
symptoms compared with intensive medical therapy alone
(109–111,215–217). A single randomized multicenter com-
parison of TMR (with a holmium:YAG laser) plus CABG
and CABG alone in patients in whom some myocardial
segments were perfused by arteries considered not amenable
to grafting (112) showed a significant reduction in periop-
erative mortality rate (1.5% versus 7.6%, respectively), and
the survival benefit of the TMR–CABG combination was
present after 1 year of follow-up (112). At the same time, a
large retrospective analysis of data from the STS National
Cardiac Database as well as a study of 169 patients from the
Washington Hospital Center who underwent combined
TMR–CABG, showed no difference in adjusted mortality
rate compared with CABG alone (113,218). In short, a
TMR–CABG combination does not appear to improve
survival compared with CABG alone. In selected patients,
however, such a combination may be superior to CABG
alone in relieving angina.
2.11. Hybrid Coronary Revascularization:
Recommendations
CLASS IIa
1. Hybrid coronary revascularization (defined as the planned combina-
tion of LIMA-to-LAD artery grafting and PCI of1 non-LAD coronary
arteries) is reasonable in patients with 1 or more of the following
(219–225) (Level of Evidence: B):
a. Limitations to traditional CABG, such as heavily calcified proxi-
mal aorta or poor target vessels for CABG (but amenable to PCI);
b. Lack of suitable graft conduits;
c. Unfavorable LAD artery for PCI (i.e., excessive vessel tortuosity or
CTO).
CLASS IIb
1. Hybrid coronary revascularization (defined as the planned combina-
tion of LIMA-to-LAD artery grafting and PCI of1 non-LAD coronary
arteries) may be reasonable as an alternative to multivessel PCI or
CABG in an attempt to improve the overall risk-benefit ratio of the
procedures. (Level of Evidence: C)
Hybrid coronary revascularization, defined as the planned
combination of LIMA-to-LAD artery grafting and PCI of
1 non-LAD coronary arteries (226), is intended to com-bine the advantages of CABG (i.e., durability of the LIMA
graft) and PCI (227). Patients with multivessel CAD (e.g.,
LAD and 1 non-LAD stenoses) and an indication for
revascularization are potentially eligible for this approach.
Hybrid revascularization is ideal in patients in whom
technical or anatomic limitations to CABG or PCI alone
may be present and for whom minimizing the invasiveness
(and therefore the risk of morbidity and mortality) of
surgical intervention is preferred (221) (e.g., patients with
severe preexisting comorbidities, recent MI, a lack of
suitable graft conduits, a heavily calcified ascending aorta, or
a non-LAD coronary artery unsuitable for bypass but
amenable to PCI, and situations in which PCI of the LAD
artery is not feasible because of excessive tortuosity or
CTO).
Hybrid coronary revascularization may be performed in a
hybrid suite in one operative setting or as a staged procedure
(i.e., PCI and CABG performed in 2 different operative
suites, separated by hours to 2 days, but typically during the
same hospital stay). Because most hospitals lack a hybrid
operating room, staged procedures are usually performed.
With the staged procedure, CABG before PCI is preferred,
because this approach allows the interventional cardiologist
to 1) verify the patency of the LIMA-to-LAD artery graft
before attempting PCI of other vessels and 2) minimize the
risk of perioperative bleeding that would occur if CABG
were performed after PCI (i.e., while the patient is receiving
DAPT). Because minimally invasive CABG may be asso-
ciated with lower graft patency rates compared with CABG
performed through a midline sternotomy, it seems prudent
to angiographically image all grafts performed through a
minimally invasive approach to confirm graft patency (221).
To date, no RCTs involving hybrid coronary revascular-
ization have been published. Over the past 10 years, several
small, retrospective series of hybrid revascularization using
minimally invasive CABG and PCI have reported low
mortality rates (0 to 2%) and event-free survival rates of 83%
to 92% at 6 to 12 months of follow-up. The few series that
have compared the outcomes of hybrid coronary revascular-
ization with standard CABG report similar outcomes at 30
days and 6 months (219–225).
3. PCI Outcomes
3.1. Definitions of PCI Success
The success of a PCI procedure is best defined by 3
interrelated components: angiographic findings, procedural
events, and clinical outcomes.
3.1.1. Angiographic Success
A successful PCI produces sufficient enlargement of the
lumen at the target site to improve coronary artery blood
flow. A successful balloon angioplasty is defined as the
reduction of a minimum stenosis diameter to 50% with a
final TIMI flow grade 3 (visually assessed by angiography)
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graphic thrombus (7). For coronary stents, a minimum
stenosis diameter of 20% (as visually assessed by angiog-
raphy) has previously been the clinical benchmark of an
optimal angiographic result. Given improvements in tech-
nology and techniques, as well as recognition of the impor-
tance of an adequately deployed stent to decrease the risks of
stent restenosis and thrombosis (12,228,229), the writing
committee concluded that a minimum diameter stenosis of
10% (with an optimal goal of as close to 0% as possible)
should be the new benchmark for lesions treated with
coronary stenting. As with balloon angioplasty, there should
be final TIMI flow grade 3, without occlusion of a signifi-
cant side branch, flow-limiting dissection, distal emboliza-
tion, or angiographic thrombus. Problems with determining
angiographic success include disparities between the visual
assessment and computer-aided quantitative stenosis mea-
surement and self-reporting of success in clinical reports or
databases.
3.1.2. Procedural Success
A successful PCI should achieve angiographic success with-
out associated in-hospital major clinical complications (e.g.,
death, MI, stroke, emergency CABG) (7,8). Issues regard-
ing the diagnosis and prognostic implications of procedure-
related MI are discussed in Sections 3.3 and 5.10.
3.1.3. Clinical Success
In the short term, a clinically successful PCI requires both
anatomic and procedural success along with relief of signs
and/or symptoms of myocardial ischemia. Long-term clin-
ical success requires that the short-term clinical success
remain durable and that relief of signs and symptoms of
myocardial ischemia persist 9 months after the procedure.
Restenosis is the principal cause of lack of long-term clinical
success after a short-term clinical success has been achieved.
Restenosis is not a complication; it is the expected biological
response to vascular injury. The frequency of clinically
important restenosis may be judged by the frequency with
which subsequent revascularization procedures are per-
formed on target arteries after the index procedure.
3.2. Predictors of Clinical Outcome After PCI
Factors associated with increased PCI complication rates
include advanced age, diabetes, CKD, ACS, congestive
heart failure, and multivessel CAD (8,230–232). Several
models have been developed and refined over the past 2
decades to predict mortality with PCI (230,233–236). At
present, perhaps the best accepted system is from the ACC
National Cardiovascular Data Registry (NCDR) CathPCI
Risk Score system, which uses clinical variables and PCI
setting to predict inpatient mortality (Appendix 4A) (236).
In general, these models perform very well (C statistic:
approximately 0.90), although predictive capability de-
creases in high-risk patients.Models have also been developed to predict procedural
success. Presently, the modified ACC/AHA score (230)
and the SCAI score (Appendix 4B) (237) are both in use,
with the latter slightly outperforming the former. Discrim-
ination as measured by the C statistic is generally good to
very good (0.70 to 0.82), depending on the outcome variable
and patient population.
The angiographic SYNTAX score (238) has been devel-
oped to predict long-term risk of MACE after multivessel
intervention. The SYNTAX score and its potential utility in
helping guide revascularization strategies are discussed in
Section 2. Composite models including angiographic and
clinical variables have been developed but generally require
validation in larger cohorts of patients.
3.3. PCI Complications
In an analysis of the NCDR CathPCI database of patients
undergoing PCI between 2004 and 2007, the overall in-
hospital mortality rate was 1.27%, ranging from 0.65% in
elective PCI to 4.81% in STEMI (236). Factors associated
with an increased risk of PCI-related death include ad-
vanced age, comorbidities (e.g., diabetes, CKD, congestive
heart failure), multivessel CAD, high-risk lesions, and the
setting of PCI (e.g., STEMI, urgent or emergency proce-
dure, cardiogenic shock) (56,230–232,236).
Causes of procedural and periprocedural MI include
acute artery closure, embolization and no-reflow, side
branch occlusion, and acute stent thrombosis. The incidence
of procedure-related MI depends to a great degree on the
definition of MI used, the patient population studied, and
whether or not cardiac biomarkers are routinely assessed
after PCI. The definition and clinical significance of PCI-
related MI have been controversial. Criteria for defining a
PCI-related MI have evolved over time (8,239,240). The
2007 universal definition of MI (240) states that after PCI,
elevations of cardiac biomarkers above the 99th percentile
upper reference limit indicate periprocedural myocardial
necrosis. Increases of biomarkers 3 times the 99th per-
centile upper reference limit were designated as defining
PCI-related MI (240). According to this definition, 15%
of patients undergoing PCI would be defined as having
periprocedural MI (241,242). Issues in procedure-related
MI are discussed in Section 5.10.
The need for emergency CABG has dramatically de-
creased with advances in PCI technology, particularly cor-
onary stents (243,244). Recently the NCDR reported the
rate of emergency CABG at 0.4% (244). Procedure-related
indications for CABG in 1 large series included coronary
dissection (27%), acute artery closure (16%), perforation
(8%), and failure to cross the lesion (8%) (245). The
strongest predictors of the need for emergency CABG in
several analyses are cardiogenic shock (OR: 11.4), acute MI
or emergency PCI (OR: 3.2 to 3.8), multivessel disease
(OR: 2.3 to 2.4), and type C lesion (OR: 2.6) (243,245).
In-hospital mortality for emergency CABG ranges from
7.8% to 14% (243,245,246).
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dence of PCI-related stroke was 0.22% (247). In-hospital
mortality in patients with PCI-related stroke is 25% to 30%
(247,248). Factors associated with an increased risk of
stroke include fibrinolytic therapy administered before PCI
(OR: 4.7), known cerebrovascular disease (OR: 2.20),
STEMI as the indication for PCI (OR: 3.2), use of an
intra-aortic balloon pump (IABP) (OR: 2.6), older age
(OR: 1.17 per 5-year increase), and female sex (247–249).
Initial imaging after a stroke in 1 small series revealed
hemorrhagic etiology in 18%, ischemic etiology in 58%, and
no clear etiology in 24% (248). One potential algorithm for
the treatment of catheterization-related stroke has been
recently proposed (250). This document includes no specific
recommendations for the management of PCI-related
stroke but refers the reader to the AHA/American Stroke
Association guidelines for the management of adults with
stroke (251).
Vascular complications from PCI are primarily related to
vascular access. Important femoral vascular complications
include access site hematoma, retroperitoneal hematoma,
pseudoaneurysm, arteriovenous fistula, and arterial dis-
section and/or occlusion (252). The incidence of these
vascular complications in various reports generally ranges
from 2% to 6% and has decreased with time (249,253–257).
Factors associated with an increased risk of vascular com-
plication include age 70 years, body surface area 1.6 m2,
emergency procedures, peripheral artery disease, periproce-
dural use of glycoprotein (GP) IIb/IIIa inhibitors, and
female sex (if not corrected for body surface area)
(249,253,254,257,258). Ultrasound guidance has been used
for femoral artery access to potentially decrease complica-
tions (259). As discussed in Section 5.11, vascular closure
devices have not been clearly demonstrated to decrease
vascular complication rates. Radial site access decreases the
rate of access-related bleeding and complications compared
with femoral access (255,260). Loss of the radial pulse has
been reported in5% of radial procedures (261). Infrequent
to rare complications occurring with the radial artery ap-
proach include compartment syndrome, pseudoaneurysm
(0.01%), and sterile abscess (occurring with previous-
generation hydrophilic sheaths) (262). Radial artery spasm
may occur and treatment at times may be challenging. Local
hematomas may occur from small-branch vessel hydrophilic
wire perforation or inexperience with wristband use.
The risk of coronary perforation is approximately 0.2%,
most commonly by wire perforation during PCI for CTO or
by ablative or oversized devices during PCI of heavily
diseased or tortuous coronary arteries (263). The risk of
tamponade and management of the perforation varies with
the type of perforation (264).
Periprocedural bleeding is now recognized to be associ-
ated with subsequent mortality (265,266), and the avoid-
ance of bleeding complications has become an important
consideration in performing PCI. The risk of bleeding is
associated with patient factors (e.g., advanced age, low bodymass index, CKD, baseline anemia), as well as the degree of
platelet and thrombin inhibition, vascular access site, and
sheath size (267–269). Issues of periprocedural bleeding are
discussed in Section 4.7.
The incidence of contrast-induced acute kidney injury
(AKI) or “contrast nephropathy” in published reports de-
pends on the definition of contrast nephropathy used and
the frequency of risk factors for contrast-induced AKI in the
patient population studied. Important risk factors for
contrast-induced AKI include advanced age, CKD, conges-
tive heart failure, diabetes, and the volume of contrast
administered. Contrast-induced AKI and strategies to pre-
vent it are discussed in Section 4.4.
4. Preprocedural Considerations
Table 4 contains recommendations for preprocedural con-
siderations and interventions in patients undergoing PCI.
4.1. Cardiac Catheterization
Laboratory Requirements
4.1.1. Equipment
Defibrillators are considered by The Joint Commission to
be life-support equipment requiring routine assessment and
completion of appropriate logs. Many hospitals require
periodic inspection of consoles for ancillary devices used in
coronary intervention (e.g., Doppler wires, pressure-tipped
sensor wires, and IVUS catheters). Point-of-care testing
devices (e.g., activated clotting time and arterial blood gas
machines) require routine calibration. Duration of storage
of digital cine images is often mandated by law. Operating
parameters for x-ray imaging equipment are adjusted at
installation and periodically assessed by a qualified physicist
in cooperation with the equipment manufacturer. Familiar-
ity with radiation dose–reducing features of catheterization
laboratory equipment and assistance from a qualified phys-
icist are important for radiation dose minimization and
image optimization.
4.1.2. Staffing
An interventional cardiologist must be present in the
laboratory for the duration of each procedure and is respon-
sible for procedure outcome. Nursing and technical person-
nel are also required to be present in the catheterization
laboratory, with specific staffing dependent on state require-
ments and laboratory caseload and mix. Catheterization
laboratory technical staff may include nurse practitioners,
registered nurses, licensed vocational or practical nurses,
physician assistants, nursing assistants, radiology techni-
cians, or catheterization laboratory technicians. All cathe-
terization laboratory staff are usually certified in basic life
support, advanced cardiovascular life support, and, where
appropriate, pediatric advanced life support. Catheterization
laboratory personnel have a nursing degree/certification or
invasive cardiovascular credentials such as registered cardio-
LOE, le
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technologists (305).
4.1.3. ‘Time-Out’ Procedures
In 2003, The Joint Commission mandated a universal
protocol requiring proper preoperative identification of the
patient by the members of the catheterization laboratory
team, marking of the operative site, and a final time-out just
before the procedure (306). Although initially intended to
prevent wrong-site surgery, this has been expanded to
include all invasive procedures despite limited scientific
evidence of its effectiveness (307). The intent of the
time-out is for all members of the team to improve
patient care by collectively discussing the case. The
content of a time-out includes confirmation of the correct
patient, correct side and site, agreement on the procedure
to be performed, correct patient position, and availability
of needed equipment, supplies, and implants. The time-
out may be checklist driven or conversational, depending
on laboratory preferences (308). The writing committee
strongly endorses the practice of conducting a time-out
before all PCI procedures.
4.2. Ethical Aspects
The 3 principles of medical ethics are beneficence, auton-
omy, and justice. Beneficence involves the physician’s duty
to act in the best interests of the patient and avoid
Table 4. Summary of Recommendations for Preprocedural Con
Recommendations
Contrast-induced AKI
Patients should be assessed for risk of contrast-induced AKI before PCI.
Patients undergoing cardiac catheterization with contrast media should rec
adequate preparatory hydration.
In patients with CKD (creatinine clearance 60 mL/min), the volume of con
media should be minimized.
Administration of N-acetyl-L-cysteine is not useful for the prevention of cont
induced AKI.
Anaphylactoid reactions
Patients with prior evidence of an anaphylactoid reaction to contrast media
receive appropriate prophylaxis before repeat contrast administration.
In patients with a prior history of allergic reactions to shellfish or seafood,
anaphylactoid prophylaxis for contrast reaction is not beneficial.
Statins
Administration of a high-dose statin is reasonable before PCI to reduce the
periprocedural MI.
Bleeding risk
All patients should be evaluated for risk of bleeding before PCI.
CKD
In patients undergoing PCI, the glomerular filtration rate should be estimate
dosage of renally cleared medications should be adjusted.
Aspirin
Patients already on daily aspirin therapy should take 81 mg to 325 mg bef
Patients not on aspirin therapy should be given nonenteric aspirin 325 mg
AKI indicates acute kidney injury; CKD, chronic kidney disease; COR, class of recommendation;
intervention.maleficence, or harm (primum non nocere). Autonomy de-scribes the physician’s duty to help the patient maintain
control over his or her medical treatments. Justice describes
the physician’s duty to treat the individual patient respon-
sibly with due consideration of other patients and stake-
holders in the healthcare system. Ethical considerations
specific to PCI have been previously discussed (309) and are
highlighted below:
• Place the patient’s best interest first and foremost
when making clinical decisions (beneficence).
• Ensure that patients actively participate in decisions
affecting their care (autonomy).
• Consider how decisions regarding one patient may also
affect other patients and providers (justice).
• Plan and perform procedures and provide care with the
intention of improving the patient’s quality of life
and/or decreasing the risk of mortality, independent of
reimbursement considerations and without inappro-
priate bias or influence from industry, administrators,
referring physicians, or other sources.
• Before performing procedures, obtain informed con-
sent after giving an explanation regarding the details of
the procedure and the risks and benefits of both the
procedure and alternatives to the procedure.
• Plan and perform procedures according to standards of
care and recommended guidelines, and deviate from
them when appropriate or necessary in the care of
ations and Interventions in Patients Undergoing PCI
COR LOE References
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III: No Benefit A (279–283)
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when such consultation would benefit the patient.
4.2.1. Informed Consent
Obtaining informed consent for procedures is a legal and
ethical necessity. Ideally, informed consent is obtained long
enough before the procedure that the patient can fully
consider informed consent issues and discuss them with
family or other providers, avoiding any sense of coercion.
Ad hoc PCI, or PCI immediately following diagnostic
procedures, presents special problems. When informed
consent for PCI is obtained before diagnostic catheteriza-
tion is performed, it is impossible to predict the levels of risk
and benefit from an ad hoc PCI (310,311). If diagnostic
catheterization reveals anatomy that poses a particularly
high risk or for which the superiority of PCI compared with
other strategies is unclear, the precatheterization informed
consent discussion may be inadequate. In such cases, defer-
ral of PCI until additional informed consent discussions
and/or consultations occur may be appropriate, even though
it inconveniences the patient and the healthcare system. It is
the responsibility of the interventionalist to act in the
patient’s best interest in these circumstances.
Informed consent before emergency procedures is partic-
ularly difficult (312–314). The patient presenting with
STEMI is usually in distress and often sedated, making true
informed consent impossible. Rapid triage, transport, and
treatment of STEMI patients create a pressured atmosphere
that by necessity limits a prolonged and detailed informed
consent process. Nevertheless, the interventionist must at-
tempt to provide information about the risks and benefits of
different strategies to the patient and family and balance the
benefit of thorough discussion with the benefits of rapid
intervention.
4.2.2. Potential Conflicts of Interest
Decisions about the performance and timing of PCI may
pose additional ethical dilemmas. When considering
whether to perform multivessel PCI in 1 stage versus 2
stages, safety and convenience for the patient must guide the
decision, regardless of payment policies that maximize
reimbursement when PCI is staged (311). A separate issue
is self-referral, through which diagnostic catheterization
often leads seamlessly to PCI by the same operator (315).
The interventionist has an ethical obligation to the patient
to consider all treatment options, consult with additional
specialists (e.g., cardiac surgeons) when their input would be
helpful to the patient, avoid unnecessary interventional
procedures, and allow the patient to consult family members
and other physicians (311).
4.3. Radiation Safety: Recommendation
CLASS I
1. Cardiac catheterization laboratories should routinely record rele-
vant available patient procedural radiation dose data (e.g., total air
kerma at the international reference point [Ka,r], air kerma airproduct [PKA], fluoroscopy time, number of cine images), and should
define thresholds with corresponding follow-up protocols for pa-
tients who receive a high procedural radiation dose. (Level of
Evidence: C)
The issue of radiation exposure during imaging procedures
has received increased attention, and the writing committee
believes that radiation safety should be addressed in this
guideline. Current standards for cardiac catheterization
laboratories include the following:
• Specific procedures and policies are in place to mini-
mize patient (and operator) risk.
• A radiation safety officer coordinates all radiation
safety issues and works conjointly with the medical or
health physicist.
• Patient radiation exposure is reduced to as low a level
as reasonably can be achieved.
• Patients at increased risk for high procedural radiation
exposure are identified.
• Informed consent includes radiation safety informa-
tion, particularly for the high-risk patient.
A basic primer on the physics of x-ray imaging, essential
to the safe practice of radiation dose management, has been
published in an ACCF/AHA/Heart Rhythm Society/SCAI
clinical competence statement (316). Appendix 4C summa-
rizes strategies to minimize patient and operator radiation
exposure. Adverse radiation effects are now well recognized
as infrequent but potentially serious complications of pro-
longed interventional procedures (317). Fluoroscopic time
does not include cine acquisition imaging and is therefore
not an accurate measure of patient radiation dose. Total air
kerma at the interventional reference point (Ka,r, in Gy) and
air kerma area product (PKA, in Gycm
2) are required to be
reported on interventional x-ray systems since 2006. These
are useful in the assessment of potential tissue adverse effects
or long-term radiation sequelae, respectively, and it is
reasonable to include them in the catheterization record at
the conclusion of each procedure. Appendix 4D summarizes
considerations for patient follow-up based on radiation dose
during the procedure (317).
4.4. Contrast-Induced AKI: Recommendations
CLASS I
1. Patients should be assessed for risk of contrast-induced AKI before
PCI (270,271). (Level of Evidence: C)
. Patients undergoing cardiac catheterization with contrast media
should receive adequate preparatory hydration (272–275). (Level of
Evidence: B)
. In patients with CKD (creatinine clearance 60 mL/min), the
volume of contrast media should beminimized (276–278). (Level of
Evidence: B)
CLASS III: NO BENEFIT
1. Administration of N-acetyl-L-cysteine is not useful for the prevention
of contrast-induced AKI (279–283). (Level of Evidence: A)
See Online Data Supplements 16 to 18 for additional data
regarding contrast-induced AKI.
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of the leading causes of hospital-acquired AKI. Major risk
factors for contrast-induced AKI include advanced age,
CKD, congestive heart failure, diabetes, and the volume of
contrast administered. A risk-scoring system is available to
predict the risk of contrast nephropathy using these risk
factors and additional variables (270). Thus far, the only
strategies clearly shown to reduce the risk of contrast-
induced AKI are hydration and minimizing the amount of
contrast media. Other than saline hydration, measures that
were believed to reduce the risk of contrast-induced AKI
have been found to be neutral, to have deleterious effects, or
to be characterized by heterogeneous and conflicting data.
Studies of hydration to reduce the risk of contrast-
induced AKI suggest that isotonic saline is preferable to half
isotonic saline, intravenous (IV) hydration is preferable to
oral hydration, hydration for hours before and after exposure
to contrast media is preferable to a bolus administration of
saline immediately before or during contrast media expo-
sure, and administration of isotonic saline alone is preferable
to administration of isotonic saline plus mannitol or furo-
semide (272–275,320). On the basis of these studies, a
reasonable hydration regimen would be isotonic crystalloid
(1.0 to 1.5 mL/kg per hour) for 3 to 12 hours before the
procedure and continuing for 6 to 24 hours after the
procedure (272–275,284,320,321).
Prior studies of N-acetyl-L-cysteine and sodium bicar-
bonate have produced conflicting results. Some, often small,
earlier studies suggested benefit, but many other more
contemporary studies and meta-analyses found no clear
evidence of benefit, and there are potential issues of publi-
cation bias and poor methodology issues in several analyses
(279–282,322–332). The recently completed largest ran-
domized study on N-acetyl-L-cysteine and contrast ne-
phropathy in patients undergoing angiographic procedures,
ACT (Acetylcysteine for Contrast-Induced Nephropathy
Trial), demonstrated no benefit in primary or secondary
endpoints. An updated meta-analysis using only high-
quality trials similarly demonstrated no benefit (283). Taken
as a whole, these studies do not support any recommenda-
tion for the use of N-acetyl-L-cysteine, they do, however,
provide sufficient data to conclude that N-acetyl-L-cysteine
does not prevent contrast-induced AKI in patients under-
going angiographic procedures.
The correlation between the volume of contrast media
and the risk of contrast-induced AKI has been documented
in several studies (276,277). Thus, minimization of contrast
media volume is important to prevent contrast-induced AKI
in patients undergoing angiography. The volume of contrast
already administered during diagnostic catheterization is an
important factor when considering possible “ad hoc” PCI.
Comparative studies of different contrast media (e.g.,
low-osmolar versus iso-osmolar, one agent versus another
agent) have produced variable and sometimes contradictory
results (334–339). Thus, current data are insufficient to
justify specific recommendations about low- and iso-osmolar contrast media. This issue is discussed in detail in
the 2011 UA/NSTEMI focused update (340). For a further
discussion of contrast media and PCI, the reader is referred
to a position statement by the SCAI (284).
4.5. Anaphylactoid Reactions: Recommendations
CLASS I
1. Patients with prior evidence of an anaphylactoid reaction to contrast
media should receive appropriate steroid and antihistamine prophy-
laxis before repeat contrast administration (252,284–286). (Level
of Evidence: B)
CLASS III: NO BENEFIT
1. In patients with a prior history of allergic reactions to shellfish or
seafood, anaphylactoid prophylaxis for contrast reaction is not
beneficial (287–289). (Level of Evidence: C)
The incidence of anaphylactoid reactions to contrast media
is 1%, and the incidence of severe reactions may be as low
as 0.04% (284). Limited data suggest that in patients with a
history of prior anaphylactoid reaction, the recurrence rate
without prophylaxis is in the range of 16% to 44% (341).
Adequate pretreatment of patients with prior anaphylactoid
reactions reduces the recurrence rate to close to zero
(284–286). A regimen of 50 mg of prednisone administered
13 hours, 7 hours, and 1 hour before the procedure (as well
as 50 mg of diphenhydramine 1 hour before the procedure)
has been shown to reduce the risk of recurrent anaphylac-
toid reaction (286). In practice, a regimen of 60 mg of
prednisone the night before and morning of the procedure
(as well as 50 mg of diphenhydramine 1 hour before the
procedure) is often used (252). There are minimal data on
the “pretreatment” of patients undergoing emergency PCI
(342). One group has suggested IV steroids (e.g., 80 mg to
125 mg of methylprednisolone, 100 mg of hydrocortisone
sodium succinate), as well as oral or IV diphenhydramine
and possible IV cimetidine (284). For a more detailed
discussion of issues related to contrast-induced anaphylac-
toid reactions, the reader is referred to several dedicated
discussions on contrast agents (284,341).
There are no data to suggest that those patients with
seafood or shellfish allergies are at risk for an anaphylactoid
reaction from exposure to contrast media. Iodine does not
mediate seafood, shellfish, or contrast media reactions. The
common misconception that seafood allergies and contrast
reactions are cross-reactions to iodine probably arose from a
survey published in 1975 in which 15% of patients with a
history of contrast reaction reported a personal history of
shellfish allergy, but nearly identical proportions of patients
reported allergies to other foods, such as milk and egg, in
the same survey (287). Pretreatment of patients with ste-
roids based only on a history of seafood or shellfish allergy
has a small but non-zero risk of adverse effect (e.g.,
hyperglycemia in a patient with diabetes) without any
demonstrated benefit (288,289).
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CLASS IIa
1. Administration of a high-dose statin is reasonable before PCI to
reduce the risk of periprocedural MI. (Level of Evidence: A for
statin-naïve patients [290–296]; Level of Evidence: B for those on
chronic statin therapy [297])
See Online Data Supplement 19 for additional data regarding
preprocedural statin treatment.
Statins have long-term benefits in patients with CAD
(343,344) and ACS (345,346). The benefits of statins in
ACS begin early, before substantial lipid lowering has
occurred (345,347), suggesting pleiotropic effects of statins.
These might include anti-inflammatory effects, improve-
ment of endothelial function, decrease of oxidative stress, or
inhibition of thrombogenic responses (348). Statins were
beneficial when pretreatment was started from 7 days to just
before PCI (290–297).
4.7. Bleeding Risk: Recommendation
CLASS I
1. All patients should be evaluated for risk of bleeding before PCI.
(Level of Evidence: C)
Periprocedural bleeding is now recognized as a major risk
factor for subsequent mortality (265,266). Bleeding may
lead to mortality directly (because of the bleeding event) or
through ischemic complications that occur when antiplate-
let or anticoagulant agents are withdrawn in response to the
bleeding. Bleeding may also be a marker of comorbidities
associated with worse prognosis (e.g., occult cancer). The
risk of bleeding is associated with a number of patient
factors (e.g., advanced age, low body mass index, CKD,
baseline anemia), as well as the degree of platelet and
thrombin inhibition, vascular access site, and sheath size
(267–269). The overall approach to PCI should be individ-
ualized to minimize both ischemic and bleeding risks.
Measures to minimize the risks of bleeding complications
are discussed in several sections of this guideline. These
include use of anticoagulation regimens associated with a
lower risk of bleeding, weight-based dosing of heparin and
other agents, use of activated clotting times to guide
unfractionated heparin (UFH) dosing, avoidance of excess
anticoagulation (349), dosing adjustments in patients with
CKD (e.g., eptifibatide, tirofiban, bivalirudin) (350), use of
radial artery access site (255), and avoidance of femoral vein
cannulation when possible. Vascular closure devices have
not been clearly demonstrated to decrease bleeding compli-
cations and are discussed in detail in Section 5.11.
4.8. PCI in Hospitals Without On-Site Surgical Backup:
Recommendations
CLASS IIa
1. Primary PCI is reasonable in hospitals without on-site cardiac
surgery, provided that appropriate planning for program develop-
ment has been accomplished (351,352). (Level of Evidence: B)CLASS IIb
1. Elective PCI might be considered in hospitals without on-site cardiac
surgery, provided that appropriate planning for program develop-
ment has been accomplished and rigorous clinical and angiographic
criteria are used for proper patient selection (352–354). (Level of
Evidence: B)
CLASS III: HARM
1. Primary or elective PCI should not be performed in hospitals without
on-site cardiac surgery capabilities without a proven plan for rapid
transport to a cardiac surgery operating room in a nearby hospital or
without appropriate hemodynamic support capability for transfer.
(Level of Evidence: C)
See Online Data Supplement 20 for additional data regarding
hospitals without on-site surgical backup.
Primary and elective PCI can be performed at hospitals
without on-site cardiac surgical backup with a high success
rate, low in-hospital mortality rate, and low rate for emergency
CABG (351,353,354). The best outcomes for patients with
STEMI are achieved at hospitals with 24/7 access to primary
PCI (355). Criteria for the performance of PCI without
on-site surgical backup have been proposed in an SCAI expert
consensus document (352). Consideration of elective PCI
without on-site cardiac surgical backup is thought to be
appropriate only when performed by experienced operators
with complication rates and outcomes equivalent or superior to
national benchmarks. Accurate assessment of complication
rates and patient outcomes via a regional or national data
registry, so that outcomes can be compared with established
benchmarks, is an important quality control component of any
PCI program. Desires for personal or institutional financial
gain, prestige, market share, or other similar motives are not
appropriate considerations for initiation of PCI programs
without on-site cardiac surgery. It is only appropriate to
consider initiation of a PCI program without on-site cardiac
surgical backup if this program will clearly fill a void in the
healthcare needs of the community. Competition with another
PCI program in the same geographic area, particularly an
established program with surgical backup, may not be in the
best interests of the community.
Tables 5 and 6 list the SCAI expert consensus document
requirements for PCI programs without on-site surgical
backup. Table 7 gives the requirements for primary PCI and
emergency CABG at hospitals without on-site cardiac
surgery, and Table 8 lists the requirements for patient and
lesion selection and backup strategy for nonemergency PCI
(352).
5. Procedural Considerations
5.1. Vascular Access: Recommendation
CLASS IIa
1. The use of radial artery access can be useful to decrease access site
complications (255,260,356–362). (Level of Evidence: A)
See Online Data Supplement 21 for additional data regarding
radial access.
rdial in
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approach in patients undergoing PCI in the United States.
Choosing a femoral artery puncture site is facilitated by
fluoroscopic landmark identification or ultrasound guid-
ance. Low punctures have a high incidence of peripheral
artery complications, whereas high punctures have an increased
risk of retroperitoneal hemorrhage. In patients with a synthetic
graft, arterial access is possible after the graft is a few months old
and complication rates are not increased (254).
Radial site access is used frequently in Europe and Canada
but not in the United States (260). A learning curve exists for
the radial approach that will affect procedure time and radia-
tion dose, with a trend toward lower procedural success rates
for radial versus femoral access (255). However, compared with
femoral access, radial access decreases the rate of access-related
Table 5. SCAI Expert Consensus Document Personnel and Fac
Without On-Site Surgical Backup
Experienced nursing and technical laboratory staff with training in interventiona
hemodynamic and electrical instability.
On-call schedule with operation of laboratory 24 h/d, 365 d/y.*
Experienced coronary care unit nursing staff comfortable with invasive hemodyn
Personnel capable of endotracheal intubation and ventilator management bo
Full support from hospital administration in fulfilling the necessary institutional
blood bank).
Written agreements for emergency transfer of patients to a facility with cardiac
2 times per year.
Well-equipped and maintained cardiac catheterization laboratory with high-reso
vehicles. The capability for real-time transfer of images and hemodynamic da
for consultation at the facility providing surgical backup support is ideal.
Appropriate inventory of interventional equipment, including guide catheters, ba
covered stents; temporary pacemakers; and pericardiocentesis trays. Pressure
other atherectomy devices should be used cautiously in these facilities becau
Meticulous clinical and angiographic selection criteria for PCI (Tables 6 and 7).
Performance of primary PCI as the treatment of first choice for STEMI to ensure
be tracked, and 90 min outlier cases should be carefully reviewed for proce
On-site rigorous data collection, outcomes analysis, benchmarking, quality impr
Participation in a national data registry where available, such as the ACC NCDR
*Required for U.S. facilities but may not be possible for all facilities worldwide.
ACC indicates American College of Cardiology; IABP, intra-aortic balloon pump; IVUS, intravasc
SCAI, Society for Cardiovascular Angiography and Interventions; and STEMI, ST-elevation myoca
Adapted with permission from Dehmer et al. (352).
Table 6. SCAI Expert Consensus Document Requirements for O
1. Interventional cardiologists establish a working relationship with cardiac sur
2. Cardiac surgeon must have privileges at the referring facility to allow review
3. Cardiac surgeon and receiving hospital agree to provide cardiac surgical bac
4. Surgeon and receiving facility ensure that patients will be accepted based o
and availability of resources. If this cannot be ensured before the start of an
5. Interventional cardiologists must review with surgeons the immediate needs
6. Hospital administrations from both facilities endorse transfer agreement.
7. Transferring and receiving facilities establish a rigorous protocol for rapid tra
8. A transport provider is available to begin transport within 20 min of the requ
including IABP and monitoring capability.
9. Transferring physician obtains consent for surgery from patient or appropria
0. Initial informed consent for PCI discloses that the procedure is being done w
transfer. The consent process should include the risk of urgent surgery (app
1. As part of the local continuous quality improvement program, a regular revi
identification of any improvement opportunities.IABP indicates intra-aortic balloon pump; PCI, percutaneous coronary intervention; and SCAI, Society fo
Adapted with permission from Dehmer et al. (352).bleeding and complications (255,260,363). In a recent large
RCT comparing radial and femoral access in patients with
ACS undergoing PCI, there was no difference in the primary
composite endpoint (death, MI, stroke, major bleeding), al-
though there was a lower rate of vascular complications with
the use of radial access (362). Radial artery access is particularly
appealing in patients with coagulopathy, elevated international
normalized ratio due to warfarin, or morbid obesity.
5.2. PCI in Specific Clinical Situations
5.2.1. UA/NSTEMI: Recommendations
CLASS I
1. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in UA/NSTEMI patients who
have refractory angina or hemodynamic or electrical instability
equirements for PCI Programs
atories. Personnel must be comfortable treating acutely ill patients with
monitoring, operation of temporary pacemaker, and management of IABP.
ite and during transfer if necessary.
ements, including appropriate support services (e.g., respiratory care,
ry. Transport protocols should be developed and tested a minimum of
digital imaging capability and IABP equipment compatible with transport
T-1 transmission line) as well as audio and video images to review terminals
, and stents in multiple sizes; thrombectomy and distal protection devices;
device and IVUS equipment are optimal but not mandatory. Rotational or
he greater risk of perforation.
mlined care paths and increased case volumes. Door-to-balloon times should
rovement opportunities.
nt, and formalized periodic case review.
United States.
asound; NCDR, National Cardiovascular Data Registry; PCI, percutaneous coronary intervention;
farction.
te Surgical Backup
at the receiving facility.
atment options as time allows.
or urgent cases at all hours and for elective cases at mutually agreed hours.
ical condition, capacity of surgeon to provide services at the time of request,
ive procedure, the case should not be done at this time.
status of any patient transferred for urgent surgery.
of patients, including the proper personnel with appropriate experience.
nd provide vehicle/helicopter with necessary life-sustaining equipment,
rogate.
t on-site surgical backup and acknowledges the possibility of risks related to
tely 0.3%) and state that a written plan for transfer exists.
all patients transferred for emergency surgery with the outcome of surgery andility R
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dures) (207,364,365). (Level of Evidence: B)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in initially stabilized UA/
NSTEMI patients (without serious comorbidities or contraindications
to such procedures) who have an elevated risk for clinical events
(207,365–367). (Level of Evidence: A)
. The selection of PCI or CABG as the means of revascularization in
the patient with ACS should generally be based on the same
considerations as those without ACS (53,156,207,368). (Level of
Evidence: B)
CLASS III: NO BENEFIT
1. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with
Table 7. SCAI Expert Consensus Document Requirements for P
at Hospitals Without On-Site Cardiac Surgery
Avoid intervention in patients with
● 50% diameter stenosis of left main artery proximal to infarct-related lesio
severely impaired
● Long, calcified, or severely angulated target lesions at high risk for PCI failu
● Lesions in other than the infarct artery (unless they appeared to be flow lim
● Lesions with TIMI flow grade 3 that are not amenable to stenting in patient
● Culprit lesions in more distal branches jeopardizing only a modest amount o
attempted intervention
ransfer emergently for coronary bypass surgery patients with
● High-grade left main or 3-vessel coronary disease with clinical or hemodyna
preferably with IABP support
● Failed or unstable PCI result and ongoing ischemia, with IABP support durin
IABP indicates intra-aortic balloon pump; LV, left ventricular; PCI, percutaneous coronary inte
Myocardial Infarction.
Adapted with permission from Dehmer et al. (352).
Table 8. SCAI Expert Consensus Document Requirements for P
for Nonemergency PCI by Experienced Operators at Hospitals W
Patient risk: expected clinical risk in case of occlusion caused by procedure
High patient risk: Patients with any of the following:
● Decompensated congestive heart failure (Killip Class 3) without evidence
● LVEF 25%
● Left main stenosis (50% diameter) or 3-vessel disease unprotected by p
coronary arteries)
● Single-target lesion that jeopardizes 50% of remaining viable myocardiu
esion risk: probability that procedure will cause acute vessel occlusion
Increased lesion risk: lesions in open vessels with any of the following chara
● Diffuse disease (2 cm in length) and excessive tortuosity of proximal se
● More than moderate calcification of a stenosis or proximal segment
● Location in an extremely angulated segment (90%)
● Inability to protect major side branches
● Degenerated older vein grafts with friable lesions
● Substantial thrombus in the vessel or at the lesion site
● Any other feature that may, in the operator’s judgment, impede successfu
Aggressive measures to open CTOs are also discouraged because of an inc
trategy for surgical backup based on lesion and patient risk:
● High-risk patients with high-risk lesions should not undergo nonemergency
● High-risk patients with non–high-risk lesions: Nonemergency patients with
room are immediately available is necessary.
● Non–high-risk patients with high-risk lesions require no additional precaut
● Non–high-risk patients with non–high-risk lesions require no additional pre
CTO indicates chronic total occlusion; CVA, cerebrovascular accident; LVEF, left ventricular eject
and Interventions.
Adapted with permission from Dehmer et al. (352).extensive comorbidities (e.g., liver or pulmonary failure, cancer) in
whom (Level of Evidence: C)
a. The risks of revascularization and comorbid conditions are likely
to outweigh the benefits of revascularization,
b. There is a low likelihood of ACS despite acute chest pain, or
c. Consent to revascularization will not be granted regardless of the
findings.
The goals of coronary angiography and revascularization in
UA/NSTEMI patients are to reduce the risk of death and MI
and provide symptom relief. To improve prognosis, early risk
stratification is essential for selection of medical and/or invasive
treatment strategies. Indications for revascularization depend
on the patient’s clinical risk characteristics and coronary anat-
ry PCI and Emergency Aortocoronary Bypass Surgery
ecially if the area in jeopardy is relatively small and overall LV function is not
h TIMI flow grade 3 present during initial diagnostic angiography
n patients with hemodynamic instability or ongoing symptoms)
left main or 3-vessel disease that will require coronary bypass surgery
cardium when there is more proximal disease that could be worsened by
stability after successful or unsuccessful PCI of an occluded vessel and
sfer
; SCAI, Society for Cardiovascular Angiography and Interventions; and TIMI, Thrombolysis In
nt and Lesion Selection and Backup Strategy
ut On-Site Cardiac Surgery
tive ischemia, recent CVA, advanced malignancy, known clotting disorders
pass surgery (70% stenoses in the proximal segment of all major epicardial
ics:
s
t deployment
d risk of perforation.
t a facility without on-site surgery.
rofile may undergo PCI, but confirmation that a cardiac surgeon and operating
ons. Best scenario for PCI without on-site surgery.
tion; PCI, percutaneous coronary intervention; and SCAI, Society for Cardiovascular Angiographyrima
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clinical presentation (e.g., dynamic electrocardiogram [ECG]
changes, elevated troponin, high Global Registry of Acute
Coronary Events score), recurrent symptoms, threatened viable
myocardium, CKD, and larger ischemic burden (Appendix
4E). For choice of revascularization technique, the anatomical
considerations are generally those used for stable CAD, al-
though PCI may initially be performed in the index lesion to
stabilize the patient (Section 2).
Contemporary studies variably comparing strategies of
very early (within hours of admission), early (within 24
hours of admission), and delayed (1 to 7 days after admis-
sion) cardiac catheterization and revascularization support a
strategy of early angiography and revascularization to reduce
the risk of recurrent ischemia and MI, particularly among
those at high risk (e.g., Global Registry of Acute Coronary
Events score 140) (367,369,370), whereas a delayed ap-
proach is reasonable in low-intermediate risk patients (based
on clinical course). There is no evidence that incremental
benefit is derived by angiography and PCI performed within
the first few hours of hospital admission (207,367,371–378).
5.2.2. ST-Elevation Myocardial Infarction
5.2.2.1. CORONARY ANGIOGRAPHY STRATEGIES IN
STEMI: RECOMMENDATIONS
CLASS I
1. A strategy of immediate coronary angiography with intent to per-
form PCI (or emergency CABG) in patients with STEMI is recom-
mended for
a. Patients who are candidates for primary PCI (351,379–382).
(Level of Evidence: A)
b. Patients with severe heart failure or cardiogenic shock who are
suitable candidates for revascularization (383,384). (Level of
Evidence: B)
CLASS IIa
1. A strategy of immediate coronary angiography (or transfer for
immediate coronary angiography) with intent to perform PCI is
reasonable for patients with STEMI, a moderate to large area of
myocardium at risk, and evidence of failed fibrinolysis (385,386).
Table 9. Indications for Coronary Angiography in STEMI
Indications
Immediate coronary angiography
Candidate for primary PCI
Severe heart failure or cardiogenic shock (if suitable revascularization c
Moderate to large area of myocardium at risk and evidence of failed fib
Coronary angiography 3 to 24 h after fibrinolysis
Hemodynamically stable patients with evidence for successful fibrinolys
Coronary angiography before hospital discharge
Stable patients
Coronary angiography at any time
Patients in whom the risks of revascularization are likely to outweigh th
benefits or the patient or designee does not want invasive care
COR indicates class of recommendation; LOE, level of evidence; N/A, not applicable; PCI, perc(Level of Evidence: B). A strategy of coronary angiography (or transfer for coronary angiog-
raphy) 3 to 24 hours after initiating fibrinolytic therapy with intent to
perform PCI is reasonable for hemodynamically stable patients with
STEMI and evidence for successful fibrinolysis when angiography
and revascularization can be performed as soon as logistically
feasible in this time frame (387–391). (Level of Evidence: A)
CLASS IIb
1. A strategy of coronary angiography performed before hospital dis-
charge might be reasonable in stable patients with STEMI who did
not undergo cardiac catheterization within 24 hours of STEMI onset.
(Level of Evidence: C)
CLASS III: NO BENEFIT
1. A strategy of coronary angiography with intent to perform PCI is
not recommended in patients with STEMI in whom the risks of
revascularization are likely to outweigh the benefits or when the
patient or designee does not want invasive care. (Level of
Evidence: C)
The historical reperfusion strategies of “primary PCI,”
“immediate PCI,” “rescue PCI,” “deferred PCI,” “facilitated
PCI,” and the “pharmacoinvasive strategy” have evolved in
parallel with advances in antithrombotic therapy and
STEMI prehospital and hospital systems of care. The
clinical challenge in primary PCI is achieving rapid time to
treatment and increasing patient access to this preferred
reperfusion strategy. The clinical challenge in patients
treated with fibrinolytic therapy is deciding for whom and
when to perform coronary angiography.
In unstable patients (e.g., severe heart failure or cardio-
genic shock, hemodynamically compromising ventricular
arrhythmias) not treated initially with primary PCI, a
strategy of immediate coronary angiography with intent to
perform PCI is implemented unless invasive management is
considered futile or unsuitable given the clinical circum-
stances (383,384).
In stable patients treated with fibrinolytic therapy and
clinical suspicion of reperfusion failure, a strategy of imme-
diate coronary angiography followed by PCI improves
outcome in those at high risk (385,386). Such a strategy is
also implemented in patients with evidence for infarct artery
COR LOE References
I A (351,379–382)
te) I B (383,384)
sis IIa B (385,386)
IIa A (387–391)
IIb C N/A
III: No Benefit C N/A
s coronary intervention; and STEMI, ST-elevation myocardial infarction.andida
rinoly
is
ereocclusion (Table 9). The clinical diagnosis of failed
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ST-segment resolution 90 minutes after initiation of ther-
apy in the lead showing the greatest degree of ST-segment
elevation at presentation. Given the association between
bleeding events and adverse cardiac events, a reasonable
approach is to select moderate- and high-risk patients for
PCI and treat low-risk patients with medical therapy. ECG
and clinical findings of anterior MI or inferior MI with right
ventricular involvement or precordial ST-segment depres-
sion, as well as ongoing pain, usually predicts increased risk
and the greatest potential benefit (392). Conversely, patients
with symptom resolution, improving ST-segment elevation,
or inferior MI localized to 3 ECG leads probably gain little
benefit.
In stable patients treated with fibrinolytic therapy and
clinical evidence for successful reperfusion, an early invasive
strategy with cardiac catheterization performed within 24
hours decreases reinfarction and recurrent ischemic events
(388,390,391). Because of the associated increased bleeding
risk, very early (2 to 3 hours) catheterization after admin-
istration of fibrinolytic therapy with intent to perform
revascularization should be reserved for patients with evi-
dence of failed fibrinolysis and significant myocardial jeop-
ardy for whom immediate angiography and revasculariza-
tion would be appropriate (393).
5.2.2.2. PRIMARY PCI OF THE INFARCT ARTERY: RECOMMENDATIONS
CLASS I
1. Primary PCI should be performed in patients within 12 hours of
onset of STEMI (379–382). (Level of Evidence: A)
2. Primary PCI should be performed in patients with STEMI presenting
to a hospital with PCI capability within 90 minutes of first medical
contact as a systems goal (394,395). (Level of Evidence: B)
. Primary PCI should be performed in patients with STEMI present-
ing to a hospital without PCI capability within 120 minutes of first
medical contact as a systems goal (396–398). (Level of Evi-
dence: B)
. Primary PCI should be performed in patients with STEMI who
develop severe heart failure or cardiogenic shock and are suitable
candidates for revascularization as soon as possible, irrespective of
time delay (383,384). (Level of Evidence: B)
. Primary PCI should be performed as soon as possible in patients
with STEMI and contraindications to fibrinolytic therapy with isch-
emic symptoms for less than 12 hours (399,400). (Level of Evi-
dence: B)
CLASS IIa
1. Primary PCI is reasonable in patients with STEMI if there is clinical
and/or electrocardiographic evidence of ongoing ischemia between
12 and 24 hours after symptom onset (401–403). (Level of Evi-
dence: B)
CLASS IIb
1. Primary PCI might be considered in asymptomatic patients with
STEMI and higher risk presenting between 12 and 24 hours aftersymptom onset. (Level of Evidence: C)CLASS III: HARM
1. PCI should not be performed in a noninfarct artery at the time of
primary PCI in patients with STEMI without hemodynamic compro-
mise (404–408). (Level of Evidence: B)
Primary PCI is preferred to fibrinolytic therapy when
time-to-treatment delays are short and the patient pres-
ents to a high-volume, well-equipped center staffed with
expert interventional cardiologists and skilled support
staff. Compared with fibrinolytic therapy in RCTs, pri-
mary PCI produces higher rates for infarct artery patency,
TIMI flow grade 3, and lower rates for recurrent isch-
emia, reinfarction, emergency repeat revascularization
procedures, intracranial hemorrhage, and death (379).
Early, successful PCI also greatly decreases the compli-
cations of STEMI that result from longer ischemic times
or unsuccessful fibrinolytic therapy, allowing earlier hos-
pital discharge and resumption of daily activities. The
greatest mortality benefit of primary PCI is in high-risk
patients. PCI outcomes may not be as successful with
prolonged time-to-treatment or low-volume hospitals
and operators (Table 10).
Several reports have shown excellent outcomes for pa-
tients with STEMI undergoing interhospital transfer where
first medical contact–to-door balloon time modestly ex-
ceeded the systematic goal of 90 minutes (396–398,409).
In these reports, the referring hospital and the receiving
hospital established a transfer protocol that minimized
transfer delays, and outcomes were similar to those of
direct-admission patients. On the basis of these results, the
PCI and STEMI guideline writing committees have mod-
ified the first medical contact–to-device time goal from 90
minutes to 120 minutes for interhospital transfer patients
(397), while emphasizing that systems should continue to
strive for times 90 minutes. Hospitals that cannot meet
these criteria should use fibrinolytic therapy as their primary
reperfusion strategy.
PCI of a noninfarct artery at the time of primary PCI in
stable patients is associated with worse clinical outcomes
unless the patient is in cardiogenic shock where PCI of a
severe stenosis in a coronary artery supplying a large
territory of myocardium might improve hemodynamic sta-
bility (404,406,408). Delayed PCI can be performed in
noninfarct arteries at a later time if clinically indicated
(410–412).
5.2.2.3. DELAYED OR ELECTIVE PCI IN PATIENTS WITH STEMI:
RECOMMENDATIONS
CLASS IIa
1. PCI is reasonable in patients with STEMI and clinical evidence for
fibrinolytic failure or infarct artery reocclusion (385,386). (Level of
Evidence: B)
. PCI is reasonable in patients with STEMI and a patent infarct artery
3 to 24 hours after fibrinolytic therapy (390,391). (Level of Evi-
dence: B)
. PCI is reasonable in patients with STEMI who demonstrate ischemia
on noninvasive testing (410,411). (Level of Evidence: B)
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1. PCI of a hemodynamically significant stenosis in a patent infarct
artery greater than 24 hours after STEMI may be considered as part
of an invasive strategy (413–417). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. PCI of a totally occluded infarct artery greater than 24 hours after
STEMI should not be performed in asymptomatic patients with 1- or
2-vessel disease if patients are hemodynamically and electrically
stable and do not have evidence of severe ischemia (418–420).
(Level of Evidence: B)
Studies and meta-analyses suggest potential benefit for PCI
in fibrinolytic failure (385,386). In stable patients treated
with fibrinolytic therapy and clinical evidence for successful
reperfusion, an early invasive strategy with cardiac catheter-
ization performed within 24 hours decreases reinfarction
and recurrent ischemic events (388,390,391).
PCI for a hemodynamically significant stenosis in a patent
infarct artery 24 hours after STEMI as part of a revascular-
ization strategy improves outcome (410,411,413–417). PCI of
an occluded infarct artery 1 to 28 days after MI in
asymptomatic patients without evidence of myocardial isch-
emia has no incremental benefit beyond optimal medical
therapy with aspirin, beta blockers, angiotensin-converting
enzyme inhibitors, and statins in preserving LV function
and preventing subsequent cardiovascular events (418–420).
t is important to note that elective PCI of an occluded
nfarct artery has not been studied in patients with New
ork Heart Association functional class III or IV heart
ailure, rest angina, serum creatinine2.5 mg/dL, left main
or 3-vessel CAD, clinical instability, or severe inducible
ischemia on stress testing in an infarct zone that is not
Table 10. Indications for PCI in STEMI
Indications
Primary PCI*
STEMI symptoms within 12 h
Severe heart failure or cardiogenic shock
Contraindications to fibrinolytic therapy with ischemic symptoms 1
Clinical and/or electrocardiographic evidence of ongoing ischemia
between 12 and 24 h after symptom onset
Asymptomatic patients presenting between 12 and 24 h after symp
onset and higher risk
Noninfarct artery PCI at the time of primary PCI in patients without
hemodynamic compromise
Delayed or elective PCI in patients with STEMI
Clinical evidence for fibrinolytic failure or infarct artery reocclusion
Patent infarct artery 3 to 24 h after fibrinolytic therapy
Ischemia on noninvasive testing
Hemodynamically significant stenosis in a patent infarct artery 24
after STEMI
Totally occluded infarct artery 24 h after STEMI in a hemodynamic
stable asymptomatic patient without evidence of severe ischemia
*Systems goal of performing primary PCI within 90 min of first medical contact when the patient prese
to a hospital without PCI capability (396–398) (Class I; LOE: B).
COR indicates class of recommendation; LOE, level of evidence; N/A, not applicable; PCI, peakinetic or dyskinetic. c5.2.3. Cardiogenic Shock: Recommendations
CLASS I
1. PCI is recommended for patients with acute MI who develop
cardiogenic shock and are suitable candidates (384,421–423).
(Level of Evidence: B)
2. A hemodynamic support device is recommended for patients with
cardiogenic shock after STEMI who do not quickly stabilize with
pharmacological therapy (384,424–427). (Level of Evidence: B)
See Online Data Supplement 22 for additional data regarding
cardiogenic shock.
Cardiogenic shock is the leading cause of in-hospital
mortality complicating STEMI. Revascularization is the only
treatment proven to decrease mortality rates (384,421–423).
Although revascularization is almost always accomplished
through PCI, selected patients with severe 3-vessel or left
main disease can benefit from emergency CABG. Revascu-
larization attempts may be futile and not indicated in cases
of severe multiorgan failure (427). Patient selection for
revascularization is more important in the elderly, but
several observational reports demonstrate acceptable out-
comes in patients with few comorbidities and a reasonable
potential for survival (428–431). Patients who present to
hospitals without PCI capability are usually emergently
transported to a PCI center, because mortality without
transfer is markedly elevated (432).
5.2.3.1. PROCEDURAL CONSIDERATIONS FOR CARDIOGENIC SHOCK
Patients with cardiogenic shock should receive standard
pharmacological therapies, including aspirin, a P2Y12 recep-
or antagonist, and anticoagulation (427,433). Inotropic and
asopressor therapy improves perfusion pressure. Histori-
COR LOE References
I A (379–382)
I B (383,384)
I B (399,400)
IIa B (401–403)
IIb C N/A
III: Harm B (404–408)
IIa B (385,386)
IIa B (390,391)
IIa B (410,411)
IIb B (413–417)
III: No Benefit B (418–420)
hospital with PCI capability (394,395) (Class I; LOE: B) and within 120 min when the patient presents
ous coronary intervention; and STEMI, ST-elevation myocardial infarction.2 h
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in observational studies but not in 1 small RCT (433).
Endotracheal intubation and mechanical ventilation with
positive end-expiratory pressure is usually necessary in
patients with respiratory failure. Placement of a temporary
pacemaker is indicated for patients with bradycardia or
high-degree atrioventricular heart block. A pulmonary ar-
tery catheter can provide information to dose and titrate
inotropes and pressors. Further hemodynamic support is
available with IABP counterpulsation or percutaneous LV
assist devices, although no data support a reduction in
mortality rates (434).
Contrast medium injections should be minimized. Or-
thogonal angiograms of the left coronary artery and a left
anterior oblique angiogram of the right coronary artery are
usually sufficient to identify the infarct artery (435). Al-
though most patients undergoing revascularization will
receive a stent as part of the procedure, there are conflicting
data on the impact of stenting over balloon angioplasty.
Some studies reveal lower mortality rates (436–438),
whereas others reveal no benefit (439) or higher mortality
rates (440). There are no data comparing the choice of BMS
versus DES in cardiogenic shock; however, BMS are often
used because compliance with long-term DAPT is often
unclear in the emergency setting.
In patients with multivessel disease, revascularization of
the noninfarct artery may be necessary to maximize myo-
cardial perfusion. Alternatively, in patients with multivessel
disease and particularly left main disease, emergency CABG
as a primary reperfusion strategy may be preferred (50,441).
Refractory cardiogenic shock unresponsive to revasculariza-
tion may necessitate institution of more intensive cardiac
support with a ventricular assist device or other hemody-
namic support devices to allow for myocardial recovery or
subsequent cardiac transplantation in suitable patients.
5.2.4. Revascularization Before Noncardiac Surgery:
Recommendations
CLASS IIa
1. For patients who require PCI and are scheduled for elective noncar-
diac surgery in the subsequent 12 months, a strategy of balloon
angioplasty, or BMS implantation followed by 4 to 6 weeks of DAPT,
is reasonable (442–448). (Level of Evidence: B)
. For patients with DES whomust undergo urgent surgical procedures
that mandate the discontinuation of DAPT, it is reasonable to
continue aspirin if possible and restart the P2Y12 inhibitor as soon
as possible in the immediate postoperative period (444). (Level of
Evidence: C)
CLASS III: HARM
1. Routine prophylactic coronary revascularization should not be per-
formed in patients with stable CAD before noncardiac surgery
(449,450). (Level of Evidence: B)
2. Elective noncardiac surgery should not be performed in the 4 to 6
weeks after balloon angioplasty or BMS implantation or the 12
months after DES implantation in patients in whom the P2Y12
inhibitor will need to be discontinued perioperatively (208,447,
451,452). (Level of Evidence: B)The 2007 and 2009 ACC/AHA Guidelines on Periopera-
tive Cardiovascular Evaluation and Care for Noncardiac
Surgery gave detailed recommendations for the evaluation
of patients undergoing noncardiac surgery (444). Patients
with evidence of ACS should receive standard therapy,
including early revascularization, to minimize the risk of
adverse events. Patients with known significant left main or
3-vessel CAD who would otherwise benefit from revascu-
larization in terms of survival or symptomatic relief also
generally undergo revascularization before elective noncar-
diac surgery.
Two RCTs (449,450) found no benefit with routine
preoperative revascularization before noncardiac surgery.
Noncardiac surgery early after coronary stenting, particu-
larly in the first 4 weeks, is associated with a high risk of
stent thrombosis and death (444,446,448). When emer-
gency surgery is necessary, the patient should proceed to
surgery without prior PCI. When surgery is required within
30 days and coronary revascularization is required before
surgery, many clinicians perform balloon angioplasty alone
to avoid the need for DAPT. In situations where preoper-
ative revascularization is required and surgery can be de-
ferred for at least 30 days, many clinicians use BMS and
discontinue DAPT after 30 days. If surgery is elective and
can be deferred for 1 year, most clinicians would consider
DES to reduce the long-term risk of restenosis. A dilemma
occurs when a patient has undergone PCI and then unex-
pectedly requires noncardiac surgery. Many patients can
undergo surgery on DAPT, where the risk-benefit ratio will
favor continued dual antiplatelet inhibition. If it is necessary
to hold P2Y12 inhibitor therapy, most clinicians will still
ontinue aspirin uninterrupted during the perioperative
eriod if the bleeding risk is not prohibitive. When the risk
f delaying surgery or performing surgery while the patient
s on DAPT exceeds the risk of stent thrombosis from
topping DAPT, the P2Y12 inhibitor is stopped before
urgery and resumed as soon as possible afterward. No
2Y12 inhibitor “bridging” strategy (e.g., GP IIb/IIIa in-
ibitor, antithrombin therapy) has been validated.
5.3. Coronary Stents: Recommendations
CLASS I
1. Before implantation of DES, the interventional cardiologist should
discuss with the patient the need for and duration of DAPT and the
ability of the patient to comply with and tolerate DAPT (212). (Level
of Evidence: C)
. DES are useful as an alternative to BMS to reduce the risk of
restenosis in cases in which the risk of restenosis is increased and
the patient is likely to be able to tolerate and comply with prolonged
DAPT (Level of Evidence: A for elective PCI [453,453a,454–456];
Level of Evidence: C for UA/NSTEMI (453); Level of Evidence: A for
STEMI [453,456–459]).
3. Balloon angioplasty or BMS should be used in patients with high
bleeding risk, inability to comply with 12 months of DAPT, or antici-
pated invasive or surgical procedures within the next 12 months,
during which time DAPT may be interrupted (208,460–462). (Level of
Evidence: B)
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1. PCI with coronary stenting should not be performed if the patient is
not likely to be able to tolerate and comply with DAPT (208–211).
(Level of Evidence: B)
2. DES should not be implanted if the patient is not likely to be able
to tolerate and comply with prolonged DAPT or this cannot be
determined before stent implantation (208,460–462). (Level of
Evidence: B)
Coronary stent implantation is commonly performed during
PCI to prevent recoil, abrupt closure, and late restenosis
(463,464). BMS are composed of either stainless steel or
cobalt chromium alloys. Because the risk of stent thrombo-
sis is greatest within the first 30 days after implantation, the
use of DAPT is required for 30 days after implantation of
BMS (208).
In the United States, 4 types of DES are currently
approved: sirolimus-eluting stents, paclitaxel-eluting stents,
zotarolimus-eluting stents, and everolimus-eluting stents.
DES vary according to stent scaffold material and design,
drug content, and the polymer used for drug elution;
however, several common clinical features are present. First,
sirolimus-eluting stents, paclitaxel-eluting stents, and
zotarolimus-eluting stents have been demonstrated in
RCTs to be associated with a reduced need for repeat
revascularization and no increase in death or MI compared
with BMS at 4 years’ follow-up (465). Everolimus-eluting
stents have been demonstrated in RCTs to be associated
with a lower need for repeat revascularization than
paclitaxel-eluting stents, and, by inference, a lower risk for
repeat revascularization than BMS (466,467), with no
increase in death or MI at 2-year follow-up (468). Second,
each of these stents is presumed to be associated with
delayed healing based on pathologic studies and longer
periods of risk for thrombosis compared with BMS and
require longer duration of DAPT (469). In the RCTs that
led to the U.S. Food and Drug Administration (FDA)
approval of these stents, the recommended minimum dura-
tion of DAPT therapy was 3 to 6 months. Recently, the
consensus of clinical practice has been 12 months of DAPT
following DES implantation to avoid late (after 30 days)
thrombosis (208), based on observational studies of
paclitaxel-eluting stents and sirolimus-eluting stents that
indicate lower risk of late stent thrombosis with 6 months
of therapy (212). Extending DAPT beyond 1 year is
considered reasonable by some practitioners based on ob-
servational data analysis (212), but RCTs to determine
whether longer DAPT is associated with reduction in stent
thrombosis risk have not been completed. Finally, DES
therapy is more expensive than BMS. Cost-effectiveness
analysis has shown a reduction in total cost associated with
DES because of avoidance of repeat procedures, yet it may
be reasonable to consider use of BMS in patient subsets in
which the risk of restenosis is low (470).
This risk-benefit profile is most favorable for DES over
BMS when the risk of restenosis with BMS is high (Table 11).
Pooled and meta-analyses have demonstrated that in pa-tients with diabetes, use of DES decreases the risk of
restenosis compared with BMS (471,472). DES may be
more appealing for unprotected left main PCI, given the
rate and clinical consequences of restenosis in this location
(473–475). The risk of stent thrombosis is higher in
populations or lesion types excluded from RCTs of DES
(e.g., STEMI, smaller arteries [2.5 mm diameter], longer
lesions, bifurcations) (210,465). Importantly, these features
also predict both stent thrombosis (476) and restenosis in
BMS (477). The greatest risk of stent thrombosis is within
the first year, ranging from 0.7% to 2.0%, depending on
patient and lesion complexity. Late stent thrombosis risk
after 1 year with DES is observed at a rate of 0.2% to 0.4%
per year (210,478).
Compared with balloon angioplasty, routine BMS im-
plantation during primary PCI decreases risk for target-
vessel revascularization and possibly reduces MI rates but
does not reduce mortality rates (479). More recent primary
PCI studies and meta-analyses have demonstrated lower
restenosis rates without increased risk of adverse stent
outcome with DES compared with BMS. Although stent
thrombosis rates in trials of STEMI are higher than in trials
of elective PCI, the rates of stent thrombosis are not higher
with DES compared with BMS in STEMI (453,456–459).
The greatest risk for DES thrombosis is early discontin-
uation of DAPT (208,460–462). It is therefore important
to determine that the patient will likely be able to tolerate
and comply with DAPT before implantation of DES.
Therefore, DES should not be used in the presence of
financial barriers to continuing prolonged DAPT, social
barriers that may limit patient compliance, or medical issues
involving bleeding risks or the need for invasive or surgical
procedures in the following year that would interrupt
antiplatelet therapy. The need for use of long-term warfarin
and the associated increased risk of bleeding with long-term
“triple therapy” is also a consideration in deciding on DES
versus BMS (480).
Patients implanted with most contemporary coronary
stents can undergo magnetic resonance imaging (MRI)
examination any time after implantation (481,482). The
effect of the MRI examination on heating of the drug or
Table 11. Clinical Situations Associated With DES or BMS
Selection Preference
DES Generally Preferred Over BMS
(Efficacy Considerations)
BMS Preferred Over DES
(Safety Considerations)
● Left main disease
● Small vessels
● In-stent restenosis
● Bifurcations
● Diabetes
● Long lesions
● Multiple lesions
● Saphenous vein grafts
● Unable to tolerate or comply
with DAPT
● Anticipated surgery requiring
discontinuation of DAPT
within 12 mo
● High risk of bleeding
BMS indicates bare-mental stent(s); DAPT, dual antiplatelet therapy; and DES, drug-eluting
stent(s).polymer coating used in DES is unknown. There is no
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sive procedures in patients with coronary stents (483).
5.4. Adjunctive Diagnostic Devices
5.4.1. FFR: Recommendation
CLASS IIa
1. FFR is reasonable to assess angiographic intermediate coronary
lesions (50% to 70% diameter stenosis) and can be useful for
guiding revascularization decisions in patients with SIHD (12,97,
484–486). (Level of Evidence: A)
See Online Data Supplement 23 for additional data regarding
FFR.
The limitations of coronary angiography for determina-
tion of lesion severity have been well described. Angiogra-
phy may under- or overestimate lesion stenosis. Various
physiologic measurements can be made in the catheteriza-
tion laboratory, including coronary flow reserve and FFR.
The correlation of ischemia on stress testing with FFR
values of 0.75 has been established in numerous compar-
ative studies with high sensitivity (88%), specificity (100%),
positive predictive value (100%), and overall accuracy (93%)
(487). The 5-year outcomes for patients with medical
therapy based on an FFR 0.75 were superior compared
with PCI in the DEFER (Deferral Versus Performance of
Balloon Angioplasty in Patients Without Documented
Ischemia) study (485). The FAME (Fractional Flow Re-
serve Versus Angiography for Multivessel Evaluation) study
identified the benefit for deferring PCI in patients with
multivessel disease and lesion FFR 0.80, with reduced
rates of cardiac events at both 1 and 2 years (97,486).
Whereas both FFR and IVUS have been used for assess-
ment of intermediate angiographic stenosis with favorable
outcomes, FFR may reduce the need for revascularization
when compared with IVUS (488). Although IVUS is often
considered in the assessment of equivocal left main stenosis,
FFR may be similarly effective (484).
5.4.2. IVUS: Recommendations
CLASS IIa
1. IVUS is reasonable for the assessment of angiographically indeter-
minant left main CAD (489–491). (Level of Evidence: B)
2. IVUS and coronary angiography are reasonable 4 to 6 weeks and 1
year after cardiac transplantation to exclude donor CAD, detect
rapidly progressive cardiac allograft vasculopathy, and provide prog-
nostic information (492–494). (Level of Evidence: B)
. IVUS is reasonable to determine the mechanism of stent restenosis
(495). (Level of Evidence: C)
CLASS IIb
1. IVUS may be reasonable for the assessment of non–left main
coronary arteries with angiographically intermediate coronary ste-
noses (50% to 70% diameter stenosis) (489,496,497). (Level of
Evidence: B)
2. IVUS may be considered for guidance of coronary stent implanta-
tion, particularly in cases of left main coronary artery stenting
(490,495,498). (Level of Evidence: B)3. IVUS may be reasonable to determine the mechanism of stent
thrombosis (495). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. IVUS for routine lesion assessment is not recommended when
revascularization with PCI or CABG is not being contemplated.
(Level of Evidence: C)
IVUS provides a unique coronary artery assessment of lesion
characteristics, minimal and maximal lumen diameters,
cross-sectional area, and plaque area. Diagnostic uses for
IVUS include the assessment of angiographic indeterminant
coronary artery stenoses, determination of the mechanism of
stent restenosis or thrombosis, and postcardiac transplanta-
tion surveillance of CAD (488,490–492,499). For left main
coronary artery stenoses, a minimal lumen diameter of2.8
mm or a minimal lumen area of 6 mm2 suggests a
hysiologically significant lesion for which patients may
enefit from revascularization. A minimal lumen area 7.5
m2 suggests that revascularization may be safely deferred
490). A minimal lumen area between 6 and 7.5 mm2
requires further physiological assessment, such as measure-
ment of FFR (487,500). For non–left main stenoses, min-
imal lumen diameter 2.0 mm and minimal lumen area
4.0 mm2 correlate with low event rates (489). However, in
maller-diameter arteries (minimal lumen area 3.0 mm2),
measurement of FFR may more accurately reflect a signif-
icant stenosis (488). Studies correlating IVUS measures
with ischemia have not specified the size of coronary arteries
for which such correlations are valid (488,489,497).
IVUS assessment after stent thrombosis may serve to
identify stent underexpansion or malapposition (499). IVUS
is superior to angiography in the early detection of the
diffuse, immune-mediated, cardiac allograft vasculopathy;
recommendations about the use of IVUS for this purpose
were published in 2010 by the International Society of
Heart and Lung Transplantation (492). Whereas IVUS has
been an important research tool in interventional cardiol-
ogy, most clinical studies of IVUS have not been able to
demonstrate that its routine use results in a reduction of
MACE or restenosis rates (498,501,502). IVUS has been
inappropriately used in clinical practice to justify implanting
stents in mildly diseased segments that may require no
intervention (503).
5.4.3. Optical Coherence Tomography
Compared with IVUS, optical coherence tomography has
greater resolution (10 to 20 micronmeter axially) but more
limited depth of imaging (1 to 1.5 mm) (504,505). Unlike
IVUS, optical coherence tomography requires that the artery
be perfused with saline solution or crystalloid during image
acquisition and therefore does not permit imaging of ostial
lesions. Clinical studies have shown low optical coherence
tomography complication rates (506,507), similar to those of
IVUS (508). The excellent resolution of optical coherence
tomography permits detailed in vivo 2-dimensional imaging of
plaque morphological characteristics (e.g., calcification, lipid,
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rupture) (508–510) and evaluation of the arterial response to
stent implantation (e.g., stent strut neointimal thickness and
apposition) (511–513) and may be of value in clinical research.
The appropriate role for optical coherence tomography in
routine clinical decision making has not been established.
5.5. Adjunctive Therapeutic Devices
5.5.1. Coronary Atherectomy: Recommendations
CLASS IIa
1. Rotational atherectomy is reasonable for fibrotic or heavily calcified
lesions that might not be crossed by a balloon catheter or ade-
quately dilated before stent implantation (514,515). (Level of Evi-
dence: C)
CLASS III: NO BENEFIT
1. Rotational atherectomy should not be performed routinely for de
novo lesions or in-stent restenosis (516–519). (Level of Evidence: A)
Rotational atherectomy in RCTs was associated with higher
rates of MACE at 30 days and no reduction in restenosis. It
has a limited role in facilitating the dilation or stenting of
lesions that cannot be crossed or expanded with PCI
(520,521). Devices for directional coronary atherectomy are
no longer marketed in the United States.
5.5.2. Thrombectomy: Recommendation
CLASS IIa
1. Aspiration thrombectomy is reasonable for patients undergoing
primary PCI (522–524). (Level of Evidence: B)
The benefit of thrombectomy in patients with STEMI
appears to be dependent on the type of thrombectomy
technique used (522–526). No clinical benefit for routine
rheolytic thrombectomy (AngioJet device, MEDRAD In-
terventional, Minneapolis, MN and Pittsburgh, PA) has
been demonstrated in primary PCI (524–526). Two RCTs
(522,523) and a meta-analysis (524) support the use of
manual aspiration thrombectomy during primary PCI to
improve microvascular reperfusion and decrease MACE. It
is not known whether a strategy of selective thrombus
aspiration in patients with a large thrombus burden might
be equivalent to routine thrombus aspiration.
5.5.3. Laser Angioplasty: Recommendations
CLASS IIb
1. Laser angioplasty might be considered for fibrotic or moderately
calcified lesions that cannot be crossed or dilated with conventional
balloon angioplasty (527). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Laser angioplasty should not be used routinely during PCI
(516,518,528). (Level of Evidence: A)
RCTs of laser angioplasty have not demonstrated improved
clinical or angiographic PCI outcomes, although some
practitioners think that laser angioplasty may be of use in
the treatment of lesions that are difficult to dilate with
balloon angioplasty (527).5.5.4. Cutting Balloon Angioplasty: Recommendations
CLASS IIb
1. Cutting balloon angioplasty might be considered to avoid slippage-
induced coronary artery trauma during PCI for in-stent restenosis or
ostial lesions in side branches (529). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Cutting balloon angioplasty should not be performed routinely
during PCI (516,529,530). (Level of Evidence: A)
Although some small, single-center trials have suggested
that cutting balloon angioplasty was more efficacious than
balloon angioplasty, it was not found to be safer or more
effective in several large trials (516,529,531). When
balloon dilation is required for in-stent restenosis, how-
ever, cutting balloons are less likely to slip and may offer
a technical advantage over conventional balloons (529).
Scoring balloons have been used by some cardiologists as
an alternative to cutting balloons, but no RCTs have been
reported (531).
5.5.5. Embolic Protection Devices: Recommendation
CLASS I
1. Embolic protection devices (EPDs) should be used during saphe-
nous vein graft (SVG) PCI when technically feasible (532–535).
(Level of Evidence: B)
The incidence of MACE doubles in SVG PCI compared
with native-artery PCI (536). A distal balloon occlusion
EPD decreased the 30-day composite outcome of death,
MI, emergency CABG, or target-lesion revascularization
(9.6% versus 16.5%) in the only RCT (532). Subsequent
noninferiority comparisons have demonstrated similar ben-
efit with proximal occlusion and distal filter EPDs, with
benefit limited to reduction in periprocedural MI (534,535)
(Section 5.10). Distal EPDs do not improve survival or
reinfarction rates in patients undergoing native-artery PCI
(524,537).
5.6. Percutaneous Hemodynamic Support Devices:
Recommendation
CLASS IIb
1. Elective insertion of an appropriate hemodynamic support device as
an adjunct to PCI may be reasonable in carefully selected high-risk
patients. (Level of Evidence: C)
IABP counterpulsation is frequently used as an adjunct to
PCI in hemodynamically unstable patients (538,539). In
single-center series, the routine prophylactic use of IABP
during PCI in high-risk patients was associated with lower
mortality and fewer major complications compared with
rescue use of IABP (540,541). In the only RCT in high-risk
PCI patients (BCIS-1 [Balloon Pump-Assisted Coronary
Intervention Study]) (542), there was no difference in the
primary composite outcome between routine and provi-
sional use of IABP. There were also no differences in major
secondary endpoints except major procedural complica-
tions (e.g., prolonged hypotension, ventricular tachycardia/
fibrillation, cardiopulmonary arrest), which were lower in the
34
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rates tended to be higher in the routine IABP group. The
“bailout” rate of IABP insertion in the provisional IABP
group was 12%, mostly for procedural hypotension (542). A
meta-analysis of IABP therapy in patients with STEMI did
not show improved outcomes with the use of IABP (434).
The Impella Recover LP 2.5 System (Abiomed, Aachen,
Germany/Danvers, Massachusetts) is a 12.5 Fr catheter that
is inserted percutaneously through a 13 Fr femoral artery
sheath and placed across the aortic valve into the left
ventricle, through which a transaxial blood pump provides
flows of up to 2.5 L/min. This has been used in patients
with cardiogenic shock (543,544) as well as elective PCI
(545). The hemodynamic effects of the Impella 2.5 have
been studied in high-risk PCI patients, demonstrating
beneficial LV unloading effect (decreased end-diastolic
pressure and wall stress) with no change in global or systolic
LV function (546). The PROTECT I (A Prospective
Feasibility Trial Investigating the Use of the IMPELLA
Recover LP 2.5 System in Patients Undergoing High-Risk
PCI) trial in 20 patients undergoing high-risk PCI with the
Impella 2.5 system concluded that this device was safe, easy
to implant, and hemodynamically effective (547). The
Europella Registry included 144 patients undergoing
high-risk PCI and reported the safety, feasibility, and
potential usefulness of the device and that RCTs were
warranted (548). The randomized PROTECT II (A
Prospective, Multicenter, Randomized Controlled Trial
of the IMPELLA Recover LP 2.5 System Versus Intra
Aortic Balloon Pump in Patients Undergoing Non
Emergent High Risk PCI) trial, which was designed to
demonstrate superiority of Impella over IABP in terms of
1-month adverse events, was halted for futility after
interim analysis of study results (549).
The TandemHeart (CardiacAssist, Inc, Pittsburgh, PA)
is a left atrial to aorta catheter-based system that includes a
centrifugal blood pump providing flows of up to 4 L/min.
This device uses a 21 Fr cannula percutaneously inserted
into the femoral vein for transseptal access of the left atrium
with a 15 Fr catheter placed in the contralateral femoral
artery and positioned above the aortic bifurcation. An
extracorporeal pump then returns oxygenated blood from
the left atrium to the arterial system, thereby unloading the
left ventricle (550,551). The hemodynamic effects have been
studied in patients undergoing high-risk PCI (552). Several
small studies have addressed the clinical efficacy of the
TandemHeart in high-risk patients undergoing PCI
(551,553–556). In a single-center report of 68 patients
undergoing high-risk PCI using either TandemHeart or
Impella Recover 2.5, success rates (90%) and vascular
complications (7%) were similar (553).
High-risk patients may include those undergoing unpro-
tected left main or last-remaining-conduit PCI, those with
severely depressed EF undergoing PCI of a vessel supplying
a large territory, and/or those with cardiogenic shock.
Patient risk, hemodynamic support, ease of application/removal, and operator and laboratory expertise are all factors
involved in consideration of use of these devices. With
devices that require large cannula insertion, the risk of
vascular injury and related complications are important
considerations regarding necessity and choice of device.
5.7. Interventional Pharmacotherapy
5.7.1. Procedural Sedation
The term conscious sedation is falling out of favor with the
recognition that there is a spectrum of procedural sedation
levels. Most patients undergoing PCI fall under the defini-
tion of either minimal sedation (anxiolysis) or moderate
sedation (depressed consciousness with the ability to re-
spond purposefully to verbal commands) (557). Nonethe-
less, an underlying principle of procedural sedation is that
the physician should be prepared to manage one level of
sedation deeper than the level intended. Thus, cardiologists
should be cognizant of the principles of managing deep
sedation (depressed consciousness without easy arousal that
may require assistance in maintaining airway patency or
spontaneous ventilation).
A full review of procedural sedation is beyond the scope
of this document, but practice guidelines for sedation and
analgesia by nonanesthesiologists, along with The Joint
Commission standards, provides a reasonable framework.
These guidelines outline several general principles
(558,559). Before the procedure the patient should be
assessed for predictors of difficult intubation or a history of
prior difficult intubation. The patient should be monitored
by someone dedicated to observing the level and effects of
sedation. Level of consciousness, respiratory rate, blood
pressure, cardiac rhythm, and oxygen saturation by pulse
oximetry should be monitored. Available equipment should
include a high-flow oxygen source, suction, airway manage-
ment equipment, a defibrillator, resuscitation drugs, and
reversal agents appropriate for the drugs being used. A
free-flowing IV line should be established. Supplemental
oxygen is usually administered, even in the absence of
preexisting hypoxia, to provide a margin of safety.
Agents used for sedation are best given in incremental
doses, allowing adequate time for the development and
assessment of peak effect. The most commonly used agents
are listed in Appendix 4F.
5.7.2. Oral Antiplatelet Therapy: Recommendations
CLASS I
1. Patients already taking daily aspirin therapy should take 81 mg to
325 mg before PCI (301–304). (Level of Evidence: B)
2. Patients not on aspirin therapy should be given nonenteric aspirin
325 mg before PCI (301,303,304). (Level of Evidence: B)
. After PCI, use of aspirin should be continued indefinitely (560–563).
(Level of Evidence: A)
. A loading dose of a P2Y12 receptor inhibitor should be given to
patients undergoing PCI with stenting (564–568) (Level of Evi-dence: A). Options include
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(Level of Evidence: B)
b. Prasugrel 60 mg (ACS patients) (567) (Level of Evidence: B)
c. Ticagrelor 180 mg (ACS patients) (568) (Level of Evidence: B)
5. The loading dose of clopidogrel for patients undergoing PCI after
fibrinolytic therapy should be 300 mg within 24 hours and 600 mg
more than 24 hours after receiving fibrinolytic therapy (565,569).
(Level of Evidence: C)
6. Patients should be counseled on the need for and risks of DAPT
before placement of intracoronary stents, especially DES, and alter-
native therapies should be pursued if patients are unwilling or
unable to comply with the recommended duration of DAPT (208).
(Level of Evidence: C)
7. The duration of P2Y12 inhibitor therapy after stent implantation
should generally be as follows:
a. In patients receiving a stent (BMS or DES) during PCI for ACS,
P2Y12 inhibitor therapy should be given for at least 12 months.
Options include clopidogrel 75 mg daily (570), prasugrel 10 mg
daily (567), and ticagrelor 90 mg twice daily (568). (Level of
Evidence: B)
b. In patients receiving DES for a non-ACS indication, clopidogrel
75 mg daily should be given for at least 12 months if patients
are not at high risk of bleeding (208,212,571). (Level of
Evidence: B)
c. In patients receiving BMS for a non-ACS indication, clopidogrel
should be given for a minimum of 1 month and ideally up to 12
months (unless the patient is at increased risk of bleeding; then
it should be given for a minimum of 2 weeks) (208,572). (Level
of Evidence: B)
CLASS IIa
1. After PCI, it is reasonable to use aspirin 81mg per day in preference
to higher maintenance doses (302,573–576). (Level of Evidence: B)
2. If the risk of morbidity from bleeding outweighs the anticipated
benefit afforded by a recommended duration of P2Y12 inhibitor
therapy after stent implantation, earlier discontinuation (e.g., 12
months) of P2Y12 inhibitor therapy is reasonable. (Level of Evidence: C)
CLASS IIb
1. Continuation of DAPT beyond 12 months may be considered in
patients undergoing DES implantation (567,568). (Level of Evi-
dence: C)
CLASS III: HARM
1. Prasugrel should not be administered to patients with a prior history
of stroke or transient ischemic attack (567). (Level of Evidence: B)
Aspirin reduces the frequency of ischemic complications
after PCI. Although the minimum effective aspirin dosage
in the setting of PCI has not been established, aspirin 325
mg given at least 2 hours, and preferably 24 hours, before
PCI is recommended (302,303), after which aspirin 81 mg
daily should be continued indefinitely.
Several investigations have explored various loading doses
of clopidogrel before or during PCI. Compared with a
300-mg loading dose, doses of either 600 mg or 900 mg
achieve greater degrees of platelet inhibition with fewer low
responders (577). A meta-analysis of 7 studies that included
25,383 patients undergoing PCI demonstrated that inten-
sified loading of clopidogrel with 600 mg reduces the rate of
MACE without an increase in major bleeding compared dwith 300 mg (578). Another study suggested that a 600-mg
loading dose of clopidogrel is associated with improvements
in procedural angiographic endpoints and 1-year clinical
outcomes in patients with STEMI who undergo primary
PCI compared with a 300-mg dose (579). There is no
benefit with increasing the loading dose to 900 mg com-
pared with 600 mg (577). Clopidogrel 75 mg daily should
be given for a minimum of 4 weeks after balloon angioplasty
or BMS implantation (a minimum of 2 weeks if increased
bleeding risk is present) (580) and for at least 12 months
after DES implantation (unless the risk of bleeding out-
weighs the anticipated benefit). Patients should be coun-
seled on the need for and risks of DAPT before stent
implantation, especially DES implantation, and alternative
therapies pursued (BMS or balloon angioplasty) if they are
unwilling or unable to comply with the recommended
duration of DAPT.
The efficacy of clopidogrel pretreatment remains contro-
versial. Although some studies have suggested that pretreat-
ment with clopidogrel is associated with decreased platelet
aggregation and a significantly lower incidence of peripro-
cedural MI after elective PCI, others have suggested no
benefit to pretreatment compared with administration of
the drug in the catheterization laboratory (572,581,582).
When prasugrel was compared with clopidogrel in pa-
tients with ACS in TRITON–TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel–Thrombolysis In Myo-
cardial Infarction), prasugrel was associated with a signifi-
cant 2.2% reduction in absolute risk and a 19% reduction in
relative risk in the composite endpoint of cardiovascular
death, nonfatal MI, or nonfatal stroke, and a significant
increase in the rate of TIMI major hemorrhage (1.8% versus
2.4%) (567). Prasugrel is contraindicated in patients with a
history of transient ischemic attack or stroke. Patients
weighing 60 kg have an increased risk of bleeding on the
10 mg daily maintenance dose. The package insert suggests
that consideration should be given to lowering the mainte-
nance dose to 5 mg daily, although the effectiveness and
safety of the 5-mg dose has not been studied. Prasugrel is
not recommended for patients 75 years of age because of
the increased risk of fatal and intracranial bleeding and lack
of benefit, except in patients with diabetes or a history of
prior MI. Prasugrel should not be started in patients likely
to undergo urgent CABG. Prasugrel has not been studied in
elective PCI, and thus no recommendation can be made
regarding its use in this clinical setting.
Ticagrelor reversibly binds the P2Y12 receptor. Unlike
lopidogrel or prasugrel, ticagrelor is not a thienopyridine. It
lso does not require metabolic conversion to an active
etabolite. Compared with clopidogrel in patients with
CS in the PLATO (Platelet Inhibition and Patient
utcomes) trial, ticagrelor was associated with a significant
.9% reduction in absolute risk and a 16% reduction in
elative risk in the primary composite endpoint of vascular
eath, nonfatal MI, or nonfatal stroke (568). Importantly, a
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mortality was observed. Although CABG-related bleeding
was not significantly increased with ticagrelor compared
with clopidogrel, a significantly greater incidence of major
bleeding was observed in patients not undergoing CABG.
Ticagrelor was associated with higher rates of transient
dyspnea and bradycardia compared with clopidogrel, al-
though only a very small percentage of patients discontinued
the study drug because of dyspnea. Based on post hoc
analysis of the PLATO study, specifically the results in the
U.S. patient cohort, a black box warning states that main-
tenance doses of aspirin above 100 mg reduce the effective-
ness of ticagrelor and should be avoided. After any initial
dose, ticagrelor should be used with aspirin 75 mg to 100
mg per day (583). Given the twice-daily dosing and revers-
ible nature of the drug, patient compliance may be a
particularly important issue to consider and emphasize.
Ticagrelor has not been studied in elective PCI or in
patients who received fibrinolytic therapy; thus, no recom-
mendations about its use in these clinical settings can be
made.
5.7.3. IV Antiplatelet Therapy: Recommendations
STEMI
CLASS IIa
1. In patients undergoing primary PCI treated with UFH, it is reason-
able to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus
eptifibatide, or high-bolus dose tirofiban), whether or not patients
were pretreated with clopidogrel (584–590). (For GP IIb/IIIa inhibi-
tor administration in patients not pretreated with clopidogrel, Level
of Evidence: A; for GP IIb/IIIa inhibitor administration in patients
pretreated with clopidogrel, Level of Evidence: C)
CLASS IIb
1. In patients undergoing primary PCI with abciximab, it may be
reasonable to administer intracoronary abciximab (589,591–604).
(Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine precatheterization laboratory (e.g., ambulance or emer-
gency department) administration of GP IIb/IIIa inhibitors as part of
an upstream strategy for patients with STEMI undergoing PCI is not
beneficial (605–612). (Level of Evidence: B)
UA/NSTEMI
CLASS I
1. In UA/NSTEMI patients with high-risk features (e.g., elevated tro-
ponin level) not treated with bivalirudin and not adequately pre-
treated with clopidogrel, it is useful at the time of PCI to administer
a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-
bolus dose tirofiban) in patients treated with UFH (613–618). (Level
of Evidence: A)
CLASS IIa
1. In UA/NSTEMI patients with high-risk features (e.g., elevated tro-
ponin level) treated with UFH and adequately pretreated with clopi-
dogrel, it is reasonable at the time of PCI to administer a GP IIb/IIIa
inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose
tirofiban) (616,619). (Level of Evidence: B)SIHD
CLASS IIa
1. In patients undergoing elective PCI treated with UFH and not
pretreated with clopidogrel, it is reasonable to administer a GP
IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus
dose tirofiban) (619–621). (Level of Evidence: B)
CLASS IIb
1. In patients undergoing elective PCI with stent implantation treated
with UFH and adequately pretreated with clopidogrel, it might be
reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-
bolus eptifibatide, or high-bolus dose tirofiban) (619,622–624).
(Level of Evidence: B)
See Online Data Supplement 24 for additional data regarding
IV antiplatelet therapy.
In the era before DAPT, trials of adequately dosed GP
IIb/IIIa inhibitors in patients undergoing balloon angio-
plasty and coronary stent implantation demonstrated a
reduction in the incidence of composite ischemic events
with GP IIb/IIIa treatment, primarily through a reduction
of enzymatically defined MI (613,615,618,620,621). Earlier
RCTs of GP IIb/IIIa inhibitors were generally conducted in
patients treated with UFH. In some trials, use of GP
IIb/IIIa inhibitors are associated with some increased bleed-
ing risk, and trials of these agents have generally excluded
patients at high risk of bleeding (e.g., coagulopathy)
(584,587–589,613–618,620–626). Thus, recommendations
about use of GP IIb/IIIa inhibitors are best construed as
applying to those patients not at high risk of bleeding
complications. Abciximab, double-bolus eptifibatide (180
mcg/kg bolus followed 10 minutes later by a second 180
mcg/kg bolus), and high-bolus dose tirofiban (25 mcg/kg)
all result in a high degree of platelet inhibition (627–629),
have been demonstrated to reduce ischemic complications
in patients undergoing PCI (608,609,613,615,618–621),
and appear to lead to comparable angiographic and clinical
outcomes (630,631).
Trials of GP IIb/IIIa inhibitors in the setting of STEMI
and primary PCI were conducted in the era before routine
stenting and DAPT. The results of these and more recent
trials, as well as several meta-analyses, have yielded mixed
results (584–590). Therefore, it is reasonable to administer
GP IIb/IIIa inhibitors in patients with STEMI undergoing
PCI, although these agents cannot be definitively recom-
mended as routine therapy. These agents might provide
more benefit in selective use, such as in patients with large
anterior MI and/or large thrombus burden. Trials of prec-
atheterization laboratory (e.g., ambulance or emergency
room) administered GP IIb/IIIa inhibitors in patients with
STEMI undergoing PCI, with or without fibrinolytic ther-
apy, have generally shown no clinical benefit, and GP
IIb/IIIa inhibitor use in this setting may be associated with
an increased risk of bleeding (605–610,612). Studies of
intracoronary GP IIb/IIIa inhibitor administration (pre-
dominantly using abciximab) consist of several small RCTs,
retrospective analyses, retrospective and prospective regis-
cable; P
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these published studies have reported some benefit of
intracoronary administration in terms of acute angiographic
parameters, infarct size, left ventricle myocardial salvage,
and composite clinical endpoints, several other studies have
not detected any benefit with intracoronary administration
(589,591–604).
Trials of GP IIb/IIIa inhibitors in patients with UA/
NSTEMI undergoing PCI demonstrated reduced ischemic
outcomes, particularly in those with high-risk features such
as positive biomarkers. Most trials were conducted in a prior
PCI era and without P2Y12 inhibitor pretreatment
(613,615,618,632,633), although several trials have also
demonstrated benefit in patients with high-risk features
pretreated with clopidogrel (616,619). In most older studies
of stable patients undergoing balloon angioplasty or coro-
nary stenting, treatment with GP IIb/IIIa inhibitors re-
sulted in a reduction of composite ischemic events, primarily
enzymatically defined MI (613–618,620,621,634,635).
More contemporary trials of patients pretreated with a
thienopyridine have not demonstrated any benefit with GP
IIb/IIIa inhibitor therapy in patients with stable symptoms
undergoing elective PCI (619,622–624).
5.7.4. Anticoagulant Therapy
5.7.4.1. USE OF PARENTERAL ANTICOAGULANTS DURING PCI:
RECOMMENDATION
CLASS I
1. An anticoagulant should be administered to patients undergoing
PCI. (Level of Evidence: C)
Anticoagulant therapy prevents thrombus formation at
the site of arterial injury, on the coronary guidewire, and
in the catheters used for PCI (8). With rare exceptions
(636), all PCI studies have used some form of anticoag-
Table 12. Dosing of Parenteral Anticoagulants During PCI
Drug
Patient Has Received
Prior Anticoagulant Therapy
UFH ● IV GPI planned: additional UFH as needed (e.g., 2,000
ACT of 200 to 250 s
● No IV GPI planned: additional UFH as needed (e.g., 2,0
an ACT of 250 to 300 s for HemoTec, 300 to 350 s for
Enoxaparin ● For prior treatment with enoxaparin, if the last SC dose
12 h earlier or if only 1 SC dose of enoxaparin has bee
of 0.3 mg/kg of enoxaparin should be given.
● If the last SC dose was administered within the prior 8
enoxaparin should be given.
Bivalirudin For patients who have received UFH, wait 30 min, then g
then 1.75 mg/kg per h IV infusion.
Fondaparinux For prior treatment with fondaparinux, administer additio
anticoagulant possessing anti-IIa activity, taking into a
receptor antagonists have been administered.
Argatroban 200 mcg/kg IV bolus, then 15 mcg/kg per min IV infusio
ACT indicates activated clotting time; IV, intravenous; GPI, glycoprotein inhibitor; N/A, not appliulant. It is the consensus of the writing committee thatPCI be performed with the use of some form of antico-
agulant therapy. Suggested dosing regimens of parenteral
agents used in PCI are given in Table 12. Recommen-
dations for antiplatelet and antithrombin pharmacother-
apy in PCI are given in Table 13.
5.7.4.2. UFH: RECOMMENDATION
CLASS I
1. Administration of IV UFH is useful in patients undergoing PCI. (Level
of Evidence: C)
As the only anticoagulant available for PCI for many years,
UFH became the standard of care by default (8). The dose
of UFH for PCI has been based on empiricism and
experience from RCTs. Suggested UFH dosing regimens
are given in Table 12. When UFH is used during PCI, most
cardiologists assess the degree of anticoagulation by mea-
suring the activated clotting time. Although measurements
are useful to show that an anti-IIa anticoagulant has been
given, the value of the activated clotting time in current
practice has been questioned. Although studies in the
balloon angioplasty era did demonstrate a relationship
between activated clotting time levels and ischemic compli-
cations (653–655), more recent analyses from the coronary
stent era have not found a clear relationship between
activated clotting time and outcomes (349,656,657). There
may, however, be a modest relation between bleeding and
activated clotting time levels (349,657). In addition, not
only are there differences between activated clotting time
levels measured by Hemochron and HemoTec devices, but
both devices have less than optimal precision (658). Thus,
although traditional target activated clotting time levels are
included in this document, the utility of measured activated
clotting time levels in current practice should be considered
Patient Has Not Received
Prior Anticoagulant Therapy
0 U) to achieve an
5,000 U) to achieve
chron
● IV GPI planned: 50 to 70 U/kg bolus to
achieve an ACT of 200 to 250 s
● No IV GPI planned: 70 to 100 U/kg bolus to
achieve target ACT of 250 to 300 s for
HemoTec, 300 to 350 s for Hemochron
dministered 8 to
inistered, an IV dose
additional
0.5 to 0.75 mg/kg IV bolus
75 mg/kg IV bolus, 0.75 mg/kg bolus, 1.75 mg/kg per h IV
infusion
treatment with an
t whether GPI
N/A
350 mcg/kg bolus, then 25 mcg/kg per min IV
infusion
CI, percutaneous coronary intervention; SC, subcutaneous; and UFH, unfractionated heparin.to 5,00
00 to
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activated clotting time falls to150 to 180 seconds or when
the activated partial thromboplastin time falls to 50
seconds. Full-dose anticoagulation is no longer used after
successful PCI procedures. Almost all large clinical trials
have enrolled patients who underwent transfemoral PCI,
but recent small studies assessing the transradial approach
have used similar doses of UFH (659) and similar activated
clotting time target levels (660).
5.7.4.3. ENOXAPARIN: RECOMMENDATIONS
CLASS I
1. An additional dose of 0.3mg/kg IV enoxaparin should be administered
at the time of PCI to patients who have received fewer than 2 thera-
Table 13. Recommendations for Antiplatelet and Antithrombin
COR LOE References
Oral antiplatelet agents
Aspirin I B (301–304, 560–56
P2Y12 inhibitors I A (564–568)
● Clopidogrel I B (564–566)
● Prasugrel I B (567)
● Ticagrelor I B (568)
GP IIb/IIIa inhibitors (abciximab, double-bolus eptifibatide, high-bolus dose
● No clopidogrel
pretreatment
STEMI: IIa A (584–590)
UA/NSTEMI: I A (613–618)
SIHD: IIa B (619–621)
● Clopidogrel
pretreatment
STEMI: IIa C (584–590)
UA/NSTEMI: IIa B (616, 619)
SIHD: IIb B (619, 622–624)
Antithrombin agents
UFH I C N/A
Bivalirudin I B (625, 637–645)
Enoxaparin IIb B (646–650)
Anti-Xa inhibitors
Fondaparinux III: Harm C (651, 652)
ACT indicates activated clotting time; COR, class of recommendation; CVA, cerebrovascular acc
intracoronary; IV, intravenous; LOE, level of evidence; MI, myocardial infarction; N/A, not applica
STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack; UA/NSTEMI, unstablepeutic subcutaneous doses (e.g., 1 mg/kg) or received the last subcu-
taneous enoxaparin dose 8 to 12 hours before PCI (649,661–664).
(Level of Evidence: B)
CLASS IIb
1. Performance of PCI with enoxaparin may be reasonable in patients
either treated with “upstream” subcutaneous enoxaparin for UA/
NSTEMI or who have not received prior antithrombin therapy and
are administered IV enoxaparin at the time of PCI (646–650). (Level
of Evidence: B)
CLASS III: HARM
1. UFH should not be given to patients already receiving therapeutic
subcutaneous enoxaparin (649,665). (Level of Evidence: B)
macotherapy at the Time of PCI
Relevant Caveats/Comments
N/A
● A loading dose of a P2Y12 inhibitor should be given to patients
undergoing PCI with stenting.
● 600-mg loading dose now recommended.
● Contraindicated in patients with prior TIA/CVA: Class III: Harm;
LOE: B.
● Generally not recommended in patients 75 y of age (Section 5.7.2).
● Consideration of using a lower maintenance dose in patients weighing
60 kg suggested by FDA (Section 5.7.2).
● Issues of patient compliance may be especially important.
ban)
● UA/NSTEMI recommendation applies to those with high-risk features.
● GPI use in STEMI may be most appropriate in those with large anterior
MI and/or large thrombus burden.
● IC abciximab administration in STEMI: Class IIb; LOE: B.
● Precatheterization laboratory GPI administration in STEMI: Class III:
No Benefit; LOE: B.
● Recommendations apply to those not at high risk for bleeding
complications.
● Dosing based on whether or not GPI was administered.
● Lower bleeding rates associated with bivalirudin are mitigated when
used concomitantly with a GPI.
● Recommendations apply to administration of IV enoxaparin at the
time of PCI for those who have not received prior antithrombin therapy
or who have received “upstream” SC enoxaparin therapy for
UA/NSTEMI.
● An additional dose of 0.3 mg/kg IV enoxaparin should be administered
at the time of PCI to patients who have received 2 therapeutic SC
doses (e.g., 1 mg/kg) or received the last SC enoxaparin dose 8 to
12 h before PCI: Class I; LOE: B.
● Patients treated with SC enoxaparin within 12 h of PCI should not
receive additional treatment with UFH during PCI (“stacking”): Class
III: Harm; LOE: B.
● PCI should not be performed with fondaparinux as the sole
antithrombin agent in patients treated with upstream fondaparinux. An
additional anticoagulant with anti-IIa activity should be administered.
DA, U.S. Food and Drug Administration; GP, glycoprotein; GPI, glycoprotein IIb/IIIa inhibitor; IC,
I, percutaneous coronary intervention; SC, subcutaneous; SIHD, stable ischemic heart disease;
/non–ST-elevation myocardial infarction; and UFH, unfractionated heparin.Phar
3)
tirofi
ident; F
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which patients with UA/NSTEMI were started on up-
stream subcutaneous enoxaparin therapy that was continued
up to the time of PCI and trials in which patients who had
received no prior antithrombin therapy were treated with IV
enoxaparin at the time of PCI (646–650,661–663,666). In
the SYNERGY (Superior Yield of the New strategy of
Enoxaparin, Revascularization and Glycoprotein IIb/IIIa
Inhibitors) trial, there was an increased incidence of bleed-
ing in those treated with upstream enoxaparin, later attrib-
uted at least in part to the fact that some patients being
treated with enoxaparin were also administered UFH at the
time of PCI (so-called “stacking”) (649,665). Almost all
patients undergoing elective PCI who are administered
enoxaparin (0.5 mg/kg IV) will have a peak anti-Xa level
0.5 IU/mL (647). Most clinical studies have used a
regimen of 0.5 to 0.75 mg IV (667). Several studies have
used this regimen in elective patients and those with
STEMI (646). Patients who have received multiple doses of
subcutaneously administered enoxaparin who undergo PCI
within 8 hours of the last subcutaneous dose generally have
adequate degrees of anticoagulation to undergo PCI, but the
degree of anticoagulation may diminish in the 8- to 12-hour
period after the last subcutaneous dose. In such patients, as
well as in patients who have received only 1 subcutaneous
dose of enoxaparin, the addition of enoxaparin (0.3 mg/kg
IV) at the time of PCI provides an additional degree of
anticoagulation and has become standard practice
(648,661–664). Patients who undergo PCI 12 hours after
the last subcutaneous dose are usually treated with full-dose
de novo anticoagulation using an established regimen (e.g.,
full-dose UFH or bivalirudin).
5.7.4.4. BIVALIRUDIN AND ARGATROBAN: RECOMMENDATIONS
CLASS I
1. For patients undergoing PCI, bivalirudin is useful as an anticoagu-
lant with or without prior treatment with UFH (625,637–645). (Level
of Evidence: B)
2. For patients with heparin-induced thrombocytopenia, it is recom-
mended that bivalirudin or argatroban be used to replace UFH
(668,669). (Level of Evidence: B)
Bivalirudin is being increasingly used in clinical practice
(670) as evidence emerges from clinical trials across the
spectrum of CAD (638–644). In individual trials and
meta-analyses, the use of bivalirudin has been associated
with reduced bleeding compared with UFH plus a GP
IIb/IIIa inhibitor, although concerns about ischemic events
have emerged in individual studies (625,637–645). Longer-
term follow-up of the major bivalirudin trials, however,
suggests that small or nominal increases in ischemic events
have not translated into long-term consequences and that
treatment at or before the time of PCI with clopidogrel may
mitigate any increased early ischemic risk (637–645). Thus,
a treatment strategy of bivalirudin compared with heparin
(or enoxaparin) plus GP IIb/IIIa inhibitor appears to lower
the risk of bleeding complications. The lower bleeding ratesassociated with bivalirudin (compared with UFH plus a GP
IIb/IIIa inhibitor) are mitigated when used concomitantly
with a GP IIb/IIIa inhibitor (639). A strategy of use of
provisional GP IIb/IIIa inhibitor in patients treated with
bivalirudin is widely accepted (639,643,644).
In patients with heparin-induced thrombocytopenia
(671,672), a direct-thrombin inhibitor (argatroban) has
been approved as an alternative parenteral anticoagulant to
be used during PCI (668). The use of bivalirudin for
heparin-induced thrombocytopenia has been reported as
well (669).
5.7.4.5. FONDAPARINUX: RECOMMENDATION
CLASS III: HARM
1. Fondaparinux should not be used as the sole anticoagulant to
support PCI. An additional anticoagulant with anti-IIa activity should
be administered because of the risk of catheter thrombosis
(651,652). (Level of Evidence: C)
Fondaparinux, a pentasaccharide, is an indirect factor Xa
inhibitor but has no effect on thrombin. On the basis of
reports of catheter thrombosis when fondaparinux is used
alone during primary PCI (651,652), the writing committee
recommends that an anticoagulant with anti-IIa activity be
used in patients undergoing PCI (651,652). One study
suggested that clinical outcomes were better when fonda-
parinux was replaced during PCI by a standard dose of UFH
(85 U/kg, 60 U/kg with GP IIb/IIIa inhibitors) rather than
by a low dose (50 U/kg) (673).
5.7.5. No-Reflow Pharmacological Therapies:
Recommendation
CLASS IIa
1. Administration of an intracoronary vasodilator (adenosine, calcium
channel blocker, or nitroprusside) is reasonable to treat PCI-related
no-reflow that occurs during primary or elective PCI (674–689).
(Level of Evidence: B)
See Online Data Supplement 25 for additional data regarding
no-reflow therapies.
No-reflow is a broad term used to describe 2 distinct
entities. The first is “interventional no-reflow” attributed to
vasospasm and downstream embolization of debris dis-
lodged during PCI, usually in the setting of atherectomy,
thrombus, or degenerated SVGs. The second entity is
suboptimal reperfusion of an infarct artery, attributed to
endothelial injury in addition to embolization and vaso-
spasm. Angiographic no-reflow is the most obvious sequela
of the same pathophysiology that produces abnormal TIMI
frame counts and TIMI blush scores, so these measures are
often used interchangeably. The principal clinical sequela of
no-reflow is myonecrosis. Efforts to prevent no-reflow
overlap with strategies to reduce MI size and prevent
periprocedural MI.
In the setting of MI, several drugs have been shown to
reduce the incidence of no-reflow. Evidence for a beneficial
effect on no-reflow exists for abciximab, adenosine, nic-
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688,690). However, their adoption into clinical practice has
depended on their effect on hard clinical endpoints such as
infarct size and mortality. These benefits, and consequen-
tially the use of these agents, have been limited.
For interventional no-reflow, several therapies have
proven effective after no-reflow has started. These include
adenosine, calcium channel blockers, and nitroprusside
(676,678,679,681,684,686,689,691). There are fewer data
to support the use of epinephrine (692). No-reflow after
rotational atherectomy was less common with nicorandil
compared with verapamil infusions in 3 studies (693–695),
and an infusion of nicorandil/adenosine during rotational
atherectomy prevented no-reflow in 98% of patients (677).
Trials of pre-PCI intracoronary verapamil, nicardipine,
and adenosine have reported them to be safe but have not
demonstrated reductions in post-PCI no-reflow (696 –
698). Mechanical devices to prevent interventional and
myocardial infarct reperfusion no-reflow are also covered
in Section 5.5.5.
5.8. PCI in Specific Anatomic Situations
5.8.1. CTOs: Recommendation
CLASS IIa
1. PCI of a CTO in patients with appropriate clinical indications and
suitable anatomy is reasonable when performed by operators with
appropriate expertise (699–703). (Level of Evidence: B)
See Online Data Supplements 26 to 28 for additional data
regarding CTOs.
Approximately one third of patients with suspected CAD
who undergo coronary angiography have 1 CTO (defined
as occlusion of a duration 3 months) (704). Although
stress-induced ischemia can be elicited in the majority of
patients with CTO despite the presence of collaterals
(706,707), only 8% to 15% of these patients undergo PCI
(708,709). The disparity between the frequency of CTOs
and percutaneous treatment underscores not only the tech-
nical and procedural complexities of this lesion subtype but
also the clinical uncertainties regarding which patients
benefit from CTO revascularization. Studies suggest that
patients who undergo successful, rather than failed, recan-
alization of CTOs fare better in terms of symptom status
and need for CABG (699), as well as LV function (710).
However, the impact of successful CTO recanalization on
long-term survival remains unsettled (701,711,712). The
decision to try PCI for a CTO (versus continued medical
therapy or surgical revascularization) requires an individu-
alized risk-benefit analysis encompassing clinical, angio-
graphic, and technical considerations. Consultation with a
cardiothoracic surgeon and use of the Heart Team approach
in cases of CTO in which a large territory is subtended
and/or multivessel CAD is present are frequently done.
From a technical perspective, successful recanalization of
CTOs has steadily increased over the years because of
adoption of dedicated wires, novel techniques, and increasedoperator experience (702). In patients who undergo success-
ful CTO recanalization, use of DES significantly reduces
the need for repeated target-vessel revascularization, com-
pared with BMS and balloon angioplasty, without compro-
mising safety (703,713–719).
5.8.2. SVGs: Recommendations
CLASS I
1. EPDs should be used during SVG PCI when technically feasible
(532–535). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Platelet GP IIb/IIIa inhibitors are not beneficial as adjunctive ther-
apy during SVG PCI (212,571,720,721). (Level of Evidence: B)
CLASS III: HARM
1. PCI is not recommended for chronic SVG occlusions (722–724).
(Level of Evidence: C)
See Online Data Supplement 29 for additional data regarding
SVG.
Adverse cardiac event rates are doubled after SVG PCI
compared with native-artery PCI (536). A distal balloon
occlusion EPD decreased the 30-day composite outcome
of death, MI, emergency CABG, or target-lesion revas-
cularization (9.6% versus 16.5%) in the only RCT com-
paring embolic protection with no embolic protection
(532). Subsequent noninferiority comparisons have dem-
onstrated similar benefit with proximal occlusion and
distal filter EPDs, with benefit limited to reduction in
periprocedural MI (534,535). PCI in chronic SVG oc-
clusion is associated with low success rates, high compli-
cation rates, and poor long-term patency rates (722,723).
Restenosis and target-vessel revascularization rates are
lower with DES compared with BMS, although mortal-
ity and stent thrombosis rates are similar (725). The use
of covered stents is limited to the treatment of the
uncommon complication of SVG perforation. Balloon
angioplasty for distal SVG anastomotic stenoses has low
restenosis rates (724), so stenting is commonly reserved at
this location for suboptimal balloon angioplasty results or
restenosis. Routine GP IIb/IIIa inhibitor therapy has not
proven beneficial in SVG PCI (720). Fibrinolytic therapy
is no longer used for thrombus-containing lesions, but
rheolytic or manual aspiration thrombectomy is some-
times employed.
5.8.3. Bifurcation Lesions: Recommendations
CLASS I
1. Provisional side-branch stenting should be the initial approach in
patients with bifurcation lesions when the side branch is not large and
has only mild or moderate focal disease at the ostium (726–729).
(Level of Evidence: A)
CLASS IIa
1. It is reasonable to use elective double stenting in patients with
complex bifurcationmorphology involving a large side branch where
the risk of side-branch occlusion is high and the likelihood of
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dence: B)
Side-branch occlusion or severe stenosis after stenting the
main artery in coronary bifurcation PCI occurs in 8% to
80% of unselected patients (732,734). The frequency of
side-branch occlusion is related to complex bifurcation
morphology (severe and/or long side-branch ostial stenosis,
large plaque burden in the side-branch ostium, and/or
unfavorable side-branch angulation) (732,735,736). Side-
branch occlusion after PCI is associated with Q-wave and
non–Q-wave MI (734,735). Therefore, preservation of
physiologic flow in the side branch after PCI is important
(736). There are 2 bifurcation PCI strategies: provisional
stenting (stenting the main vessel with additional balloon
angioplasty or stenting of the side branch only in the case of
an unsatisfactory result) and elective double stenting of the
main vessel and the side branch. When there is an unsatis-
factory result in the side branch from the provisional stent in
the main branch, sometimes balloon angioplasty alone in
the side branch will improve the result and stenting the side
branch is not necessary. Some experts have suggested that
using the side-branch balloon alone will distort the main
branch stent and thus this always needs to be a kissing
balloon inflation.
In patients with low-risk bifurcation lesions (minimal or
moderate ostial side-branch disease [50% diameter steno-
sis] of focal length [5 to 6 mm]), provisional stenting yields
similar clinical outcome to elective double stenting, with
lower incidence of periprocedural biomarker elevation
(726–729). Conversely, in patients with high-risk bifurca-
tions, elective double stenting is associated with a trend
toward higher angiographic success rates, lower in-hospital
MACE, and better long-term patency of the side branch
compared with provisional stenting (193). Culotte, Crush,
and T-stent techniques have been studied in RCTs (726–
729,737). Use of DES yields better outcomes than BMS
(738), and sirolimus-eluting stents yield better outcomes
than paclitaxel-eluting stents (739–742). Clinical evidence
supports the use of final kissing balloon inflation after
elective double stenting (743).
5.8.4. Aorto-Ostial Stenoses: Recommendations
CLASS IIa
1. IVUS is reasonable for the assessment of angiographically indeter-
minant left main CAD (744,745). (Level of Evidence: B)
2. Use of DES is reasonable when PCI is indicated in patients with an
aorto-ostial stenosis (746,747). (Level of Evidence: B)
Aorto-ostial stenoses of native coronary arteries (left main
coronary artery and right coronary artery) are most com-
monly caused by atherosclerosis, but they can also occur in
patients with congenital malformations, radiation exposure,
vasculitides, and aortic valve replacement. The angiographic
diagnosis of aorto-ostial disease is not always straightfor-
ward, especially in the ostial left main coronary artery,
where eccentricity and angulation can be mistaken forstenosis (490,748). Aorto-ostial disease can be evaluated
with IVUS (744,745); FFR (with IV adenosine) has also
been used (484,749). The treatment of aorto-ostial ste-
noses with balloon angioplasty has been associated with
lower procedural success rates, more frequent in-hospital
complications, and a greater likelihood of late restenosis
(750). Although atherectomy devices (directional
atherectomy, rotational atherectomy, and excimer laser
angioplasty) have improved acute angiographic results
over balloon angioplasty, restenosis has remained a lim-
itation (751). In patients with aorto-ostial stenoses un-
dergoing PCI, use of DES has been shown to reduce
restenosis compared with BMS (176,746,752).
5.8.5. Calcified Lesions: Recommendation
CLASS IIa
1. Rotational atherectomy is reasonable for fibrotic or heavily calcified
lesions that might not be crossed by a balloon catheter or ade-
quately dilated before stent implantation (514,515,520). (Level of
Evidence: C)
The presence of coronary calcification is a marker for
significant CAD and increased long-term mortality (753).
Calcified coronary lesions are not a homogenous entity, and
their response to PCI varies according to severity of calci-
fication. Severely calcified lesions respond poorly to balloon
angioplasty (230,754), and when stents are implanted in
such lesions, an incomplete and asymmetrical stent expan-
sion occurs in the majority of cases (755). Attempts to
remedy the underexpanded stents with aggressive high-
pressure balloon dilatation may result in coronary artery
rupture (756). All the published prospective RCTs that
evaluated the various catheter-based coronary interventional
devices excluded patients with severely calcified lesions.
Therefore, the evidence base for best PCI practices in
patients with severely calcified lesions comes from nonran-
domized single-arm studies. Among the various adjunct
devices that are used to facilitate PCI in severely calcified
lesions, only rotational atherectomy has been shown to have
potential utility (514,757). Although rotational atherectomy
increases the chances of angiographic success in severely
calcified lesions, its use as a stand-alone device has not led
to a reduction in restenosis (520,521,758). Several retro-
spective studies have shown that in patients with severely
calcified lesions, the use of rotational atherectomy before
implantation of BMS (514) or DES (515) is safe.
Intermediate-term patency is more favorable with DES
than BMS (759).
5.9. PCI in Specific Patient Populations
Several specific patient subsets with higher risks for PCI,
and at times higher absolute clinical benefit, have tradition-
ally been underrepresented in RCTs and are described
below.
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The elderly constitute a growing proportion of patients
considered for PCI (760). In 1 series examining trends over
a 25-year period, the proportion of patients undergoing PCI
who were 75 to 84 years of age doubled, and those 85
years of age increased 5-fold (761). Age is one of the
strongest predictors of mortality after PCI (762), and elderly
patients present with a substantially higher clinical risk
profile (760). Nonetheless, the angiographic success rates
and clinical benefits of PCI in elderly patients are similar to
younger patients (763). In fact, the absolute benefit is
typically greater because of higher absolute risk of adverse
outcomes in these patients (764). However, increased risks
of complications such as major bleeding and stroke mandate
careful consideration of the benefits and risks of PCI in
elderly patients (373).
5.9.2. Diabetes
Patients with diabetes represent approximately one third of
patients undergoing PCI in the United States. Restenosis,
which had been a major limitation of PCI, is significantly
reduced in patients with diabetes treated with DES com-
pared with BMS (471). However, there are no definitive
data from RCTs supporting different clinical outcomes for
different types of DES (765), with a recent meta-analysis of
35 RCTs involving 3,852 patients with diabetes unable to
find major differences between patients receiving sirolimus-
eluting stents or paclitaxel-eluting stents (472). Numerous
analyses and clinical studies have evaluated how the pres-
ence of diabetes may impact the clinical outcome of patients
undergoing PCI and decisions about PCI or CABG
(14,116,163,164,186). These studies and the approach to
revascularization decisions in diabetes are addressed in
Section 4.
Diabetes is an important risk factor for the development
of contrast-induced AKI. Strategies to reduce the risk of
contrast-induced AKI in patients with diabetes are dis-
cussed in Section 4.4.
5.9.3. Women
Cardiovascular disease is the leading cause of death in
women in the United States and Europe (766), and an
estimated 35% of PCIs in the United States are performed
in women (767,768). Women undergoing PCI usually have
more risk factors (including hypertension, advanced age,
elevated cholesterol, and more significant and diffuse CAD)
compared with men (769). Women with STEMI are also
less likely to receive early medical treatments and experience
longer delays to reperfusion therapy (770,771). In subgroup
analyses of clinical trials, use of DES appears to be similarly
efficacious in women and men (772).5.9.4. CKD: Recommendation
CLASS I
1. In patients undergoing PCI, the glomerular filtration rate should be
estimated and the dosage of renally cleared medications should be
adjusted (298–300). (Level of Evidence: B)
CKD is an independent risk factor for the development and
progression of CAD (773,774), and is also associated with
worse prognosis after MI or PCI (369,775). A glomerular
filtration rate of 60 mL/min per 1.73 m2 of body surface
rea should be considered abnormal. Patients with CKD
ndergoing PCI have a higher risk of complications, includ-
ng bleeding (776), AKI, and death (236,777), but CKD is
ot a strong predictor of restenosis after BMS or DES
778). Strategies to reduce the risk of contrast-induced AKI
n patients with CKD are discussed in Section 4.4. Platelet
ysfunction and overdosing of antiplatelet and antithrombin
rugs (350) in patients with CKD contribute to the in-
reased risk of bleeding. The Cockcroft-Gault formula is
ommonly used as a surrogate marker for estimating creat-
nine clearance, which in turn estimates glomerular filtration
ate (298,299,779,780). Medications that require dosage
djustments in patients with CKD include eptifibatide,
irofiban, bivalirudin, enoxaparin, and fondaparinux (781).
.9.5. Cardiac Allografts
ardiac allograft vasculopathy is a major cause of death in
ardiac transplant recipients after their first year of survival
782). In general, revascularization for cardiac allograft
asculopathy with PCI is only palliative, with no evidence
upporting benefit in regard to long-term survival or avoid-
nce of retransplantation. The restenosis rate after PCI in
atients with cardiac allograft vasculopathy is high, al-
hough stent implantation reduces early and midterm reste-
osis compared with balloon angioplasty. DES have been
hown to have a tendency to lower restenosis rates compared
ith BMS (783,784). Thus, many clinicians perform stent-
ng with DES or BMS in cardiac transplant patients with
iscrete lesions who have an abnormal stress test or symp-
oms suggestive of myocardial ischemia.
5.10. Periprocedural MI Assessment:
Recommendations
CLASS I
1. In patients who have signs or symptoms suggestive of MI during or
after PCI or in asymptomatic patients with significant persistent
angiographic complications (e.g., large side-branch occlusion, flow-
limiting dissection, no-reflow phenomenon, or coronary thrombo-
sis), creatine kinase-MB and/or troponin I or T should be measured.
(Level of Evidence: C)
CLASS IIb
1. Routine measurement of cardiac biomarkers (creatine kinase-MB
and/or troponin I or T) in all patients after PCI may be reasonable.
(Level of Evidence: C)
Major events leading to ischemia or MI after PCI include
acute closure, embolization and no-reflow, side-branch
occlusion, and acute stent thrombosis. Issues surrounding
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complex, especially given that the definition of PCI-related
MI has evolved over the years and most events are asymp-
tomatic. The most recent consensus definition of MI
considers troponin elevations of 3 times the upper limit of
normal as a PCI-related MI in patients with normal
baseline levels; this is further classified as a type 4a MI
(240). This definition is supported by studies with delayed-
enhancement MRI confirming that there is irreversible
injury in the myocardium associated with biomarker eleva-
tions and that the size of this injury correlates with the
degree of elevation (785). Furthermore, a meta-analysis of
15 observational studies found that troponin elevations at
any level were linked with worse in-hospital and long-term
outcomes; elevations 3 times the upper limit of normal
predicted even worse outcomes (242). Other observational
data, however, have raised concerns about whether the
relationship is causal (786,787). A recent study found
creatinine kinase-MB to correlate better with MRI-
detected MI than troponin level (788). Definitions of
PCI-related MI are being reevaluated by the Task Force for
the Redefinition of Myocardial Infarction. Although there
may be value for individual operators and hospitals to
routinely measure cardiac biomarkers to track rates of
PCI-related MI, at present there are not compelling data to
recommend this for all PCI procedures.
5.11. Vascular Closure Devices: Recommendations
CLASS I
1. Patients considered for vascular closure devices should undergo a
femoral angiogram to ensure their anatomic suitability for deploy-
ment. (Level of Evidence: C)
CLASS IIa
1. The use of vascular closure devices is reasonable for the purposes of
achieving faster hemostasis and earlier ambulation compared with
the use of manual compression (257,789–791). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. The routine use of vascular closure devices is not recommended for
the purpose of decreasing vascular complications, including bleed-
ing (256,257,789–792). (Level of Evidence: B)
See Online Data Supplement 30 for additional data regarding
vascular closure devices.
Vascular (arteriotomy) closure devices have been ex-
tensively reviewed (790), most recently in a 2010 AHA
scientific statement (257), which issued several formal
recommendations. The results of 4 meta-analyses have
found that vascular closure devices decrease time to
hemostasis compared with manual compression but do
not decrease vascular complications, bleeding complica-
tions, or the need for blood transfusions (256,789,
791,793). Future studies of vascular closure devices need
to be randomized, include “high-risk” patients and “high-
risk” anatomy, use blinded endpoint adjudication as
much as possible, use well-defined and comprehensive
complication endpoints, and be adequately powered to rdetect clinically important endpoints, particularly bleed-
ing and vascular complications.
6. Postprocedural Considerations
Postprocedural considerations in patients undergoing PCI are
discussed below and summarized in Table 14. Some recom-
mendations and text regarding DAPT in Section 5.7.2 are
intentionally repeated in this section for reader ease of use.
6.1. Postprocedural Antiplatelet Therapy:
Recommendations
CLASS I
1. After PCI, use of aspirin should be continued indefinitely (560–563).
(Level of Evidence: A)
2. The duration of P2Y12 inhibitor therapy after stent implantation
should generally be as follows:
a. In patients receiving a stent (BMS or DES) during PCI for ACS,
P2Y12 inhibitor therapy should be given for at least 12 months.
Options include clopidogrel 75 mg daily (570), prasugrel 10 mg
daily (567), and ticagrelor 90 mg twice daily (568). (Level of
Evidence: B)
b. In patients receiving DES for a non-ACS indication, clopidogrel
75 mg daily should be given for at least 12 months if the
patient is not at high risk of bleeding (208,212,571). (Level of
Evidence: B)
c. In patients receiving BMS for a non-ACS indication, clopidogrel
should be given for a minimum of 1 month and ideally up to 12
months (unless the patient is at increased risk of bleeding; then
it should be given for a minimum of 2 weeks) (572). (Level of
Evidence: B)
. Patients should be counseled on the importance of compliance with
DAPT and that therapy should not be discontinued before discus-
sion with their cardiologist (208). (Level of Evidence: C)
CLASS IIa
1. After PCI, it is reasonable to use aspirin 81mg per day in preference
to higher maintenance doses (302,573–576). (Level of Evidence: B)
2. If the risk of morbidity from bleeding outweighs the anticipated
benefit afforded by a recommended duration of P2Y12 inhibitor
therapy after stent implantation, earlier discontinuation (e.g., 12
months) of P2Y12 inhibitor therapy is reasonable. (Level of Evidence: C)
CLASS IIb
1. Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12
months may be considered in patients undergoing placement of
DES (567,568). (Level of Evidence: C)
Continued treatment with the combination of aspirin and a
P2Y12 inhibitor antagonist after PCI appears to reduce
ACE (570,572). On the basis of RCT protocols, second-
ry prevention measures, and expert consensus opinion,
spirin 81 mg daily should be given indefinitely after PCI.
Likewise, P2Y12 inhibitors should be given for a mini-
um of 1 month after BMS (minimum 2 weeks for patients
t significant increased risk of bleeding) (580) and for 12
onths after DES and ideally in all patients who are not at
igh risk of bleeding.
The 2009 STEMI/PCI guidelines update (10) listed theecommendation “if the risk of morbidity because of bleed-
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Recommendations COR LOE References
Aspirin
After PCI, use of aspirin should be continued indefinitely. I A (560–563)
After PCI, it is reasonable to use aspirin 81 mg/d in preference to higher
maintenance doses.
IIa B (302,573–576)
P2Y12 inhibitors
In patients receiving a stent (BMS or DES) during PCI for ACS, P2Y12 inhibitor
therapy should be given for at least 12 mo. Options include clopidogrel 75 mg/d,
prasugrel 10 mg/d, and ticagrelor 90 mg twice daily.
I B (567,568,570)
In patients receiving DES for a non-ACS indication, clopidogrel 75 mg/d should be
given for at least 12 mo if patients are not at high risk of bleeding.
I B (208,212,571)
In patients receiving BMS for a non-ACS indication, clopidogrel should be given for
a minimum of 1 mo and ideally up to 12 mo (unless the patient is at increased
risk of bleeding; then it should be given for a minimum of 2 wk).
I B (572)
Patients should be counseled on the importance of compliance with DAPT and that
therapy should not be discontinued before discussion with their cardiologist.
I C (208)
PPIs should be used in patients with a history of prior GI bleeding who require
DAPT.
I C (794)
If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by
a recommended duration of P2Y12 inhibitor therapy after stent implantation,
earlier discontinuation (e.g., 12 mo) of P2Y12 inhibitor therapy is reasonable.
IIa C N/A
Use of PPIs is reasonable in patients with an increased risk of GI bleeding (e.g.,
advanced age, concomitant use of warfarin, steroids, NSAIDs, Helicobacter pylori
infection) who require DAPT.
IIa C (794)
Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12 mo may be
considered in patients undergoing placement of DES.
IIb C N/A
Routine use of a PPI is not recommended for patients at low risk of GI bleeding,
who have much less potential to benefit from prophylactic therapy.
III: No Benefit C (794)
Exercise testing
For patients entering a formal cardiac rehabilitation program after PCI, treadmill
exercise testing is reasonable.
IIa C (567,568)
Routine periodic stress testing of asymptomatic patients after PCI without specific
clinical indications should not be performed.
III: No Benefit C (795)
Cardiac rehabilitation
Medically supervised exercise programs (cardiac rehabilitation) should be
recommended to patients after PCI, particularly for patients at moderate to high
risk, for whom supervised exercise training is warranted.
I A (796–804)
Secondary prevention (recommendations included from the 2011 AHA/ACCF Secondary Prevention and Risk Reduction Therapy Guideline) (805)
Lipid management with lifestyle modification
and lipid-lowering pharmacotherapy
Lifestyle modification I B (806,807)
Statin therapy I A (344,806,808–810,810a)
Statin therapy which lowers
LDL cholesterol to 100
mg/dL and achieves at
least a 30% lowering of
LDL cholesterol
I C (344,806,808–810,810a)
Statin therapy which lowers
LDL cholesterol to 70
mg/dL in very high-risk*
patients
IIa B (345,808–810,810a,811,812)
Blood pressure control (with a blood pressure
goal of 140/90 mm Hg)
Lifestyle modification I B (813–817)
Pharmacotherapy I A (813,818,819)
Diabetes management (e.g., lifestyle modification and pharmacotherapy)
coordinated with the patient’s primary care physician and/or endocrinologist
I C N/A
Complete smoking cessation I A (820–823)
*Presence of established cardiovascular disease plus 1) multiple major risk factors (especially diabetes), 2) severe and poorly controlled risk factors (especially continued cigarette smoking), 3) multiple
risk factors of the metabolic syndrome (especially high triglycerides 200 mg/dL plus non–HDL cholesterol 130 mg/dL with low HDL cholesterol [40 mg/dL]), and 4) acute coronary syndromes.ACS indicates acute coronary syndromes; BMS, bare-metal stent(s); COR, class of recommendation; DAPT, dual antiplatelet therapy; DES, drug-eluting stent(s); GI, gastrointestinal; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; LOE, level of evidence; N/A, not applicable; NSAID, nonsteroidal anti-inflammatory drug; PCI, percutaneous coronary intervention; and PPI, proton pump inhibitor.
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opyridine therapy, earlier discontinuation should be consid-
ered” as a Class I recommendation, although the language
used, in part, was consistent with a Class IIa recommenda-
tion. To clarify the intent of the recommendation, as well as
to acknowledge the inherent difficulties in weighing bleed-
ing and stent thrombosis risks, the recommendation is
designated a Class IIa recommendation, using the phrase
“earlier discontinuation is reasonable.” Recommendations
regarding P2Y12 inhibitor discontinuation before elective or
urgent CABG are provided in the “2011 ACCF/AHA
Guideline for Coronary Artery Bypass Graft Surgery” (824).
6.1.1. PPIs and Antiplatelet Therapy:
Recommendations
CLASS I
1. PPIs should be used in patients with a history of prior gas-
trointestinal (GI) bleeding who require DAPT (794). (Level of
Evidence: C)
CLASS IIa
1. Use of PPIs is reasonable in patients with an increased risk of GI
bleeding (e.g., advanced age, concomitant use of warfarin, steroids,
nonsteroidal anti-inflammatory drugs, Helicobacter pylori infection)
who require DAPT (794). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Routine use of a PPI is not recommended for patients at low risk of
GI bleeding, who have much less potential to benefit from prophy-
lactic therapy (794). (Level of Evidence: C)
See Online Data Supplement 31 for additional data regarding
the clopidogrel–PPI interaction.
PPIs are often prescribed prophylactically when clopi-
dogrel is started to prevent GI complications such as
ulceration and bleeding due to DAPT (825). There is
pharmacodynamic evidence that omeprazole interferes with
clopidogrel metabolism (826,827), but there is no clear
evidence implicating other PPIs. However, even with
omeprazole, there are no convincing data supporting an
important clinical drug–drug interaction (826). The FDA
communication about an ongoing safety review of clopi-
dogrel advises that healthcare providers avoid the use of
clopidogrel in patients with impaired CYP2C19 function
due to known genetic variation or drugs that inhibit
CYP2C19 activity. The FDA notes that there is no evidence
that other drugs that reduce stomach acid, such as
histamine-2 receptor antagonists (except cimetidine) or
antacids, interfere with clopidogrel responsiveness. The
COGENT (Clopidogrel and the Optimization of Gastro-
intestinal Events) trial randomized patients with DAPT to
clopidogrel and omeprazole or clopidogrel and placebo, and
while there was no difference in cardiovascular events
between the 2 groups, GI events were halved in those
randomized to omeprazole (828). It is reasonable to care-
fully evaluate the indication for PPI therapy in patients
treated with clopidogrel, based on the presence or absence ofthe risk factors discussed above (794). The need for GI
protection increases with the number of risk factors for
bleeding. Prior upper GI bleeding is the strongest and most
consistent risk factor for GI bleeding on antiplatelet ther-
apy. Patients with ACS and prior upper GI bleeding are at
substantial cardiovascular risk, so DAPT with concomitant
use of a PPI may provide the optimal balance of risk and
benefit. It should be noted that PPIs, by decreasing adverse
GI effects related to clopidogrel, might decrease patients’
discontinuation of clopidogrel. In patients in whom there is
a clear indication for PPI therapy, some clinicians may
choose to use a PPI other than omeprazole.
6.1.2. Clopidogrel Genetic Testing: Recommendations
CLASS IIb
1. Genetic testing might be considered to identify whether a patient at
high risk for poor clinical outcomes is predisposed to inadequate
platelet inhibition with clopidogrel (829). (Level of Evidence: C)
2. When a patient predisposed to inadequate platelet inhibition with
clopidogrel is identified by genetic testing, treatment with an alter-
nate P2Y12 inhibitor (e.g., prasugrel or ticagrelor) might be consid-
ered (829). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. The routine clinical use of genetic testing to screen patients treated
with clopidogrel who are undergoing PCI is not recommended (829).
(Level of Evidence: C)
On March 12, 2010, the FDA approved a new label for
clopidogrel with a “boxed warning” about the diminished
effectiveness of clopidogrel in patients with impaired ability
to convert the drug into its active metabolite (829). Patients
with decreased CYP2C19 function because of genetic poly-
orphisms metabolize clopidogrel poorly and have higher
ates of cardiovascular events after ACS and PCI than
atients with normal CYP2C19 function. The warning also
otes that tests are available to identify patients with genetic
olymorphisms and that alternative treatment strategies
hould be considered for patients who are poor metaboliz-
rs. The clopidogrel boxed warning leaves the issue of
hether to perform CYP2C19 testing up to the individual
hysician. It does not specifically require genetic testing or
ther changes in evaluation or treatment and does not imply
hat there are solid evidence-based reasons for such actions.
ather, it serves to inform clinicians of genetic variations in
esponse to clopidogrel and to emphasize that clinicians
hould use this knowledge to make decisions about how to
reat individual patients. At the present time, the evidence
ase is insufficient to recommend routine genetic testing in
atients undergoing PCI. There may be a potential role for
enetic testing for patients undergoing elective high-risk
CI procedures (e.g., unprotected left main, bifurcating left
ain, or last patent coronary artery).
.1.3. Platelet Function Testing: Recommendations
CLASS IIb
1. Platelet function testing may be considered in patients at high riskfor poor clinical outcomes (829). (Level of Evidence: C)
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alternative agents, such as prasugrel or ticagrelor, might be consid-
ered (829). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. The routine clinical use of platelet function testing to screen pa-
tients treated with clopidogrel who are undergoing PCI is not
recommended (829). (Level of Evidence: C)
Platelet function testing to tailor antiplatelet therapy has
received considerable interest. The GRAVITAS (Gauging
Responsiveness With A VerifyNow Assay-Impact On
Thrombosis And Safety) trial and several other ongoing
trials test the concept that tailoring antiplatelet therapy
based on platelet responsiveness assessed in an ex vivo P2Y12
assay will improve cardiovascular outcomes (830). In
GRAVITAS, treatment with high-dose clopidogrel for 6
months in patients with high platelet reactivity on standard-
dose clopidogrel was not beneficial. At the present time, the
evidence base is insufficient to recommend routine platelet
function testing. The results of 2 ongoing trials (DANTE
[Dual Antiplatelet Therapy Tailored on the Extent of
Platelet Inhibition] and ARCTIC [Double Randomization
of a Monitoring Adjusted Antiplatelet Treatment Versus a
Common Antiplatelet Treatment for DES Implantation,
and Interruption Versus Continuation of Double Antiplate-
let Therapy, One Year After Stenting]) will provide further
information on the issue (www.clinicaltrials.gov).
6.2. Stent Thrombosis
The majority of stent thrombosis occurs early (0 to 30 days
after PCI). In broad clinical practice, the expected rate of
early stent thrombosis is 1%, and beyond 30 days it is
0.2% to 0.6% per year (210,831). Acute stent thrombosis
often presents as STEMI, and emergency revascularization
is indicated. Acute stent thrombosis is associated with
mortality rates of 20% to 45% (832). Survivors are also at
risk of recurrent stent thrombosis (833).
Mechanical and pharmacological factors are the most
frequent cause of acute stent thrombosis. After the usual
measures to restore flow in the infarct-related artery, it is
important to consider the etiology of stent thrombosis as it
pertains to further therapy and avoidance of recurrence.
IVUS may identify factors such as an undersized stent,
incomplete stent apposition, residual stenosis, or dissection
and can guide subsequent treatment. The most common
cause of acute stent thrombosis is nonadherence to DAPT;
however, resistance to aspirin or thienopyridines and pro-
thrombotic states such as congenital or acquired thrombophilic
states (malignancy) are additional risk factors (834,835).
Given the poor prognosis of stent thrombosis and the
uncertainties surrounding treatment, the importance of
prevention must be emphasized. This includes ensuring
compliance with DAPT and adequate stent sizing and
expansion (836).6.3. Restenosis: Recommendations
CLASS I
1. Patients who develop clinical restenosis after balloon angioplasty
should be treated with BMS or DES if anatomic factors are appro-
priate and if the patient is able to comply with and tolerate DAPT
(837). (Level of Evidence: B)
2. Patients who develop clinical restenosis after BMS should be
treated with DES if anatomic factors are appropriate and the patient
is able to comply with and tolerate DAPT (838–840). (Level of
Evidence: A)
CLASS IIa
1. IVUS is reasonable to determine the mechanism of stent restenosis
(495). (Level of Evidence: C)
CLASS IIb
1. Patients who develop clinical restenosis after DES may be consid-
ered for repeat PCI with balloon angioplasty, BMS, or DES contain-
ing the same drug or an alternative antiproliferative drug if ana-
tomic factors are appropriate and the patient is able to comply with
and tolerate DAPT (495). (Level of Evidence: C)
6.3.1. Background and Incidence
After balloon angioplasty, mechanisms contributing to re-
stenosis include smooth muscle cell migration and prolifer-
ation, platelet deposition, thrombus formation, elastic re-
coil, and negative arterial remodeling. Stents block elastic
recoil and negative remodeling, and the predominant mech-
anism for restenosis after stent implantation is neointimal
hyperplasia. Restenosis rates vary, depending on whether
angiographic restenosis (defined as 50% diameter stenosis
at follow-up angiography) or clinical restenosis (symptom-
atic and requiring target-lesion revascularization or target-
vessel revascularization) is measured, as well as on patient
characteristics, coronary anatomy considerations, and device
type (balloon angioplasty, BMS, or DES). The incidence of
angiographic restenosis rates for uncomplicated lesions
treated in RCTs ranges from 32% to 42% after balloon
angioplasty (463,464) and from 16% to 32% after BMS
(463,464), and is generally 10% after DES (454,841).
Less than half of patients with angiographic restenosis
present with symptomatic, clinically relevant restenosis at
1-year follow-up, and a pooled analysis of 6,186 patients
from 6 trials of BMS showed target-lesion revascularization
was performed in 12% and target-vessel revascularization in
14% at 1 year (842,843). Patients with clinical restenosis
typically present with recurrent exertional angina, but 5% to
10% of patients present with acute MI and 25% with UA
(844,845).
Factors associated with an increased risk of restenosis in
various models include clinical setting (STEMI, ACS, daily
angina), patient characteristics (diabetes, age 55 to 60
years, prior PCI, male sex, multivessel CAD), lesion loca-
tion (unprotected left main, SVG), and procedural charac-
teristics (minimum stent diameter 2.5 mm, total stent
length 40 mm) (778,846).
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plasty, BMS, and DES are reviewed in the following
sections. In addition to repeat PCI, intensified medical
therapy or CABG are often also reasonable strategies,
dependent on initial treatment (e.g., balloon angioplasty,
BMS), pattern of restenosis, likelihood of recurrent reste-
nosis, ability to intensify medical therapy, suitability for
CABG, and patient preference. Repeat PCI with BMS or
DES is not appropriate if the patient is not able to comply
with and tolerate DAPT.
6.3.2. Restenosis After Balloon Angioplasty
For clinical restenosis after balloon angioplasty, stent im-
plantation is superior to repeat balloon angioplasty or
atheroablation devices. The REST (REstenosis STent)
study showed that target-lesion revascularization rates were
10% for stent-treated patients and 27% for balloon-treated
patients (p0.001) (837).
6.3.3. Restenosis After BMS
In-stent restenosis is classified according to these angio-
graphic characteristics: Pattern I includes focal lesions 10
mm in length; Pattern II is in-stent restenosis 10 mm
within the stent; Pattern III includes in-stent restenosis
10 mm extending outside the stent; and Pattern IV is
totally occluded in-stent restenosis (847). Treatment of
in-stent restenosis with balloon angioplasty, repeat BMS, or
atheroablation devices for Patterns I to IV resulted in 1-year
target-lesion revascularization rates of 19%, 35%, 50%, and
83%, respectively. For clinical restenosis after BMS, repeat
stenting with DES is preferred. Studies have demonstrated
lower recurrent restenosis rates with DES compared with
BMS or vascular brachytherapy (495,838–840).
6.3.4. Restenosis After DES
Clinical restenosis after placement of DES is becoming
increasingly common due to the large numbers of patients
who have been treated with DES. The predominant angio-
graphic pattern for DES in-stent restenosis is focal (10
mm in length). Several biologic, mechanical, and technical
factors may contribute to DES in-stent restenosis, including
drug resistance, hypersensitivity, stent underexpansion,
stent strut fracture, nonuniform stent strut coverage, gap in
stent coverage, and residual uncovered atherosclerotic le-
sion. IVUS might be considered to determine the cause for
in-stent restenosis and help guide treatment strategy. Inter-
ventionists may treat focal DES restenosis with balloon
angioplasty and treat nonfocal DES restenosis with BMS,
CABG, or repeat DES with the same or an alternative
antiproliferative drug (848,849). Small, observational cohort
studies have demonstrated angiographic restenosis rates of
25% to 30% with repeat DES either with the same or an
alternative drug (495,849,850). There are no RCTs, and the
most appropriate treatment of restenosis of DES remains
unknown.6.4. Clinical Follow-Up
At the time of discharge, patients are instructed to contact
their physician or seek immediate medical attention if
symptoms recur. Most physicians will give the patient
instructions on return to work and timing of return to full
activities. The importance of strict compliance with aspirin
and P2Y12 inhibitor therapy is ideally emphasized to the
patient at the time of discharge and during follow-up visits.
Secondary prevention measures after PCI are an essential
part of long-term therapy, reducing both future morbidity
and mortality associated with CAD, and are discussed in
Section 6.5. A follow-up visit after PCI is usually scheduled
to assess the patient’s clinical status, the patient’s compli-
ance with secondary prevention therapies, and the success of
secondary prevention measures (e.g., blood pressure control,
low-density lipoprotein levels, smoking cessation). Routine,
periodic stress testing of asymptomatic patients is not
considered part of standard patient follow-up.
6.4.1. Exercise Testing: Recommendations
CLASS IIa
1. In patients entering a formal cardiac rehabilitation program after
PCI, treadmill exercise testing is reasonable. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Routine periodic stress testing of asymptomatic patients after PCI
without specific clinical indications should not be performed (795).
(Level of Evidence: C)
Treadmill exercise testing before cardiac rehabilitation pro-
vides information about peak exercise capacity and heart
rate, helping to stratify patients for the level of supervision
during training, and seems reasonable for this purpose
(851); nuclear imaging to assess ischemia in this context
usually adds little.
The role of exercise testing to evaluate restenosis is much
less certain. Although the presence of symptoms may not be
a reliable means of detecting restenosis, there is no evidence
that the detection of silent restenosis leads to improved
outcome (852,853). Routine testing of all patients after PCI
will also lead to many false-positive tests, particularly in the
era of DES. As restenosis rates decline from 30% to 10%,
the false-positive rate of stress imaging increases from 37%
to 77% (854). A recent analysis of a national health
insurance claims database and accompanying editorial find
that stress testing after PCI is likely overused and rarely
leads to repeat revascularization (855,856). In summary,
there is no proven benefit or indication for routine periodic
stress testing in patients after PCI, and, thus, it is not
indicated (8,851). In cases in which there is a clear clinical
indication for stress testing in a patient after PCI, exercise
ECG alone is an insensitive predictor of restenosis
(857,858); therefore, stress imaging is the preferred stress
test (8). In cases of recurrent angina after PCI in which the
pretest likelihood of restenosis is high and repeat revascu-
larization based on symptoms is likely indicated, most
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6.4.2. Activity and Return to Work
The timing of return to physical activity depends on the
presenting condition as well as previous functional status.
For STEMI, for example, daily walking is encouraged
immediately, and driving can begin within 1 week after
uncomplicated MI if allowed by local motor vehicle laws
(859). Sexual activity usually can be resumed within days,
provided exercise tolerance is adequate, normally assessed by
the ability to climb a flight of stairs (859). Similar recom-
mendations have been issued for UA/NSTEMI (860).
Patients with UA who have undergone successful revascu-
larization and are otherwise doing well may return to
physical activity on an accelerated schedule, usually within a
few days (860).
Return to work is more complex. Return to work rates
after MI range from 63% to 94% and are confounded by
factors such as job satisfaction, financial stability, and
company policies (861). The physical demands and degree
of stress of a particular job require that recommendations be
individualized. In the PAMI-2 (Primary Angioplasty in
Myocardial Infarction) trial, patients were encouraged to
return to work 2 weeks after primary PCI for STEMI, and
no adverse events were reported (862). In the RITA
(Randomized Intervention Treatment of Angina) trial,
revascularization with PCI led to earlier return to work
compared with CABG, and subsequent employment rates
were associated with relief of angina (105). Many practitio-
ners use graded exercise treadmill testing to determine the
safety of activity and return to work by measuring the
metabolic equivalent of task (MET) level achieved and
comparing that level to energy levels required to perform
different activities (863).
6.4.3. Cardiac Rehabilitation: Recommendation
CLASS I
1. Medically supervised exercise programs (cardiac rehabilitation)
should be recommended to patients after PCI, particularly for
moderate- to high-risk patients for whom supervised exercise train-
ing is warranted (796–804). (Level of Evidence: A)
Participation in cardiac rehabilitation is associated with
significant reductions in all-cause mortality (OR: 0.80, 95%
CI: 0.68 to 0.93) and cardiac mortality (796,797). Reports
from community-based surveys, which in general enroll
older and higher-risk patients than clinical trials, have
confirmed that participation in comprehensive rehabilita-
tion is independently associated with a reduction in recur-
rent MI and reduced mortality (799). Cardiac rehabilitation
is also associated with improvements in exercise tolerance,
cardiac symptoms, lipid levels, cigarette smoking cessation
rates (in conjunction with a smoking cessation program),
stress levels, improved medical regimen compliance, and
improved psychosocial well-being (800). Cardiac rehabili-
tation is cost-effective as well (864). Physician referral maybe the most powerful predictor of patient participation in a
cardiac rehabilitation program (865).
6.5. Secondary Prevention
The treatment of the patient does not end with PCI;
secondary prevention measures are a critical component of
patient management. Important secondary prevention mea-
sures were presented in detail in the “2006 AHA/ACC
Guidelines for Secondary Prevention for Patients With
Coronary and Other Atherosclerotic Vascular Disease”
(562) and have recently been updated in the “AHA/ACCF
Secondary Prevention and Risk Reduction Therapy for
Patients With Coronary and Other Atherosclerotic Vascular
Disease: 2011 Update” (805). The reader is referred to this
document for detailed discussions of secondary prevention.
Among the important recommendations are the following:
• Lipid management with lifestyle modification (Class I;
Level of Evidence: B) (805–807) and statin therapy are
recommended. (Level of Evidence: A) (344,806,808–
810,810a) An adequate statin dose should be em-
ployed which reduces low-density lipoprotein choles-
terol to 100 mg/dL AND achieves at least a 30%
lowering of low-density lipoprotein cholesterol. (Class
I; Level of Evidence: C) (806–810,810a) It is reason-
able to treat patients with statin therapy which lowers
low-density lipoprotein cholesterol to 70 mg/dL in
very high-risk* patients. (Class IIa; Level of Evidence:
C) (345,808–810,810a,811,812) Patients who have
triglycerides 200 mg/dL should be treated with
statins to lower non–high-density lipoprotein choles-
terol to 130 mg/dL. (Class I; Level of Evidence: B)
(344,809,810,866) In patients who are very high risk*
and have triglycerides 200 mg/dL, a non–high-
density lipoprotein cholesterol goal of 100 mg/dL is
reasonable. (Class IIa; Level of Evidence: C) (344,809,
810,866)
• Blood pressure control with lifestyle modification
(Class I; Level of Evidence: B) (813–817) and pharma-
cotherapy (Class I; Level of Evidence: A) (805,813,
818,819), with the goal of blood pressure 140/90
mm Hg.
• Diabetes management (e.g., lifestyle modification and
pharmacotherapy), coordinated with the patient’s pri-
mary care physician and/or endocrinologist. (Class I;
Level of Evidence: C) (805)
• Advising patients on the need for complete smoking
cessation. (Class I; Level of Evidence: A) (805,820–823)
*Presence of established cardiovascular disease plus 1) multiple major risk factors
(especially diabetes), 2) severe and poorly controlled risk factors (especially continued
cigarette smoking), 3) multiple risk factors of the metabolic syndrome (especially high
triglycerides 200 mg/dL plus non–high-density lipoprotein cholesterol 130
mg/dL with low high-density lipoprotein cholesterol [40 mg/dL]), and 4) acute
coronary syndromes.
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7.1. Quality and Performance: Recommendations
CLASS I
1. Every PCI program should operate a quality-improvement program
that routinely 1) reviews quality and outcomes of the entire pro-
gram; 2) reviews results of individual operators; 3) includes risk
adjustment; 4) provides peer review of difficult or complicated
cases; and 5) performs random case reviews. (Level of Evidence: C)
. Every PCI program should participate in a regional or national PCI
registry for the purpose of benchmarking its outcomes against
current national norms. (Level of Evidence: C)
PCI quality and performance considerations are defined by
attributes related to structure, processes, and risk-adjusted
outcomes. Structural attributes include elements such as
equipment, supplies, staffing, institutional and operator-
level volumes, and the availability of electronic medical
records. Processes include strategies for the appropriate
patient, protocols for pre- and postprocedural care, appro-
priate procedural execution and management of complica-
tions, and participation in databases and registries for
benchmarking performance of the program and individual
operator. Risk-adjusted outcomes are the end result of these
structures and processes of care, and when available are
more reliable measures of quality than the institutional and
individual operator volumes discussed in Section 7.4.
PCI process and outcomes assessments can be used for
internal quality-improvement efforts and public reporting.
Public reporting of institutional risk-adjusted outcomes is
becoming more common. Although operator-level out-
comes can be assessed and risk adjusted, the results are
much less reliable due to lack of statistical power resulting
from lower volumes. Any public reporting must use statis-
tical methods that meet the high criteria established by the
AHA Work Group (867).
7.2. Training
The cognitive knowledge and technical skill required to
perform PCI continue to grow. Details on the training
required for interventional cardiology are found in the most
recent ACCF Core Cardiology Training Statement (868).
7.3. Certification and Maintenance of Certification:
Recommendation
CLASS IIa
1. It is reasonable for all physicians who perform PCI to participate in
the American Board of Internal Medicine interventional cardiology
board certification and maintenance of certification program. (Level
of Evidence: C)
The American Board of Internal Medicine established
interventional cardiology board certification in 1999 as an
“added qualification” to the cardiovascular disease board
certification. Since 1990 all certificates from the American
Board of Internal Medicine are time limited for a 10-year
period and require all diplomats to participate in mainte-
nance of certification to maintain their board-certifiedstatus. Maintenance of certification in interventional cardi-
ology requires physicians to document a minimum of 150
interventional cases over the 2 years before expiration of the
current certification, complete self-assessment modules of
their medical knowledge, participate in practice-based quality-
improvement activities, and pass a secure, knowledge-based
examination (869–871). For those who cannot meet the
case volume requirement, an alternative option is to submit
a log of 25 consecutive cases including patient characteristics
and procedural outcomes. The maintenance of certification
process is likely to change, as the American Board of
Internal Medicine intends to evolve maintenance of certifi-
cation from an episodic event that occurs once every 10 years
to a more continuous process of continuous professional
development.
7.4. Operator and Institutional Competency
and Volume: Recommendations
CLASS I
1. Elective/urgent PCI should be performed by operators with an
acceptable annual volume (75 procedures) at high-volume cen-
ters (400 procedures) with on-site cardiac surgery (872,873).
(Level of Evidence: C)
2. Elective/urgent PCI should be performed by operators and institu-
tions whose current risk-adjusted outcomes statistics are compara-
ble to those reported in contemporary national data registries.
(Level of Evidence: C)
3. Primary PCI for STEMI should be performed by experienced
operators who perform more than 75 elective PCI procedures per
year and, ideally, at least 11 PCI procedures for STEMI per year.
Ideally, these procedures should be performed in institutions that
perform more than 400 elective PCIs per year and more than 36
primary PCI procedures for STEMI per year (872,874–877).
(Level of Evidence: C)
CLASS IIa
1. It is reasonable that operators with acceptable volume (75 PCI
procedures per year) perform elective/urgent PCI at low-volume
centers (200 to 400 PCI procedures per year) with on-site cardiac
surgery (872). (Level of Evidence: C)
. It is reasonable that low-volume operators (75 PCI procedures per
year) perform elective/urgent PCI at high-volume centers (400
PCI procedures per year) with on-site cardiac surgery. Ideally, oper-
ators with an annual procedure volume of fewer than 75 procedures
per year should only work at institutions with an activity level of
more than 600 procedures per year. Operators who perform
fewer than 75 procedures per year should develop a defined
mentoring relationship with a highly experienced operator who
has an annual procedural volume of at least 150 procedures per
year. (Level of Evidence: C)
CLASS IIb
1. The benefit of primary PCI for STEMI patients eligible for fibrinolysis
when performed by an operator who performs fewer than 75
procedures per year (11 PCIs for STEMI per year) is not well
established. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. It is not recommended that elective/urgent PCI be performed bylow-volume operators (75 procedures per year) at low-volume
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cardiac surgery. An institution with a volume of fewer than 200
procedures per year, unless in a region that is underserved because
of geography, should carefully consider whether it should continue
to offer this service (872). (Level of Evidence: C)
Older observational evidence supported a volume-outcome
relationship in PCI at both the institutional and operator
level (873). However, this relationship is complicated and
may be inconsistent across low-volume institutions or op-
erators. More recent data on primary PCI suggest that
operator experience may modify the volume-outcome rela-
tionship at the institutional level (876,878). Risk-adjusted
outcomes remain preferable to institutional and individual
operator volumes as quality measures.
Operator and hospital volume recommendations have been
carried over from the 2005 PCI guideline. However, the
writing committee recognizes that these volume recommenda-
tions are controversial. In addition, after extensive review of all
relevant data, the writing committee believes that the LOE in
support of all the above recommendations is best categorized as
LOE C rather than LOE B as it has been in prior guidelines
for some recommendations. We encourage the ACCF/AHA/
ACP Clinical Competence and Training writing group for
PCI and other expert writing groups to review this issue so that
new recommendations can be considered by the next PCI
guideline writing committee.
7.5. Participation in ACC NCDR or
National Quality Database
Assessment of PCI quality and outcomes is important both
at the level of the entire program and at the level of the
individual physician. This requires collection of clinical and
procedural data for PCI that allows regular comparison of
risk-adjusted outcomes and complications with national
benchmarks. The ACC NCDR CathPCI Registry is an
example of a national registry to fulfill the goals of assessing
and benchmarking quality and outcomes.
8. Future Challenges
Although this latest guideline reflects significant advance-
ments in the field of PCI, there remain future challenges to
the formulation and updating of guidelines for PCI. The
proliferation of studies comparing the many newer drugs
and devices with older therapies (or other newer therapies),
often using different or novel study endpoints, endpoint
definitions, and noninferiority designs, pose increasing chal-
lenges to objectively evaluating newer therapies and gener-
ating recommendations for their use. Numerous potential
advances in the field of PCI, including intracoronary stem
cell infusions for chronic and acute ischemic heart disease,
designer drugs, novel intracoronary imaging technologies
such as optical coherence tomography and virtual histology,
new stent composition and designs (e.g., drug-eluting,
biodegradable, bifurcation), and drug-eluting balloons wereconsidered for formal evaluation by the current writing com-
mittee, but it was thought that there were insufficient data at
present to formulate any formal recommendations on these
topics. These and other emerging technologies and treatments
will need to be addressed in future PCI guidelines.
Finally, with this proliferation of new technology, the
amount of data generated in the evaluation of these poten-
tial therapeutic advances will grow dramatically, adding
significant challenges to future guideline generations. Of
note, the Web site www.clinicaltrials.gov currently lists
several hundred PCI-related clinical trials.
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APPENDIX 3. ABBREVIATION LIST
ACS  acute coronary syndromes
AKI  acute kidney injury
BMS  bare-metal stent(s)
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CKD  chronic kidney disease
CTO  chronic total occlusion
DAPT  dual antiplatelet therapy
DES  drug-eluting stent(s)
ECG  electrocardiogram
EF  ejection fraction
EPD  embolic protection device
FDA  U.S. Food and Drug Administration
FFR  fractional flow reserve
GDMT  guideline-directed medical therapy
GI  gastrointestinal
GP  glycoprotein
IABP  intra-aortic balloon pump
IV  intravenous
IVUS  intravascular ultrasound
LAD  left anterior descending
LIMA  left internal mammary artery
LV  left ventricular
LVEF  left ventricular ejection fraction
MACE  major adverse cardiac event
MI  myocardial infarction
MRI  magnetic resonance imaging
NCDR  National Cardiovascular Data Registry
PCI  percutaneous coronary intervention
PPI  proton pump inhibitor
RCT  randomized controlled trial
SIHD  stable ischemic heart disease
STEMI  ST-elevation myocardial infarction
SVG  saphenous vein graft
TIMI  Thrombolysis In Myocardial Infarction
TMR  transmyocardial laser revascularization
UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction
UFH  unfractionated heparin
e120 Levine et al. JACC Vol. 58, No. 24, 2011
2011 ACCF/AHA/SCAI PCI Guideline December 6, 2011:e44–122APPENDIX 4. ADDITIONAL TABLES/FIGURES
Appendix 4A. The NCDR CathPCI Risk Score System
Risk Score Calculation
Variable Scoring Response Categories Total Points
Risk of In-Patient
Mortality (%)
Age 60 60,70 70,80 80 0 0.0
0 4 8 14 5 0.1
Cardiogenic shock No Yes 10 0.1
0 25 15 0.2
Prior CHF No Yes 20 0.3
0 5 25 0.6
Peripheral vascular disease No Yes 30 1.1
0 5 35 2.0
Chronic lung disease No Yes 40 3.6
0 4 45 6.3
GFR 30 30-60 60-90 90 50 10.9
18 10 6 0 55 18.3
NYHA functional class IV No Yes 60 29.0
0 4 65 42.7
PCI status (STEMI) Elective Urgent Emergent Salvage 70 57.6
12 15 20 38 75 71.2
PCI status (no STEMI) Elective Urgent Emergent Salvage 80 81.0
0 8 20 42 85 89.2
90 93.8
95 96.5
100 98.0CathPCI indicates catheterization percutaneous coronary intervention; CHF, congestive heart failure; GFR, glomerular filtration rate; NCDR, National Cardiovascular Data Registry; NYHA, New York Heart
Association; and STEMI, ST-elevation myocardial infarction. Reproduced with permission from Peterson et al. (236).
Society for Cardiovascular Angiography and Interventions. Reprinted with permission from Krone
et al. (879).
p
FOV indicates field of view; and FT, fluoroscopy time.
Adapted with permission from Chambers et al. (317).
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to Patient and Operator
Precautions to minimize exposure to patient and operator
Use radiation only when imaging is necessary to support clinical care
Minimize use of cine
Minimize use of steep angles of x-ray beam
Minimize use of magnification modes
Minimize frame rate of fluoroscopy and cine
Keep the image receptor close to the patient
Utilize collimation to the fullest extent possible
Monitor radiation dose in real time to assess patient risk-benefit during
procedure
Precautions to specifically minimize exposure to operator
Use and maintain appropriate protective garments
Maximize distance of operator from x-ray source and patient
Keep above-table and below-table shields in optimal position at all times
Keep all body parts out of field of view at all times
Precautions to specifically minimize exposure to patient
Keep table height as high as comfortably possible for operator
Vary imaging beam angle to minimize exposure to any single skin area
Keep patient’s extremities out of beamAppendix 4B. The SCAI Lesion Classification System
Type I lesions (highest success expected, lowest risk)
1. Does not meet criteria for C lesion
2. Patent
Type II lesions
1. Meets any of these criteria for ACC/AHA C lesion
Diffuse (2 cm length)
Excessive tortuosity of proximal segment
Extremely angulated segments, 90°
Inability to protect major side branches
Degenerated vein grafts with friable lesions
2. Patent
Type III lesions
1. Does not meet criteria for C lesion
2. Occluded
Type IV lesions
1. Meets any of these criteria for ACC/AHA C lesion
Diffuse (2 cm length)
Excessive tortuosity of proximal segment
Extremely angulated segments, 90°
Inability to protect major side branches
Degenerated vein grafts with friable lesions
Occluded for 3 mo
2. Occluded
ACC indicates American College of Cardiology; AHA, American Heart Association; and SCAI,Appendix 4D. Patient Care Consideration Based on Procedural Radiation Dose
Ka,r* PKA† FT‡ Action
5 Gray 500 Gray cm2 60 min Physician charts documentation about why exposure at this level occurred, documents whether
multiple skin entry angles were used, assesses risk, educates patient about potential for
skin injury, and arranges for appropriate follow-up within 30 d. Phone calls may be sufficient
with an office visit arranged if issues/questions arise or a potential tissue injury is
suspected.
10 Gray Physician contacts radiation safety officer/medical physicist. The radiation safety
officer/medical physicist should perform a detailed analysis of PSD. Document a) FOV,
b) skin entrance port number, c) known geometry, with a “rough” geometric setup required.
Educate patient about the potential for skin injury and document this in chart. Schedule an
office visit in 2 to 4 wk.
PSD§ 15 Gray If calculated PSD is indeed 15 Gray, the physician and/or radiation safety officer/
medical physicist should contact hospital risk management within 24 h. Report the event
to the Joint Commission and as needed to the appropriate State Department of Health.
*Ka,r is total air kerma at reference point; †PKA is air kerma-area product; ‡FT is total fluoroscopy time, does not include cine; §PSD is peak skin dose, which requires calculations made by a qualified
hysicist.
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Early Invasive Strategy Generally Preferred Initial Conservative Strategy Generally Preferred or Reasonable
● Recurrent angina or ischemia at rest or with low-level activities despite intensive
medical therapy
● Elevated cardiac biomarkers (TnT or TnI)
● New or presumably new ST-segment depression
● Signs or symptoms of heart failure
● Hemodynamic instability
● High-risk score (e.g., GRACE, TIMI)
● Sustained ventricular tachycardia
● PCI within 6 mo
● Prior CABG
● Diabetes mellitus
● Mild to moderate renal dysfunction
● Reduced LV function (LVEF 40%)
● Low-risk score (e.g., GRACE, TIMI)
● Absence of high-risk features
● High risk for catheterization-related complications
● Patient not a candidate for revascularization (with either PCI or CABG)
● Patient prefers conservative therapyCABG indicates coronary artery bypass graft surgery; GRACE, Global Registry of Acute Coronary Events; LV, left ventricular; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention;
TIMI, Thrombolysis In Myocardial Infarction; TnI, troponin I; and TnT, troponin T.Appendix 4F. Agents for Procedural Sedation and Analgesia
Drug Clinical Effects Dose Onset Duration Comments
Midazolam Sedation, anxiolysis.
No analgesia.
Initial 0.5 to 1 mg IV,
then titrated.
2 to 3 min 45 to 60 min Reduce dose when used in combination
with opioids. May produce
paradoxical excitement. Reversible
with flumazenil.
Fentanyl Analgesia 50 mcg IV. May
repeat every 3
min, titrate to
effect.
3 to 5 min 30 to 60 min Reduce dosing when combined with
benzodiazepines. Reversible with
naloxone.
Etomidate Sedation, anxiolysis.
No analgesia.
Sedation: 0.1 mg/kg
IV; repeat if
inadequate
response.
1 min 5 to 15 min Respiratory depression may occur;
institutional guidelines vary about
administration to nonintubated
patients by nonanesthesiologists.
May cause myoclonus, nausea, and
vomiting. Adrenocortical suppression
occurs but is rarely of clinical
significance. Not reversible.
Propofol Sedation, anxiolysis.
No analgesia.
Load 1 mg/kg IV;
may administer
additional 0.5 mg/
kg doses as
needed to enhance
or prolong
sedation.
1 min 5 to 15 min Frequent hypotension and respiratory
depression; institutional guidelines
vary concerning administration to
nonintubated patients by
nonanesthesiologists. Avoid with egg
or soy allergies. Not reversible.
Reversal Agents
Naloxone Opioid reversal 0.4 to 2 mg IV 2 min 20 to 40 min If shorter acting than reversed drug,
serial doses may be required.
Flumazenil Benzodiazepine
reversal
0.2 mg IV. May
repeat every 1 min
up to 1 mg.
1 to 2 min 30 to 60 min If shorter acting than reversed drug,
serial doses may be required. Do not
use in patients receiving long-term
benzodiazepines, cyclosporine,
isoniazid, lithium, propoxyphene,
theophylline, or tricyclic
antidepressants.IV indicates intravenous.
